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Abstract 
UNIVERSITY OF SOUTHAMPTON 
ABSTRACT 
INFECTION, INFLAMMATION AND REPAIR DIVISION 
SCHOOL OF MEDICINE 
Doctor of Medicine 
MALARIA IMMUNOLOGY AND VACCINE DEVELOPMENT 
By Fiona Mary Thompson 
 
This thesis describes work undertaken by the author at the University of Oxford. It 
begins by providing an introduction to malaria infection and pathophysiology, and 
a review of the latest attempts to produce an effective malaria vaccine. It goes on 
to describe the rationale behind the vaccines developed by the University of 
Oxford and others. A brief introduction to the process of planning and carrying out 
clinical trials of vaccines is then provided, and is followed by chapters describing 
two clinical trials, designed to test the safety, immunogenicity and then efficacy of 
candidate malaria vaccines. These trials were performed in Oxford, to examine 
two different vaccination approaches. The first intended to broaden the specificity 
of the vaccine induced immune response, by providing multiple antigens in one 
vaccine, aiming thereby to improve protection from malaria infection. The second 
regimen used a combination vaccine intending to induce both humoral and cellular 
immunity simultaneously, thereby providing enhanced efficacy against malaria 
infection. Neither approach was sufficient to provide protection from infection in the 
challenge studies described; however, some impact on the disease was detected 
in the second study. This is examined in detail. The laboratory work described 
studies background immune responses (both cellular and humoral) to vaccine 
antigens in a malaria exposed population, intended to support the inclusion of 
these antigens in the multi-antigen vaccine. The remaining chapters describe work 
in parasite life cycle modelling, undertaken to aid interpretation of results of these 
clinical trials, and finally an examination of the clinical course of malaria in the 
control volunteers who have taken part in the many challenge studies conducted in 
Oxford. 
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Chapter 1   Introduction 
1.1  Purpose 
The work described in this thesis is part of the ongoing work at the Jenner 
Institute, in the Centre for Clinical Vaccinology and Tropical Medicine, part of the 
Nuffield Department of Medicine, under the supervision of Professor Adrian Hill at 
the University of Oxford. The work described here includes a summary of the 
methodology for conducting a clinical trial of a malaria vaccine, followed by two 
candidate malaria vaccine trials, performed in Oxford, along with some laboratory 
work relating to the clinical trials, and some computational modelling of malaria 
infection, also relevant for the clinical trials. Finally there is an analysis of safety 
data compiled from a large number of the studies conducted by Professor Hill’s 
group in Oxford over the last 8 years.  
 
1.2  Malaria Introduction 
1.2.1  Burden and Importance 
Malaria is a global disease, affecting approximately 40% of the world’s population. 
It is estimated that there were 515 million clinical episodes of P. falciparum malaria 
in 2002 alone [1] and at least a million people die annually from the disease in 
Africa [2]. In most tropical and many subtropical developing countries, malaria is a 
major cause of morbidity and mortality, especially among infants, young children 
and pregnant women [2]. Malaria also represents a serious health hazard for 
travellers who visit malaria-endemic areas. The widespread resistance of 
Anopheles mosquitoes to insecticides has crippled national and regional malaria 
control programs based on vector control interventions. Furthermore, the 
increasing prevalence of chloroquine and anti-folate resistant strains of P. 
falciparum in Asia, Africa and South America has created a crisis in the clinical 
treatment of malaria in many countries. These drug resistant strains have made 
devising well-tolerated and effective prophylactic regimens challenging. Given 
these facts, there is an urgent need for new, effective interventions that can be Chapter 1 Introduction 
  2 
applied to the control of malaria. One such approach involves immunoprophylaxis 
by means of malaria vaccines. An effective vaccine could make an enormous 
impact on this problem, both for people in the developing world and for those 
travelling to malaria endemic countries [1, 3]. It could also contribute significantly 
to the longer term goal of eradication of malaria. 
 
The scale of the problem that malaria causes across the world is gradually 
becoming more widely understood. Despite this, it is still shocking that a child dies 
every 30 seconds from this disease [2]. Most of these deaths occur in sub-
Saharan Africa, where children under five are most at risk [4]. The UN 
acknowledged malaria in its Millennium Development Goals; goal number 6 is to 
‘Halt and begin to reverse the incidence of malaria and other major diseases’. At 
present, the main strategies employed to control malaria include indoor residual 
spraying (IRS), bed nets and effective treatment. IRS involves coating the walls 
and other surfaces of a house with a residual insecticide, which is intended to kill 
mosquitoes and other insects that come into contact with these surfaces for 
several months afterwards. This can be a highly effective measure: when used in 
a study in Bolivia, it dramatically reduced the annual parasite index (the number of 
cases of malaria per 1000 people per year) [5] and reduced malaria transmission 
by up to 90% [6]. The number of spray programmes declined in the 1980s, largely 
as a result of health and environmental concerns surrounding DDT, these are 
gradually being reintroduced. The use of insecticide-treated bed nets is also 
known to be an effective means of reducing transmission, although their efficacy 
depends largely on the local mosquito population, where mosquitoes bite largely at 
night (as the majority of African vectors do), they are more effective than where 
mosquitoes bite mainly in the evening (for example in South America) [7]. The 
prompt provision of effective antimalarial medication, particularly in areas where 
the parasite is resistant to conventional drugs is also important. These strategies, 
combined with improved diagnosis of infection, can successfully reduce the impact 
of disease. But, however effective these methods are, they can only hope to 
control malaria infection, rather than to eradicate it.  
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1.2.2  Life Cycle and Pathogenesis 
There are over a hundred species of the malaria parasite (Plasmodium species), 
but only four of these species have humans as their vertebrate host [8]. These are 
Plasmodium falciparum, Plasmodium vivax (these first two cause most of the vast 
number of clinical cases of malaria), Plasmodium malariae and Plasmodium ovale. 
Rare zoonotic infections have been recorded from non-human primate malarias 
such as P. knowlesi, P. simium, and P. cynomolgi. Although each of the human 
malarias has distinguishing biological, morphological, and clinical characteristics, 
their overall biology and lifecycles are similar. Research into malaria has used a 
number of animal models of malaria infection, those most commonly used are the 
murine pathogens, P. yoelii and P. berghei, along with the non-human primate 
malarias mentioned above. The fight against malaria has been focussed largely on 
P. falciparum as this is the type associated with the highest mortality, and is the 
cause of the majority of malaria deaths. The Plasmodium parasite is spread to 
humans by the bite of an infected female Anopheles mosquito.  
 
When a mosquito feeds on an individual, it injects saliva as it probes for blood. 
The saliva of an infectious mosquito contains malaria parasites – sporozoites. 
Originally it was assumed that these were injected directly into the blood stream, 
but groups have shown experimentally that removal or heat treatment of the 
injection site can prevent infection in animals probed upon by infected mosquitoes 
[9, 10] suggesting they are deposited into the dermis. The number of sporozoites 
injected by a single infectious mosquito was previously estimated in studies using 
membrane feeders at 5 – 20 [11, 12]. However, quantitative PCR analysis of the 
injection site after single mosquito feeds using the rodent malaria parasite 
Plasmodium yoelii, showed that a single infected mosquito injected between 0 and 
1,297 sporozoites, with a mean of 123 and a median of 18 [13]. 20% of infected 
mosquitoes injected no sporozoites after 3 min of probing [13], a result also 
observed when salivating mosquitoes were analyzed [12]. These data 
demonstrate that the sporozoite inoculum itself is highly variable. Sporozoites 
move randomly in the skin, until they contact the vascular or lymphatic 
endothelium [14]. It had been assumed that sporozoites were rapidly carried away 
from the injection site, as some do enter the circulation within minutes of injection Chapter 1 Introduction 
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[10], and the infectivity of sporozoites dissected from mosquito salivary glands and 
kept at 37° C for 1 hour wanes rapidly [15]. Again, initial assumptions have proven 
to be incorrect, with detailed quantitative studies of the kinetics showing that 90% 
of sporozoites remain at the injection site 1 hour post infection [16], and they leave 
the site in a slow trickle between 1 and 3 hours post injection. As many as 20% of 
sporozoites leave the injection site via lymphatics, and some of these sporozoites 
begin to develop in the draining lymph node, an important site for the initiation of 
anti-sporozoite immune responses [14] and [16]. Once sporozoites enter the 
circulation, they travel in the blood to the liver. Their circulation is arrested in the 
liver by specific interactions between the circumsporozoite protein (CS) and the 
highly sulphated HSPGs of hepatocytes [17, 18].  
 
Sporozoites will typically migrate through several hepatocytes before settling in 
one [19, 20], and initiating a process of asexual replication to give rise to an 
exoerythrocytic schizont. Up to this point, infection is clinically silent, and non-
pathogenic. After about seven days the liver shizonts rupture to release many 
thousands (estimated at 20,000 – 30,000) of merozoites into the bloodstream. 
Here they attach to and invade circulating erythrocytes, where they develop 
through a series of morphological changes from ‘ring’ forms to trophozoites and 
finally dividing mitotically to produce schizonts containing up to 20 daughter 
erythrocytic merozoites. These are liberated by red-cell lysis and can go on to 
invade fresh uninfected erythrocytes, giving rise to a cyclical blood-stage infection 
with a periodicity of 48–72 hours, depending on the Plasmodium species. The 
intra-erythrocytic cycle of infection is usually fairly synchronous (particularly in P. 
vivax and P. ovale infections, although less so in P. falciparum) so red-cell lysis 
and merozoite release occur at regular intervals in infected individuals. ‘Malarial 
pyrogens’ released at the time of RBC lysis induce cytokine production (for 
example, tumour necrosis factor-α (TNF-α) and interleukin-1 (IL-1)) giving rise to 
the periodic ‘agues’ or paroxysms of fever that have long been a diagnostic feature 
of malaria infection. The asexual blood forms are the only forms of the parasite 
that give rise to clinical symptoms. As-yet-unknown factors trigger a subset of 
developing merozoites to differentiate into male and female gametocytes. When 
another mosquito feeds on the same individual, these sexual stage parasites are 
taken up by the feeding mosquito, and give rise to extracellular gametes. In the Chapter 1 Introduction 
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mosquito mid-gut, the gametes fuse to form a motile zygote (ookinete), which 
penetrates the mid-gut wall and forms an oocyst, within which meiosis takes place 
and haploid sporozoites develop. Sporozoites then migrate across the gut wall and 
into the salivary glands of the mosquito to complete the cycle. This life cycle is 
illustrated in Figure 1.1. 
 
 
Figure 1.1: Life cycle of malaria in humans 
Sporozoites are injected into human dermis through the bite of infected Anopheles 
mosquito. After inoculation, sporozoites migrate to liver cells to establish the first 
intracellular replicative stage. Merozoites generated from this exoerythrocytic phase then 
invade erythrocytes (RBCs), and it is during this erythrocytic stage that severe conditions of 
malaria occur. The life cycle is completed when sexual stages (gametocytes) are ingested 
by a mosquito. From [21] © Nature Medicine 2006. Chapter 1 Introduction 
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1.2.3  Molecular Biology  
The genome of P. falciparum was sequenced in 2002 [22], and was found to have 
an extraordinarily high adenine and thymine (A + T) content of around 82%. The 
23-megabase nuclear genome consists of 14 chromosomes and encodes about 
5300 genes.  
 
One result of the availability of genome sequence data is the possibility for 
detection of genome wide single-nucleotide polymorphisms (SNPs). This process 
may assist in pinpointing the origin and mapping the spread of infectious diseases, 
to identify and track new mutations that confer resistance to drugs or vaccine-
induced immunity, and potentially to identify candidate genes for novel therapeutic 
or immunological intervention. One such approach identified a disproportionate 
number of polymorphisms in genes encoding surface proteins or those associated 
with the cell membrane. These genes are targets for only 22% of the 
oligonucleotide probes used in this analysis, but account for 69% of the 
polymorphisms identified [23]. 
 
The major antigen on the sporozoite surface is the circumsporozoite protein (CS) 
which facilitates sporozoite migration to the liver and binds specifically to regions 
of the plasma membrane of hepatocytes exposed to circulating blood in the space 
of Disse [17].  An associated protein, the thrombospondin related adhesion protein 
(TRAP) also plays a key role in sporozoite invasion of hepatocytes [24, 25]. The 
surface of the merozoite contains the merozoite surface proteins (MSPs) of which 
a number have been identified, but for many, their role has yet to be defined. 
Merozoite surface proteins (MSP-1, 2, 4, 5, 8 and 10) link to the membrane via a 
glycosylphosphatidylinositol (GPI) membrane anchor, whilst others, such as MSP-
3, MSP-6, MSP-7 and MSP-9 are soluble and are, in part, associated with the 
merozoite surface [26]. MSP-1 was the first Plasmodium MSP to be discovered 
and is the most well characterised member of the MSP family. It appears that 
MSP-1 is essential for red blood cell invasion and survival of the malarial parasite 
as strains of knock-out parasite with this gene removed are not viable [26]. 
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Many other parasite-derived proteins are produced in the course of the life cycle, 
not all of which are exported to the membrane of the infected cell. Some others 
are secreted into the cells, and some interact specifically with the red-cell 
cytoskeleton modifying the host-cell environment in favour of the parasite [8]. 
 
1.2.4  Molecular Pathology 
The cause of malaria was unknown for centuries, but it was noted to be 
characterized by periodic fevers. Ronald Ross first confirmed the presence of 
oocysts within the mosquito gut, and recorded that the parasite was transmitted 
through the mosquito bite [27]; work which won him the Nobel Prize for Medicine 
in 1902. It was subsequently realized that the bouts of fever generally coincided 
with the release of new merozoites into the blood, as each cycle of replication was 
completed (observation published by Golgi in 1889 [28]). Initially, it was assumed 
that the release of infected cell contents that occurs at this time was responsible 
for fever induction, it was not until more recently that it was proven that 
components of the infected cell such as the lipid, glycosylphosphatidylinositol 
(GPI) anchor of a parasite membrane protein could directly induce the release of 
cytokines such as TNF-α and IL-1 from macrophages [29]. GPI has subsequently 
emerged as a central toxin that induces the expression of many host genes 
implicated in malaria pathogenesis [30]. GPIs anchor proteins in the membrane of 
virtually all eukaryotic cells [31]. A considerable fraction of GPI in parasites 
appears at the plasma membrane without protein attachment as free GPI [32-34]. 
Although evolutionarily conserved, species-dependent branching of the core 
molecular structure results in unique GPI molecules comprising epitopes that can 
be recognized by the mammalian immune system. Serological studies using GPIs 
purified from P. falciparum have indicated that sera from malaria-endemic regions 
contain naturally occurring anti-GPI antibodies [35-37]. Purified GPI induces the 
expression of many genes that are implicated in malaria pathogenesis: for 
example, genes that encode pro-inflammatory cytokines – such as tumour-
necrosis factor (TNF), interleukin-1 (IL-1) and IL-12 [37, 38] – inducible nitric-oxide 
synthase [39], and various adhesion molecules that are expressed at the surface 
of the vascular endothelium and are recognized by P. falciparum EMP1 [40], which 
increases endothelial-cell binding by parasitized RBCs [40]. In a sepsis-shock Chapter 1 Introduction 
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model, GPI alone is sufficient to cause symptoms that are similar to those of acute 
malaria, such as transient pyrexia, hypoglycaemia and death of recipients as a 
consequence of TNF-mediated coagulopathy, as seen in the malarial shock-like 
syndrome [38]. Parasite GPI-glycan appears to play a similar role in other parasitic 
diseases, such as trypanosomiasis and toxoplasmosis [41, 42], in which they have 
also been shown to induce TNF-α. Measurements of TNF-α in children suffering 
from malaria demonstrated that very high levels of this cytokine were associated 
with severe disease [43] and cerebral malaria with a poor outcome [44], although 
the correlation was not sufficient to be a useful prognostic indicator. 
 
It has been demonstrated that more mature parasites within erythrocytes are 
differentially sensitive to physiological increases in temperature [45], so that the 
effect of fever is both to limit parasite multiplication and to maintain synchronous 
development. More recently, Oakley et al. have confirmed that cultivation of P. 
falciparum parasites at 41° C leads to parasite death in a time-dependent manner 
[46], and suggested that an apoptosis-like cell death mechanism might be induced 
in response to febrile temperatures. However, this hypothesis was not borne out 
by analysis of differential gene expression in these parasites. 
 
The pathology associated with malaria infection is largely related to asexual 
parasite multiplication in the bloodstream and in the case of the most virulent 
human malaria, P. falciparum, this has been linked to the effects infection has on 
parasitised erythrocytes [47]. Although sporozoites can and do induce some anti 
parasite activity, the relatively small numbers of parasites involved in the liver 
stages do not appear to be related to any significant symptoms. Circulating 
gametocytes also do not appear to be related to any adverse effects. Infection with 
P. falciparum can have a wide range of consequences, from the relatively benign 
fever through to the potentially fatal severe anaemia and cerebral malaria. 
Metabolic acidosis, often manifesting as respiratory distress, is an important 
component of the severe malaria syndrome [48, 49]. Metabolic acidosis has been 
demonstrated to be the best independent predictor of a fatal outcome [48-51]. 
 
The effect that seems to underlie the pathology of most manifestations of severe 
falciparum malaria is the result of the appearance of parasite encoded proteins on Chapter 1 Introduction 
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the red cell surface. These proteins mediate adherence to a variety of host tissues, 
including the vascular endothelium, resulting in sequestration of infected cells. 
Only red cells that have been infected for longer than 16 hours exhibit these 
receptors, resulting in high levels of circulating immature parasites, and 
sequestration of more mature forms [47]. This process occurs in all infections, and 
is thought to be an important factor in the pathogenesis of severe disease where 
concentration of organisms in particular organs such as the brain occurs. Binding 
of sequestered parasitized erythrocytes to uninfected red cells to form erythrocyte 
rosettes is linked to disease severity [52]. The distribution of infected RBCs found 
in tissue sections suggests that the chief sites of infected cell sequestration 
correlate with specific organ dysfunction, for example in the cerebral circulation 
leading to cerebral malaria [53].  
 
It is assumed, but not formally proven, that the microvascular obstruction 
secondary to cytoadhesion of parasitised RBCs [54], rosetting [55] and reduced 
RBC deformability [56] leads to a reduction in local blood flow, or obstruction of 
small vessels and this results in reduced perfusion and tissue damage. It has also 
been suggested that the sequestered cells exert a direct toxic effect, triggering the 
activation of host immune factors that include cytokines, such as TNF and pro-
inflammatory interleukins, oxygen free radicals and nitric oxide, which result in 
damage to host endothelium and tissues [57]. This results in a host response 
syndrome similar to the systemic inflammatory response syndrome (SIRS) or 
sepsis syndrome [58]. 
 
The detailed mechanisms by which sequestered cells result in the specific 
symptoms seen in cases of severe falciparum malaria are still being elucidated, 
however, the molecular mechanisms leading to sequestration are becoming 
clearer. Specific receptors and parasite molecules involved in adhesion have been 
identified. Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) 
plays a central role in the pathogenesis of malaria; mediating infected cell 
cytoadherence to a range of ligands on endothelial cells, placental cells, and other 
red cells leading to rosetting, and on infected red cells and platelets leading to 
auto-agglutination, which, as described above, are related to disease severity. 
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Despite the life-threatening nature of severe falciparum malaria, and the enormous 
number of childhood deaths that it causes in sub-Saharan Africa, the mortality rate 
of all malaria infections is relatively low. In holoendemic areas, infections in 
children are universal and constant, yet only a small proportion of those infected 
show clinical symptoms at any one time and only a fraction of these go on to 
develop severe illness. This is probably only partially explained by the known 
innate resistance factors and acquired immunity, and so it is likely that unidentified 
factors are also important in determining how far individual infections progress 
from parasitaemia to clinical illness and finally to severe disease. 
 
1.3  Immunology of Infection 
Individuals living in areas where malaria is endemic do acquire some level of 
immunity to infection. In other infections, individuals rapidly become resistant to 
subsequent infections with the same organism. In contrast, immunity to malaria 
infection is acquired over several years and repeated episodes of clinical malaria. 
This is evident from the fact that the burden of disease falls on young children. 
Older children and adults are resistant to severe morbidity and death [59], though 
remaining susceptible to infection. These individuals are often parasitaemic, but 
are protected from clinical symptoms of disease. It is therefore important to define 
precisely what we mean by susceptibility to malaria. As outlined by Marsh et al. 
[60], parasite prevalence, prevalence of clinical malaria and prevalence of severe 
life threatening malaria must all result from exposure to infection and be a 
measure of susceptibility; all show evidence of acquisition of resistance with 
increasing age, but each indicator has a quite different relationship with age – see 
Figure 1.2. Chapter 1 Introduction 
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Figure 1.2: Population indices of immunity to malaria – Kilifi.  
The figure shows representative data from a number of studies in Kilifi District on the coast 
of Kenya. The age pattern of asymptomatic parasite prevalence and the period prevalence 
of both mild and severe clinical malaria are shown in relation to maximum prevalences 
recorded. (Taken from Marsh et al. [60]). 
 
The mechanisms responsible for protection against severe malaria are not 
necessarily the same as those that protect against infection per se, or against mild 
episodes of disease. Field studies of immune responses and mechanisms are 
almost entirely restricted to examining these outcomes for logistic reasons, and 
this remains a major problem with research in this area [60]. 
 
1.3.1  Pre-erythrocytic Immunity 
Immunity to the pre-erythrocytic stages of malaria infection may act at any point 
from the injection of a sporozoite into the blood stream of an individual, to its 
invasion of a hepatocyte, and the development of an intrahepatic schizont. In 
individuals living in endemic areas, responses to the pre-erythrocytic stages 
develop relatively late on in life, compared with responses to the blood stages [60]. 
The importance of immune responses to this stage of the life cycle is 
demonstrated by the observation that immunization with radiation-attenuated Chapter 1 Introduction 
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sporozoites induces sterile protective immunity against parasite challenge [61, 62]. 
This immunity is targeted primarily against the intrahepatic parasite and appears to 
be sustained long term even in the absence of sporozoite exposure [62, 63]. The 
mechanisms are multi-factorial, encompassing both cell mediated and antibody 
mediated immunity [63, 64]. 
 
Extensive polymorphisms in the circumsporozoite protein exist in wild parasites 
and this is thought to indicate that it may be under direct immune selection 
pressure. However, studies have suggested that these polymorphisms are not 
necessarily a result of immune selection of parasites [65]. Possible alternative 
mechanisms for their development include adaptations to structural differences in 
salivary gland receptors of different mosquito vector species [66] or to hepatocyte 
receptors in different human populations [67]. Individuals in endemic areas are 
undoubtedly exposed to sporozoite proteins on a more or less regular basis, but 
the short time to re-infection in adults in all studies indicates that any naturally 
induced immunity to these antigens is not particularly effective [60]. Possible 
reasons for the low levels of naturally induced immunity compared to those 
induced experimentally to these stages include the difference in numbers (natural 
infections deliver 1-100 sporozoites per bite [68], whilst each individual was 
vaccinated with hundreds of thousands of irradiated sporozoites in order to 
achieve protection [62]), and the possible persistence of irradiated sporozoites in 
the liver (in experimental models attenuated sporozoites were present up to 6 
months after vaccination) [69]. Irradiated sporozoites have also been shown to 
induce hepatocyte apoptosis shortly after infection [70], dendritic cells may then 
phagocytose apoptotic infected hepatocytes containing parasite antigens, 
providing a pathway for presentation of sporozoite antigens to the immune system. 
In animal models of the irradiated sporozoite system, the CS protein has been 
shown to be immunodominant – responses against it are estimated to be 
responsible for 90% of the induced protection, although in this system, an immune 
response against PyCSP is not required for protective immunity [71]. 
 
In theory, antibodies against the circumsporozoite protein could prevent the initial 
event in the infection cycle and protect against disease. High titres of antibodies to 
CS are induced by irradiated sporozoite vaccination, and are largely directed Chapter 1 Introduction 
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against the immunodominant repeat (NANP)n region of CS, with small numbers of 
low level responses to other regions. In contrast, in individuals from an endemic 
region (in West Africa) high level antibody responses to several non repeat regions 
of CS were seen. Responses to the repeat region were also seen, but these were 
lower level responses, and were not present in children [72]. It therefore seems 
unlikely that this mechanism is important in protection from natural infections. 
Antibodies to other sporozoite antigens such as TRAP [73], liver stage antigen 1 
(LSA-1) [74] and STARP [75] are detectable following natural exposure to malaria 
infection, and these may have a role in blocking sporozoite invasion. However 
there is no clear evidence from field studies that the presence, or levels, of 
antibodies recognizing the sporozoite are related to protection against infection or 
disease [60]. 
 
Cell mediated immunity also has a significant role in the protective response. 
Immunisation of mice with irradiated sporozoites induces protection against 
malaria challenge [76]. Further studies showed that protection induced in this way 
was abrogated in T cell deficient mice, whilst B cell deficient mice were still 
protected [77]. It was subsequently shown that CD8+ T cells specific to an epitope 
within the CS protein were capable of conferring protection on mice [78]. This 
protective immunity to Plasmodium berghei sporozoite challenge could be 
transferred to other mice by transferring the T lymphocyte clones that were 
induced by irradiated sporozoites. T lymphocyte recognition of circumsporozoite 
protein-derived peptide on infected hepatocytes led to lysis of the infected cell and 
parasite death [79]. More recently, Doolan et al. [80] examined the responses that 
led to protection in inbred strains of mice, and established a marked diversity of T 
cell-dependent immune responses. They demonstrated a total of five distinct 
mechanisms of protective immunity, all of which were absolutely dependent on 
CD8+ T cells [80]. They have gone on to confirm IFN-γ as a critical effector 
molecule and to show that IL-4 secreting CD4+ T cells are required for induction of 
the CD8+ T cell responses, and Th1 CD4+ T cells provide help for optimal CD8+ T 
cell effector activity [63]. In natural infection, the draining lymph node may be the 
site at which the immune response to the sporozoite stage is initiated and it has 
been recently demonstrated that a sporozoite-specific cytotoxic T-cell (CTL) 
response is evident in the draining lymph node 2 days after intradermal Chapter 1 Introduction 
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immunization with irradiated sporozoites [81]. When the draining lymph node was 
surgically ablated to prevent early local priming, the number of sporozoite-specific 
CTLs in the liver was significantly reduced, highlighting the importance of skin-
draining lymph nodes in the initiation of the immune response to sporozoites 
during natural infection [81]. In humans there are several pieces of indirect 
evidence for a T lymphocyte role in protection. Firstly, human leukocyte antigen 
(HLA) class-I restricted T lymphocyte responses have been demonstrated in both 
residents of endemic areas repeatedly exposed to P. falciparum, and in malaria-
naïve volunteers protected from sporozoite challenge by irradiated sporozoite 
immunization [82-84]. T cells specific to P. falciparum epitopes were shown to be 
present in low levels in adult Gambians [85, 86]. Secondly, HLA-B*53, which 
restricts the immune response of CD8+ T lymphocytes, and HLA-DRB1*1302 
which restricts the immune response of CD4+ T lymphocytes, were associated 
with resistance to severe malaria in a large case-control study of Gambian children 
[87]. Cytotoxic T lymphocytes to a conserved P. falciparum epitope restricted by 
HLA-B*53 have been identified and these derive from the Liver Stage Antigens 
(LSA) LSA1 and LSA3 [83, 88]. Thirdly, some P. falciparum T lymphocyte epitopes 
are in highly polymorphic regions in which all nucleotide substitutions encode 
amino acid changes. The observation that no synonymous changes occur argues 
strongly that these regions are subject to selection pressure from T lymphocytes. 
This is supported by the identification of altered peptide ligand antagonism of T 
lymphocytes as an immune escape mechanism [89].  
 
Components of the innate immune system, including gamma-delta T cells, natural 
killer cells and natural killer T cells, also play a role in protection [63]. The precise 
nature of pre-erythrocytic stage immunity in humans, including the contribution of 
these immune responses to the age-dependent immunity naturally acquired by 
residents of malaria endemic areas, is still poorly defined. A CD4+ T cell response 
to an epitope from the CS protein has been strongly associated with protection 
both from infection and disease [90] in adults in The Gambia. However, it is likely 
that in the normal human population a variety of different mechanisms co-exist, 
with different individuals being protected by different mechanisms. 
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1.3.2  Erythrocytic Immunity 
The targets for responses against the blood stages of malaria infection are the 
emerging merozoites, and infected red blood cells. The process of invasion of red 
blood cells involves many parasite proteins, including the merozoites surface 
proteins MSP1 to 9, AMA-1[91-93] and some secreted proteins [94]. Antibodies to 
these proteins may prevent invasion of merozoites, although relatively few studies 
have confirmed this [95]. Some studies have concluded that antibodies against 
AMA-1 [96] and MSP-1 [97, 98] are associated with protection from clinical 
malaria, although this is not supported by others [99, 100]. These proteins are 
found to be highly polymorphic, which facilitates immune evasion by the parasite, 
and antibodies with slightly different specificities may be expected to vary in their 
ability to prevent invasion and protect against infection. It is possible that 
measuring absolute levels of antibodies is not helpful, and qualitative assessment 
of function may be a better measure of protection by these antibodies. Functional 
assays are not without their complications, as demonstrated by the studies that 
showed that purified antibodies reported to inhibit parasite growth in vitro are not 
associated with immunity from clinical malaria [101, 102]. 
 
The infected red cell displays a number of parasite proteins on its surface, again 
providing putative antigens for a host immune response. Plasmodium falciparum 
erythrocyte membrane protein 1 (PfEMP1) is a potentially important family of 
target antigens, because these proteins are inserted into the red cell surface and 
are prominently exposed. They are also highly polymorphic and undergo clonal 
antigenic variation [54], a mechanism of immune evasion maintained by a large 
family of var genes. Other highly polymorphic proteins may also be expressed on 
the cell surface, products of other multigene families such as rifs or stevor [103]. 
Antibody responses to some of these variants, but not others are associated with 
protection from malaria [104]. The association of responses to particular antigens 
and protection seems to vary with time and geographical setting. Responses to a 
restricted subset of these variants are associated with protection from placental 
malaria [105, 106]. The response to these gene families appears to be closely 
linked to the pathogenesis and severity of malaria infection [107].  
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Whilst antibody responses to the erythrocytic stages are clearly important, they are 
not the whole story. T cell immunity against blood-stage antigens can induce 
protection against P. yoelii murine malaria [108]. In humans, non-immune 
volunteers repeatedly challenged with low doses of blood stage parasites and then 
treated were immune to subsequent challenge [109]. These individuals did not 
have any detectable antibody response to schizont-stage (3D7 strain) soluble 
antigen or to recombinant MSP1, MSP2 or AMA1. However, cellular responses, 
including proliferative responses, interferon gamma production and raised 
concentrations of nitric oxide synthase, characteristic of a Th 1 type immune 
response were detected [109]. It is not clear what role responses like these may 
play in endemic areas. 
 
1.4  Vaccines for Malaria 
1.4.1  Background 
Vaccines have classically comprised either attenuated or inactivated pathogenic 
organisms, or antigens derived from them, delivered in such a way as to provide a 
‘depot’ of antigen together with an immunological adjuvant that will initiate an 
immune response via innate pathways. In applying this approach to malaria 
vaccine development, mature sporozoites were inactivated within mosquito 
salivary glands by irradiating the mosquitoes one hour before immunization, by 
exposing them to 15,000 rad of gamma radiation from a 
60Co or 
137Cs source. 
Humans ‘immunised’ by the bites of these mosquitoes were protected from 
subsequent malaria infection [61, 62]. These studies demonstrated that it was 
possible to achieve protection from malaria by vaccination. However, until recently 
it has been considered clinically and logistically impractical to immunise large 
numbers of people with irradiated sporozoites, primarily because individuals 
needed to receive more than 1,000 immunising bites before they were protected 
[62]. However, this approach is being investigated further by Hoffman et al., who 
have established a biotechnology company (Sanaria, [110]) to develop irradiated 
sporozoite vaccines, aiming to convert the current protocol for whole-parasite 
vaccination into a more practical parenteral immunization regime with 
cryopreserved parasites [111].  Chapter 1 Introduction 
  17 
 
The first clinical trials using a purified protein malaria vaccine began 20 years ago 
[112], but so far only volunteers immunized with vaccines based on the 
circumsporozoite protein have been reproducibly protected against P. falciparum 
sporozoite challenges. However, the protective immunity induced by the best 
circumsporozoite-protein vaccine is far lower [113, 114] than that induced by 
radiation-attenuated P. falciparum sporozoites [62]. The main explanation for this 
difference is thought to be related to the huge number of antigens presented in a 
whole parasite vaccine, compared to one single antigen contained in the vaccine 
[115]. Many approaches have therefore focussed on identifying other sporozoite 
antigens that may be important targets for protective immunity. Opinion is divided 
as to whether protective immunity relies on one, or many proteins, and whether 
the best vaccine will be one that combines several antigens or one that targets a 
single, immunodominant protein.  
 
The malaria vaccine candidate currently at the most advanced stage of 
development is a sporozoite vaccine, based on the circumsporozoite protein, and 
is named RTS,S. It consists of a protein particle vaccine in a complex adjuvant 
[116] (formulated with a variety of adjuvant systems, including AS01 and AS02). It 
is the result of a long-term collaborative programme between the Walter Reed 
Army Institute of Research and GlaxoSmithKline Biologicals, Rixensart, Belgium 
[117], and has been shown to confer complete or partial protection against 
experimental infection [113, 116]. Short-term protection against infection was 
shown in immunised adult men in Gambia in 1998 [118]. A study in 2004 
immunised children in Mozambique aged 1 to 4 years, this trial established that 
RTS,S reduced the risk of P. falciparum infection, uncomplicated malaria, and 
severe disease [114], and that this protection lasted for at least 18 months [119]. 
More recently, a phase I/IIb trial in infants in Mozambique has been reported [120], 
and although this trial was designed mainly to assess safety, it also had sufficient 
power to assess efficacy against new infections. Vaccine efficacy for new 
infections was 65% over a 3-month follow-up after completion of immunisations 
[120], considerably higher than previously reported efficacy, although confidence 
intervals overlap, so it is not a statistically significant change. Importantly, for the 
first time in this study, there was evidence of an association between vaccine Chapter 1 Introduction 
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induced anti-circumsporozoite antibodies and a reduction in the risk of infection. 
These findings clearly need to be corroborated, and phase III studies across Africa 
are planned.  
 
Other approaches to generating protective immunity against sporozoites have 
been explored, these are described in more detail in [121]. Particularly relevant to 
this thesis is a product developed by the Swiss biotechnology company Pevion 
Biotech. Ltd. This is a virosome based vaccine including two P. falciparum 
peptides. Virosomes (see Figure 1.3) are influenza derived virus-like particles, 
they incorporate the influenza virus haemagglutinin and neuraminidase proteins to 
facilitate antigen processing. There are currently two licensed virosomal vaccines: 
Inflexal V (Influenza) & Epaxal (Hepatitis A). 
 
Figure 1.3: Virosome 
Diagrammatic representation of a virosome, used in the production of the Pevion malaria 
vaccine. 
 
Cyclized, conformationally constrained peptides with lipid tails can be incorporated 
into the membrane of these immunogenic liposomes [122]. A Phase I clinical trial 
of a malaria vaccine using virosomes incorporating the Asn-Ala-Asn-Pro (NANP) 
repeat from CS protein or part of domain III of the blood-stage protein AMA1 
showed good safety and antibody immunogenicity [123]. One of the studies 
described in this thesis used a vaccine prepared from a mixture of these two 
virosomal formulations, and the vaccine is described in more detail in Chapter 4. 
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1.4.2  Development of a T Lymphocyte Inducing Vaccine 
In light of the important role of T cell mediated immune responses described 
above, an alternative rationale for the design of pre-erythrocytic vaccines targeting 
T cell immunity has been adopted by other groups. Although CD8+ T cells are 
important in most host–parasite combinations in mice, CD4+ T cells may also be 
required for protection [64, 80]. Results from adoptive-transfer experiments with T 
cell clones specific for the CS protein or TRAP (thrombospondin-related adhesion 
protein, also known as SSP2) in mice [78, 124], and  evidence of an HLA class I 
association with malaria resistance in Gambian children [83], have also 
encouraged pursuit of this cell mediated mechanism. A peptide-based approach 
using allele-specific motifs was applied to several other class I HLA molecules. In 
total fourteen class I epitopes were identified in six pre-erythrocytic P. falciparum 
antigens [82]. In a series of immunisation studies in mice, various potential vaccine 
types (recombinant particles, peptides, plasmid DNA, numerous adjuvants and 
recombinant vectors such as recombinant BCG, Salmonella, adenovirus, MVA and 
FP9), encoding malaria epitopes and antigens, were compared [125, 126]. Most of 
these approaches induced only modest levels of T cell immunogenicity that 
invariably failed to protect against sporozoite challenge.  
 
However, a priming immunisation with plasmid DNA encoding an entire P. berghei 
pre-erythrocytic antigen followed by a booster immunisation with a MVA vector 
carrying the same antigen induced complete protection [126] in strains of mice 
highly susceptible to sporozoite challenge [127]. Protection was associated with 
very high frequencies of splenic peptide-specific interferon-γ (IFN- γ) secreting 
CD8+ T cells, and the level of these cells measured in IFN- γ enzyme-linked 
immunospot (ELISPOT) assays correlated well with protection. The US Navy 
group have reported similar results for P. yoelii malaria using NYVAC (a highly 
attenuated vaccinia virus, New York Vaccinia) as the boosting vector [128].  
 
The highest T-cell immunogenicity and efficacy has been achieved with 
heterologous prime–boost approaches, in which a pox virus vector is used as the 
boosting agent [127, 129-133]. In these vaccine regimens, two different vectors 
are usually used, each encoding the same malaria antigen. Plasmid DNA, and Chapter 1 Introduction 
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vectors derived from pox viruses such as the attenuated orthopoxvirus, modified 
virus Ankara (MVA) and an attenuated strain fowlpox virus (FP9), as well as 
adenoviruses have been used in these regimens. Part of the enhanced T cell 
immunogenicity of these systems can be attributed to the avoidance of the effect 
of anti-vector immunity that tends to impair the boosting capacity of other 
vaccines. Other factors are probably also important, including the ability of some of 
these viruses to boost pre-existing T cell responses.  
 
Viral vectored vaccines act as an attenuated pathogen with intrinsic innate-
stimulatory activity, and encode an antigen of choice against which an immune 
response is desired. The antigen is incorporated into the DNA sequence of the 
virus, and the vector then expresses the antigen as though it were a viral protein 
(i.e. within the infected cell cytoplasm). From here the antigen is processed via the 
endogenous pathway and epitopes are presented on major histocompatibility 
complex (MHC) class I molecules to CD8+ T cells [134]. Dendritic cells (DCs) are 
professional antigen presenting cells (APCs), and are therefore able to acquire the 
antigen by direct infection with the virus. Alternatively, a process of cross-priming 
can occur – infected macrophages providing a source of antigen, which is taken 
up from infected or dying cells and debris. Antigen taken up in this way enters the 
alternative exogenous processing pathway, and it is presented by MHC class II to 
CD4+ T cells [135]. Poxviruses, and in particular vaccinia, were the first viruses to 
be investigated as antigen-encoding vectors. This followed the observation that 
vaccinia was a highly immunogenic vector for generating cell-mediated immunity 
in the form of T cells [136]. Following vaccination with vaccinia, the migration of 
infected APCs to draining lymph nodes is a rapid process, peaking at 6 hr and 
declining rapidly thereafter [134]. It was concluded that early antigen expression is 
essential for CD8+ T cell induction, but these cells need only a brief contact with 
antigen to proliferate [137]. These viruses also contain pathogen associated 
molecular patterns, which may be recognised by various pattern recognition 
receptors, including members of the Toll-like receptor family. This provides a 
mechanism for stimulation of the innate immune response. The characterization of 
the innate immune responses generated by infection of cells by pox viral vectors is 
the subject of current investigation in the author’s laboratory [135]. 
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Studies by various groups have now found that prime-boost using poxviruses is 
highly immunogenic for CD4+ and CD8+ T cell induction against, tuberculosis 
[138], HIV [139, 140], and Ebola (DNA/adenovirus) [141] and cancer [142].  
 
1.4.3  Malaria Vaccine Studies at the University of Oxford 
A series of Phase I/IIa clinical studies have been carried out at the University of 
Oxford since 1999. These have assessed the prime-boost immunisation approach 
in healthy, malaria-naïve human volunteers. These studies, using a variety of 
vaccines, encoded either by DNA, or viral vectors, have demonstrated safety and 
immunogenicity, with significant ex vivo ELISPOT responses [133, 143, 144].  
Following immunisation subjects are invited to participate in a subsequent 
challenge study, where they are infected with the 3D7 strain of P. falciparum under 
close observation to assess vaccine efficacy.  
 
In this work, the most extensively studied T-cell antigen has been the sporozoite 
antigen TRAP fused to a multi-epitope string of mainly CD8+ T-cell epitopes from 
six pre-erythrocytic antigens [145]. Most T-cell responses induced by these 
vectors are specific for the TRAP component, with the smaller multi-epitope string 
being less immunogenic [146]. These vaccination regimens induce mainly CD4+ T 
cell immune responses against TRAP. Boosting plasmid DNA with an MVA 
vaccine vector encoding ME–TRAP amplified T cell responses and induced a 
significant delay in time to parasitaemia in sporozoite-challenge studies [146].  
 
More recently, the vector FP9 was incorporated into this strategy. Using two pox 
viruses in this heterologous prime boost system resulted in complete protection 
against heterologous malaria challenge in two out of five vaccinated subjects who 
had received two doses of FP9 ME-TRAP followed by one dose of MVA ME-TRAP 
[132]. Furthermore, several immunisation regimes using the ME-TRAP insert have 
led to highly statistically significant delays in time to patient parasitaemia. As in all 
studies with CS protein and ME–TRAP vectored vaccines, antibody levels induced 
by this regime were low or absent and were not associated with protection. 
However, both ex vivo and cultured IFNγ ELISPOT assays, which measure mainly 
effector and central memory T cells, respectively, showed association with Chapter 1 Introduction 
  22 
protection [132, 147]. The ME–TRAP vaccine that was delivered using an FP9–
MVA regime has been found to be immunogenic in Gambian [148] and Kenyan 
adults [149]. These findings led to a Phase IIb efficacy trial in Kenyan children to 
assess protection against febrile malaria, but this study did not demonstrate any 
efficacy [150]. A prime–boost vaccination regime, using recombinant viral vectors, 
may provide one avenue against infections such as the liver stage of malaria. 
Evidence suggests that effective regimens will include a prime with a vaccine 
which generates good memory  responses, followed by a boost with a vaccine that 
generates a strong secondary effector and central memory response.  
 
1.5  Vaccine Vectors 
1.5.1  Modified Vaccinia Virus Ankara (MVA) Vector 
Modified Vaccinia virus Ankara (MVA) is derived from the vaccinia virus. The 
successful worldwide eradication of smallpox by vaccination with live vaccinia 
virus highlighted it as a candidate vaccine vector. However, the small but definite 
risk of live vaccinia virus (both to researchers and future patients) led to the 
development of several strains of attenuated virus, both during the smallpox 
vaccination campaign, and more recently. MVA is one of these strains, and 
recombinant MVA is attractive as a vector for several reasons, for safety - 
particularly because the host-range restriction of MVA is extremely attenuated 
compared with other vaccinia viruses, it has demonstrated immunogenicity, and 
avirulence in animal models as well as an excellent safety record as a smallpox 
vaccine [151].  
 
MVA was originally derived from the vaccinia strain Ankara by over 500 serial 
passages in primary chicken embryo fibroblasts. The passage attenuation of the 
virus resulted in around 31 kb of genomic deletions. These comprise six major 
genomic deletions compared to the parental Ankara genome and as a result, MVA 
is severely compromised in its ability to replicate in mammalian cells. No 
replication has been documented in non-transformed mammalian cells [151]. 
Thus, MVA has a large recombinant DNA capacity to accommodate large 
antigens, such as those from malaria.  Chapter 1 Introduction 
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MVA also showed no cytopathic effect or plaque formation in cells of human origin. 
In irradiated mice MVA did not elicit any morbidity or lethality even when 
administered at high doses intra-cerebrally, indicating its safety even in immuno-
compromised organisms [152]. The viral genome has been proven to be stable 
through a large series of passages in chicken embryo fibroblasts. Using restriction 
enzyme analysis virtually no difference was observed between passage 500 – 572 
[152]. 
 
Apart from studies in mice, rabbits and elephants [153] MVA has been shown to 
be safe in humans. From 1972 until 1980 (the end of compulsory smallpox 
vaccination) MVA was licensed in Germany [153] and was included in the official 
immunisation schedule [154]. In a large field study carried out in Germany in the 
late 1970s, over 120,000 previously unvaccinated individuals were vaccinated with 
MVA (0.2 mL) administered either intra-dermally or subcutaneously. The study 
population included high-risk groups (e.g. people suffering from allergies, elderly 
people, alcoholics). Given intra-dermally, a red nodule of up to 4 mm in diameter 
was observed at the injection site at day 4 or 5. Only a small proportion showed 
any systemic side effects, such as fever over 38.5°C [152]. MVA proved to be non-
contagious and avirulent. Viral replication is blocked late during infection of cells 
but importantly viral and recombinant protein synthesis is unimpaired even during 
this abortive infection. Replication-deficient recombinant MVA has been viewed as 
an exceptionally safe viral vector. When tested in animal model studies 
recombinant MVAs have been shown to be avirulent, yet protectively immunogenic 
as vaccines against viral diseases and cancer [152]. Recent studies in macaques 
severely immuno-suppressed by SIV infection have further supported the view that 
MVA should be safe in immuno-compromised humans [155]. 
 
Compared with vaccinia, MVA lacks certain immune-suppressive signalling 
molecules and soluble receptors, making it potentially more immunogenic [151]. It 
does however retain the ability to induce type I IFN expression in infected cells 
and this may have a profound contribution to an enhanced generation of memory 
T cells by direct cytokine action [156]. MVA gene expression in mature and Chapter 1 Introduction 
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immature dendritic cells (DCs) is restricted to viral early gene transcription. In 
general MVA is more efficient at infecting immature DCs as measured by 
transgene expression, however both serve as functional antigen presenting cells 
(APC) to stimulate class I T cell responses [157]. Although MVA infection of 
murine DCs in vitro reduces MHC class I expression and T cell stimulatory 
capacity, and causes cell death, MVA-infected murine DCs retained their ability to 
generate a CTL response in vivo, [158], perhaps by providing a source of 
immunogenic antigen for cross-priming. Indeed, mice administered MVA showed 
an overall enhanced T cell stimulatory capacity of their DCs. Furthermore, co-
administration of MVA with antigen was shown to generate enhanced T-cell and 
antibody responses, suggesting that the virus has potent adjuvant activity [159]. 
 
All MVA constructs are made by ligating the selected sequence into the vaccinia 
shuttle vector pSC11, placing it under the control of the vaccinia P7.5 early/late 
promoter. This vector also encodes a copy of the β-galactosidase gene to allow 
plaque picking [160]. 
 
1.5.2  Fowlpox Strain FP9 Vector 
Fowlpox virus is a member of the avian poxvirus family and is an obligate 
pathogen of chickens causing cutaneous or mucosal symptoms. FP9 is a highly 
attenuated form of an avian pox virus derived by 438 serial passages of the wild-
type fowlpox virus HP-1 [161], giving rise to 25 kb of genomic deletions. It was 
originally developed and used as a vaccine for poultry, but its ability to infect 
mammalian cells and produce proteins without replicating [162] led to interest in its 
use as a recombinant viral vector for mammalian, including human, vaccination.  
 
FP9 was shown to be an effective vector, delivering antigen to both human and 
murine dendritic cells. Murine DCs infected with fowlpox vectors were shown to be 
potent at stimulating transgene-specific CD8+ T cells for up to 3 days and also up- 
regulated MHC and co-stimulatory molecules [163]. Human DCs were able to 
express the transgene for up to 20 days [163]. This suggests that fowlpox may be 
less cytopathic than MVA and allow for longer transgene, and hence antigen, Chapter 1 Introduction 
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expression. The FP9 genome has now been sequenced and found to have 118 
mutations when compared to the pathogenic US fowlpox strain [164].  
 
FP9 recombinants are constructed using an established protocol [165]. The DNA 
sequence of interest is ligated into the SmaI cloning site of the Fowlpox shuttle 
vector pEFL29 [165] placing expression of this gene under the control of the 
vaccinia virus P7.5 promoter. The pEFL29 plasmid also encodes a copy of the β-
galactosidase gene under the control of the FP4b fowlpox late promoter, allowing 
identification of recombinant viruses by X-gal staining as described previously for 
vaccinia virus [160]. Recombinant viruses are prepared by in vitro recombination 
of the shuttle vector with the FP9 fowlpox strain in primary cultures of chick 
embryo fibroblasts (CEF). Recombinant viruses are repeatedly plaque purified in 
CEF monolayers until homogenous.  
 
1.6  Contribution of this Thesis 
The work in this thesis comprises a variety of laboratory based studies, 
computational modelling and clinical trials. A summary of each chapter follows. 
 
1.6.1  Clinical Trials 
Chapter 2 beings by outlining the basic methods required for performing small 
scale clinical trials for the testing of candidate malaria vaccines. Although 
Professor Hill’s group at the University of Oxford has been conducting similar 
studies for some years, some changes needed to be made to comply with new 
legislation. This work was required because of the introduction of the Medicines for 
Human Use (Clinical Trials) Regulations [166] in 2004, requiring that all trials be 
conducted according to strict principles of Good Clinical Practice. The chapters 
that follow describe two such clinical trials, namely VAC027 and VAC030. These 
were both Phase I/IIa clinical trials, conducted in Oxford, in healthy, malaria naïve 
volunteers. 
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1.6.2  VAC027 
VAC027 was a study consisting of both a vaccination and a challenge protocol. 
The vaccines used were novel candidate malaria vaccines, found to be 
immunogenic in mice [167]. MVA and FP9 were used as vectors, and an insert 
coding for 6 malaria antigens (the ‘polyprotein’) was designed. The idea of 
combining multiple antigens into one vaccine has been used before [168] with 
some success (of 35 volunteers challenged, one was protected from malaria and 
there was a delay in time to infection in the other vaccinated volunteers). The 
hypothesis behind the design of the polyprotein vaccine was that multiple antigens 
would broaden the target antigen range of vaccine-induced immunity and increase 
the number of potential epitopes available for immunogenetically diverse human 
populations. Also, inducing responses against multiple antigens should prevent the 
development of escape mutants of P. falciparum. As described earlier, the 
mechanism for protection in irradiated sporozoite immunisation clearly involves 
multiple antigens, and so a multi-antigen vaccine is a logical step. The main focus 
of this trial was to establish the safety and immunogenicity of the new vaccines, 
but two groups of immunised volunteers went on to participate in a subsequent 
challenge study to assess efficacy. Chapter 3 describes the conduct of this trial 
and the methods that were specific to this study. The outcome measures used for 
this study, of safety, immunogenicity and efficacy are then detailed, and the results 
for each outcome are reported.  
 
1.6.3  VAC030  
VAC030 was designed to test a novel approach to improving the immunogenicity 
of vaccines – combining existing vaccine strategies with the hypothesis that they 
might work synergistically. This was suggested as a strategy following some 
animal studies that combined partially protective antibody and T cell inducing 
vaccines, and found evidence of substantially increased protection [169]. The 
vaccines used in the human trial were FP9 and MVA ME-TRAP, a vaccine with a 
well characterised response, which has been shown to be partially protective 
[132]; and the virosomal vaccine PEV3A. PEV3A consists of a combination of two 
virosomal formulations, one containing a peptide derived from the (NANP) repeat Chapter 1 Introduction 
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of the CS protein, and the second containing a peptide from the blood stage 
antigen AMA-1. The idea of combining an antibody inducing and a T cell inducing 
vaccine regimen also appeals as inducing responses in both humoral and cell 
mediated arms of the immune system would intuitively improve the efficacy of 
such a vaccine. This trial was designed to test the efficacy of these two vaccine 
regimens in combination. In Chapter 4, the planning, administration and specific 
methods for this study are reported, along with the results for each of the outcome 
measures. Additional analyses performed after the trial was completed are also 
reported in this chapter. A report of this study, written by the author, has been 
published [170] and is included as Appendix 5. 
 
1.6.4  Lab Work 
Chapter 5 contains a description of laboratory studies, undertaken to further 
investigate the antigens used in the polyprotein vaccine of VAC027. The aim was 
to investigate the presence and size of immune responses to these antigens in an 
African population, naturally exposed to malaria infection. Both cellular and 
antibody mediated immune responses were examined. Responses were 
correlated with time to malaria infection in an attempt to identify which antigens 
might be important in mediating protection. This approach, though limited [60], can 
provide indications of potentially important antigens, and may inform further 
vaccine development. The work described in this chapter was presented by the 
author, at the Multilateral Initiative on Malaria meeting in Yaoundé, Cameroon in 
November 2005 [171]. 
 
1.6.5  Parasite Life Cycle Modelling  
Chapter 6 reviews the literature on parasite modelling, describing the most 
relevant methods and their relative advantages and disadvantages. Two of these 
models are then selected, as the most relevant for the studies described here, and 
used to perform a comparison, using data from the clinical trial VAC030. One 
model is selected as providing the most accurate estimation of both parasite 
growth rates, and the estimated numbers of infected hepatocytes. This model is 
then used to analyse data from VAC027, and from other clinical trials conducted Chapter 1 Introduction 
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by the University of Oxford. Although multiple models of parasite growth within the 
human host have been published, no such comparison, using data obtained in 
vivo, has been performed previously. 
 
1.6.6  Challenge Safety Data 
The final chapter of this thesis takes advantage of the unique data set that 
performing malaria challenge studies provides. In every challenge study, a group 
of unvaccinated, malaria naïve, control volunteers are infected with malaria. The 
data collected from these volunteers provides an ideal opportunity to study early 
malaria infection. The recorded symptoms from control volunteers from each 
challenge study performed in Oxford to date are collated to provide an account of 
common symptoms, and the relationship of symptoms to parasitaemia is 
examined. A recent paper published by the US navy group [172], has also 
undertaken such a review, although the data set described in their paper is limited, 
and includes both vaccinated and unvaccinated individuals. This chapter has the 
advantage of describing a larger data set of only unvaccinated control individuals. 
A comparison of the Oxford data and the published US Navy data is reported. 
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Chapter 2   Vaccine Trials 
Background 
2.1  Introduction 
This chapter briefly reviews the methods used to perform clinical trials of novel 
malaria vaccines. The purpose is to describe the preparation, procedures, and 
administration required to undertake a successful small scale clinical trial of a 
vaccine. These procedures were used to conduct both of the trials described later 
in this thesis. The topic of vaccine development and study design is complex, and 
beyond the scope of this thesis, but an introduction is included here to put the rest 
of the work in context. 
 
2.2  Vaccine Development 
A Phase I clinical study tests a new vaccine or drug in humans for the first time. 
Phase I studies are therefore carried out in healthy volunteers, with the aim of 
determining the safety of the new product. If the Phase I study is successful, the 
vaccine or drug proceeds on to Phase II studies. In malaria vaccine development, 
a phase IIa study tests efficacy in healthy volunteers, whilst a Phase IIb looks at 
efficacy in a population where malaria is endemic, again in healthy volunteers. 
Phase III studies are larger, field trials, performed in the target population for the 
vaccine, designed to demonstrate efficacy in a variety of settings. Phase IV 
studies are undertaken once a drug or vaccine is licensed by a regulatory 
authority, these involve long term safety data collection. 
 
The malaria vaccine studies performed in Oxford by Professor Hill’s group are 
commonly Phase I/IIa clinical trials. These studies aim primarily to look at the 
safety of a vaccine in humans. As a first step it is important to evaluate a new 
vaccine in completely healthy individuals, before it can be given to those with other 
illnesses. A vaccine is administered to a small number of healthy volunteers, who Chapter 2 Vaccine Trials 
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are then followed closely, and any side effects or adverse reactions recorded. A 
new vaccine is usually tested at a variety of different doses and safety is assessed 
by monitoring routine serum biochemistry and haematological parameters. Blood 
samples taken from volunteers in these Phase I studies also provide an 
opportunity to look at any immune responses that the vaccine may have produced.  
 
Despite decades of research in this area, there is no single immunological 
correlate of protection from infection with malaria. In order to test new vaccines, 
vaccinated volunteers are therefore challenged with malaria infection. A Phase IIa 
malaria challenge study provides a way of obtaining biologically relevant data 
concerning the efficacy of the candidate vaccine. Previously, challenge studies for 
malaria and other infectious diseases have provided important information about 
innate and acquired immune responses to infectious pathogens. They are now 
also used to demonstrate protection against a defined strain of organism in a 
controlled setting. In this case, a volunteer is given the potential vaccine and then 
infected with malaria. Immunity to the disease is monitored and if parasites are 
observed the volunteer is swiftly treated with effective therapy before the disease 
is established. By this means, efficacy can be assessed in a small number of 
volunteers more rapidly than through natural exposure. Data obtained in this way 
can provide compelling evidence that would otherwise require much greater 
numbers of volunteers in Phase II-III studies. The specific issues raised by these 
sorts of challenge studies are discussed in section 2.3, and in more detail in [173]. 
 
Once a vaccine has gone through these stages, and there is some evidence of 
'proof of concept', it can be taken on into larger Phase IIb and Phase III studies. 
These are studies that take place in areas where malaria is endemic, for instance 
in Africa and India. Vaccines are generally field-tested first in adults in endemic 
areas, but because most adults have substantial immunity from natural exposure 
and develop malarial disease less often than children, this might be an insensitive 
means of testing partially effective vaccines. Children and infants, particularly in 
Africa, represent the most important target population for new vaccines and 
efficacy against clinical malaria can be measured in samples of a few hundred 
children. Two measures of efficacy are commonly used: a reduction in disease 
incidence rate and a reduction in overall cases per unit time. For vaccines with a Chapter 2 Vaccine Trials 
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short duration of efficacy, these numbers can differ significantly. Opinions also 
differ on the importance of demonstrating efficacy against severe malaria before a 
vaccine is licensed. This would involve studies of many thousands of children, but 
as, for some vaccines, efficacy might be greater against severe malaria than 
uncomplicated malaria [114], this approach may be necessary. 
 
2.3  Challenge Studies – Ethical Issues 
Malaria is unusual in that the efficacy of vaccines can be tested in small numbers 
of individuals as part of a phase IIa study, by infection with Plasmodium 
falciparum. The deliberate infection of healthy volunteers with a potentially fatal 
disease raises concern about the potential for causing harm, and the lack of any 
tangible benefit for the volunteer taking part. Guidelines produced by the Royal 
College of Physicians on this issue introduce the concept of ‘minimal harm’, and 
stipulate that - “However valuable the research, the degree of risk of harm can be 
no more than ‘minimal’” [174]. The potential risks to volunteers must be within 
acceptable limits, as assessed by an Ethics Committee – the key issue to consider 
is whether the study puts those participating at an unacceptable level of risk. All 
studies must also obtain approval from the MHRA. A malaria challenge study is 
considered as an additional protocol within the Clinical Trial Authorization 
package, as it is an outcome measure to determine the efficacy of the vaccine. 
The risks involved in these trials may be minimized by careful consideration of 
protocols for vaccination and challenge, with emphasis on ensuring safety of 
participants.  
 
These clinical challenge models benefit from the ability of drugs to effect sterile 
clearance of fully characterized, drug-sensitive P. falciparum parasites. Insectary-
reared Anopheles stephensi mosquitoes are fed with blood containing 
gametocytes of the 3D7 strain of P. falciparum and five infectious bites (containing 
sporozoites) are administered to each vaccinee or non-vaccinated control. The 
method is discussed in section 2.4.5, and in detail in chapter 7 of this thesis. At 
least two endpoints are of interest: the proportion of vaccinated volunteers who are 
fully protected and the delay in time to infection, assessed by blood-film 
microscopy, in partly protected vaccinees. All non-vaccinated volunteers should Chapter 2 Vaccine Trials 
  32 
develop malaria with a mean time to patency of about 11 days. A substantial 
reduction in the number of sporozoites or liver-stage parasites will delay the mean 
time to patency, providing a measure of partial efficacy.  
 
The selection of appropriate volunteers is particularly important for these challenge 
studies. The primary determinant of inclusion/exclusion criteria should be the 
safety of the volunteers, taking into account scientific and social issues (such as 
previous malaria infection). The studies are also constrained by the limitations of 
language, to recruit only volunteers who are fluent in English - safety is the prime 
concern, where signs and symptoms of early disease are likely to be subtle and 
may be missed if communication with study staff is suboptimal. The process of 
obtaining informed consent is vital, volunteers must clearly understand the 
potential risks involved in taking part in one of these studies. Long, detailed 
information sheets reflect the complexity of the trials, and the amount of important 
information required for a volunteer to give their fully informed consent. The study 
is explained with an emphasis on their safety to each prospective volunteer in 
great detail before they agree to participate. The consent form makes it clear that 
while volunteers are free to withdraw at any time, if they do so after being infected 
with malaria, they must take a course of anti-malarial medication. 
 
2.4  Performing Vaccine Trials 
Once a research question has been defined, and it is decided that a clinical trial is 
required to provide an answer, trial planning begins. The MRC and the 
Department of Health have jointly designed a website, the Clinical Trials Tool Kit 
[175] http://www.ct-toolkit.ac.uk/ and this provides an overview of the necessary 
steps. They have produced a flow chart to guide researchers through the process, 
a copy of which is included in Figure 2.1. 
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Figure 2.1: Flow chart 
Flowchart for planning a new study, from Clinical Trials Tool Kit [175]. 
 
 
Before detailed planning can start, the roles of the key parties need to be defined. 
Under the 2004 Medicines for Human Use (Clinical Trials) Regulations [166], a 
Sponsor, and an Investigator must be appointed, each having specific 
responsibilities to fulfil. A source of funding also needs to be identified, and it is 
usually necessary to have a clear idea of the outline of the trial and main 
objectives in order to secure funding.  
 
The design of a clinical trial is determined by the main objectives of the study, and 
the procedures used to measure these outcomes. The primary objective of each 
study is agreed upon by the Investigators and Sponsors of the trial, often following 
a process of negotiation. Once these principal objectives and outcome measures 
have been agreed, then a trial protocol can be written. Each clinical trial that is 
performed requires a clear and detailed protocol. This describes what is to be 
tested, and exactly how it is to be tested, what the expected outcomes might be, 
and how the Investigators will know if the trial has been successful. The protocol Chapter 2 Vaccine Trials 
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must specify all the procedures to be carried out during the trial, and refer to 
standard operating procedures where applicable. A template protocol was 
designed by the author to assist in protocol development for malaria vaccine 
studies, to ensure all essential information has been included. This template is 
attached as appendix 1. Multiple other documents are also needed, including 
information sheets, consent forms, GP information, adverts, Investigators 
Brochure (IB) – a document containing information concerning the vaccine (or 
other medicinal product) and/or Investigational Medicinal Product Dossier (IMPD), 
which contains more detailed information concerning the design and manufacture 
of the vaccine, quality control procedures, conditions for storage and use. The 
information required for each of these documents must be collected and collated, 
and each document drawn up according to the relevant guidance (either European 
guidance, or that issued by the UK regulatory authority, or the National Research 
Ethics Service), in preparation for submission. 
 
All clinical trials that are carried out in the UK must be conducted in accordance 
with the Declaration of Helsinki [176] and the principles of Good Clinical Practice 
(GCP) [177]. The World Medical Association developed the Declaration of Helsinki 
as a statement of ethical principles to provide guidance to physicians and other 
participants in medical research involving human subjects. This document [176] is 
publicly available and on the internet at http://www.wma.net/.  
 
The International Conference on Harmonisation (ICH) tripartite Good Clinical 
Practice (GCP) guideline [177] (http://www.ich.org/) was amended and finalised on 
10th June 1996 and also adopted by the European Union Committee on 
Proprietary Medicinal Products (CPMP) in June 1996. This is an international 
ethical and scientific quality standard for designing, conducting, recording and 
reporting trials that involve the participation of human subjects. Compliance with 
GCP provides public assurance that the rights, safety and well being of the trial 
subjects are protected, and that the clinical trial data are credible.  
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2.4.1  Gaining Approval – MHRA, NRES  
Under the Medicines for Human Use (Clinical Trials) Regulations [166], all clinical 
trials carried out in the UK, or by a UK sponsor, must be approved by a recognised 
ethics committee, such as one of the Oxfordshire Research Ethics Committees 
(Committee A, B or C), and by the Medicines and Healthcare products Regulatory 
Agency (MHRA). Prior to applying for approval all trials must registered on a 
European database of clinical trials, the EudraCT database, when they are issued 
with a EudraCT number. Each protocol also requires an ethics reference number, 
usually supplied when the protocol is registered for submission. 
 
The National Research Ethics Service (NRES) replaced COREC on the 1st April 
2007. The studies outlined in this thesis were completed before this date. 
Application for ethical approval requires completion of a standard on-line 
application form [178], and submission of this along with the trial protocol, and 
other supporting documentation to a recognised ethics committee. The supporting 
documentation required include: volunteer information sheets, consent forms, and 
any advertising material, along with an Investigators Brochure. As the clinical trials 
included in this study were both Phase I/IIa studies, involving healthy volunteer 
subjects, it was possible to submit directly to the Oxfordshire Research Ethics 
Committee A, who were specifically designated a Phase I committee. The ethics 
committee consider the ethical aspects of the research, from the information 
provided to potential participants, to the conduct of the trial, and the potential 
impact of the research.  
 
Submission to the MHRA for a Clinical Trial Authorisation (CTA) can be performed 
in parallel with the ethics process. Again, this submission requires completion of 
an online application form and the provision of supporting documentation. The 
MHRA requires detailed information about the vaccine (or other medicinal product) 
to be used in the study, including information concerning its manufacture, storage, 
use and disposal after the study. In addition the MHRA will consider the study 
protocol and other documentation.  
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Following consideration by the relevant authorities, the study may receive a 
favourable ethical opinion, and a Clinical Trial Authorisation. No study related 
procedures can be carried out before both of these approvals have been received. 
 
2.4.2  Gaining Approval - GMSC and GTAC 
Whilst all clinical trials must be approved by the MHRA and a recognised ethics 
committee, there are some additional requirements for the malaria vaccine studies 
described in this thesis. This is because some of the vaccines used in the studies 
described are based on live viruses, which have been genetically modified.  
 
Genetic modification means the altering of the genetic (‘heritable’) material of an 
organism using a method that does not occur naturally by mating and / or 
recombination. Under the Contained Use Regulations [179] all genetic modification 
work is controlled by requirements of the Health and Safety Executive. All work 
involving Genetically Modified Organisms (GMOs) which is carried out must be 
assessed and appropriate containment measures approved, by the local NHS 
Trust’s Genetic Modification Safety Committee (GMSC). ‘Work’ with GMOs 
includes (but is not limited to) their culture, storage, transport, destruction or 
disposal. 
 
A risk assessment is needed, and the results must be submitted to the GMSC for 
review. The committee reviews the project in two phases, looking at the 
containment level required to undertake the project, and the feasibility of providing 
that containment in the proposed premises. The approval of the local GMSC must 
be submitted to the MHRA before they will issue a Clinical Trial Authorisation. 
 
In addition, the Gene Therapy Advisory Committee (GTAC) is legally required to 
give approval for any clinical trials involving ‘gene therapy’. The definition of gene 
therapy in the European legislation is "… [a] gene therapy medicinal product shall 
mean a product obtained through a set of manufacturing processes aimed at the 
transfer, to be performed either in vivo or ex vivo, of a prophylactic, diagnostic or 
therapeutic gene (i.e. a piece of nucleic acid), to human/animal cells and its 
subsequent expression in vivo. The gene transfer involves an expression system Chapter 2 Vaccine Trials 
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contained in a delivery system known as a vector, which can be of viral, as well as 
non-viral origin. The vector can also be included in a human or animal cell." [180]. 
This has been interpreted very broadly by the Department of Health, and GTAC’s 
definition of gene therapy is as follows:  
"The deliberate introduction of genetic material into human somatic cells for 
therapeutic, prophylactic or diagnostic purposes."  
This includes techniques for delivering synthetic or recombinant nucleic acids into 
humans: 
genetically modified biological vectors (such as viruses or plasmids) 
genetically modified stem cells 
oncolytic viruses 
nucleic acids associated with delivery vehicles 
naked nucleic acids 
antisense techniques (for example, gene silencing, gene correction or gene 
modification) 
genetic vaccines 
DNA or RNA technologies such as RNA interference 
xenotransplantation of animal cells (but not solid organs). 
Trials using virally vectored vaccines to induce an immune response are therefore 
classified as gene therapy. GTAC therefore needs to be informed of the live, virally 
vectored vaccines to be used. More recently, GTAC have been designated a 
recognised ethics committee by the NRES, and so the two requirements of ethical 
and GTAC approval are combined into one application. 
2.5  Trial Documentation 
2.5.1  Trial Master File  
The process of applying for and gaining approval for a given clinical trial requires 
the collation of large amounts of relevant information concerning the 
investigational vaccine, and the methods to be used to assess its safety, and 
where appropriate, efficacy. The guidelines for GCP lay out the essential 
documents for the conduct of a clinical trial. These are not all required for 
submission to the regulatory authority, or to the ethics committee, but must 
nevertheless be produced and stored. The ‘Essential Documents’ are those which Chapter 2 Vaccine Trials 
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“individually and collectively permit evaluation of the conduct of a trial, and the 
quality of the data produced” [177]. These documents serve to demonstrate the 
compliance of the Investigator, Sponsor and Monitor with the standards of GCP 
and applicable regulatory requirements. They are collected within a Trial Master 
File, which is held by the Investigator. 
 
2.5.2  Case Report Forms 
Before the study can begin, the Investigator must have a method in place for 
collecting all the data required in the protocol. Each subject in the study must have 
a case record form, which contains all the information relating to that subject, and 
has space for entering details concerning the vaccines administered, as well as 
any adverse reactions or other events that occur throughout the study. These can 
be either paper or electronic, although specific requirements are made of 
electronic CRFs, so that any changes made to the data can be tracked, and the 
individual making the change, and the date on which it was made, can be traced. 
For the trials described, the Investigators elected to use an electronic system, 
capturing data from each study visit directly onto a web based database. The 
software was provided by a company called StudyBuilder™, and the case report 
forms for each study were designed and built by the Investigators. This was a 
process that required substantial testing and reformulation until a satisfactory set 
of forms were produced. These were then used for the study, and all data was 
stored securely on a server owned by the University of Oxford. The advantage of 
this system was that all the data could be exported directly into a spreadsheet 
such as Microsoft Excel ™ for analysis. It was also intended to be flexible, allowing 
the Investigators to design different forms for each trial, and accessible over the 
internet, so data could be added from wherever a study visit or procedure was 
taking place. Unfortunately, although the system was flexible, designing the forms 
and questions required a considerable amount of computer coding expertise, and 
the interface provided was not user friendly. It provided a secure method for data 
capture for the two studies described here, but will not be used within the group for 
any future studies. 
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2.5.3  Trial Monitoring 
Another of the stipulations of GCP is that trials are adequately monitored. This 
process is performed by an appropriately trained Monitor, who is appointed by the 
Sponsor of the study. The Monitor visits the study site before the trial begins, to 
ensure all the trial related documentation is in place, and the facilities are 
adequate, and that the vaccine or other investigational product is ready and 
correctly labelled and stored. The Monitor may then visit on a number of occasions 
during the trial, and then again, once the trial is over.  The Monitor’s role is clearly 
defined in GCP: they are required to ensure that the trial is conducted and 
documented properly. They need to verify independently that the trial is carried out 
according to the protocol, and that any deviations from the protocol are 
appropriately documented and reported. They ensure that all essential documents 
are contained within the trial master file, and identify any errors or omissions. Both 
trials described in this thesis were monitored by an independent research 
monitoring company; Appledown Ltd. 
2.6  Trial Management 
The clinical trials tool kit website [175] also includes a flow chart to provide an 
overview of the processes involved in actually running a clinical trial, once all the 
approvals have been obtained. This involves recruitment and screening of 
volunteers, safety and progress reporting. This is shown in Figure 2.2. Once the 
trial is over, a final report must be completed and submitted to the MHRA and the 
ethics committee. Chapter 2 Vaccine Trials 
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Figure 2.2: Trial management 
Flow chart from Clinical Trials Tool Kit [175]. 
 
2.6.1  Recruitment and Screening  
Recruitment of healthy volunteers for these studies was by widespread poster 
campaign in universities and colleges, libraries, health centres and places of 
worship. Advertisements were also taken in the local press and radio. Subjects are 
initially screened by telephone and then scheduled for a formal screening visit. At 
the screening visit, the volunteers are counselled about participation in the study, 
including the following general principles: 
 
•  participation in the study is entirely voluntary 
•  refusal to participate involves no penalty or loss of medical benefits 
•  the subject may withdraw from the study at any time 
•  the subject is free to ask questions at any time to allow him or her to understand 
the purpose of the study and the procedures involved 
•  the study involves research of an investigational vaccine 
•  there is no direct benefit for participating 
•  the volunteer’s GP will be contacted to corroborate their medical history Chapter 2 Vaccine Trials 
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If the volunteer agrees to undergo screening, written informed consent was 
obtained. Formal screening involved checking inclusion and exclusion criteria, a 
brief medical history, a physical examination, full blood count, kidney and liver 
biochemistry, urinalysis, serological studies for human immunodeficiency virus 
(HIV), hepatitis B and hepatitis C, human leukocyte antigen typing. Females also 
had a urine pregnancy (β-hCG) test. 
 
2.6.2  Obtaining Consent 
Information sheets must be provided to potential volunteers at least 24 hours prior 
to the screening visit, and it is necessary for them to have read the information. At 
the screening visit, the trial is described again in detail to the volunteer, who is 
then given the opportunity to ask questions about the study. They are then given 
some time to consider whether or not they want to take part, usually a period of 10 
– 15 minutes, but longer is allowed when necessary. If they do decide to 
participate, they sign and date two copies of the consent form, one for them to 
take away and keep, and one to be kept in the study file. These forms are 
countersigned by the Investigator. Copies of the consent forms for the trials 
included in this thesis may be found in appendix 2. 
 
2.6.3  Selection of the Trial Population 
Selection of volunteers to participate in these studies is important, in order to 
ensure that the risks to the volunteers are minimised, and that any immunogenicity 
data can be interpreted correctly. Inclusion and exclusion criteria do vary from one 
trial to another. All volunteers selected were healthy, malaria naïve individuals, 
between the ages of 18 and 55 years. Detailed inclusion and exclusion criteria 
may be found in the relevant chapters of this thesis. 
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2.6.4  Evaluation Criteria 
2.6.5  Primary Evaluation Criteria: Safety 
As the malaria vaccine studies performed from the Centre for Clinical Vaccinology 
and Tropical Medicine in Oxford are largely Phase I studies (with some Phase I/IIa 
studies), collection of safety data relating to the vaccines used is vital.  
 
Following the incident at Northwick Park Hospital, where several healthy 
volunteers were given a dose of a new product one after the other, and all of them 
developed serious reactions, some of them life threatening, it was decided to 
modify the procedures used when giving a vaccine for the first time in humans. 
The first dose is given to one individual only, who is then evaluated before doses 
of the same vaccine are given to other volunteers.  
 
Safety is assessed by recording any immediate reactions (within 30 minutes after 
each injection, with an emphasis on allergic reactions) to the vaccines, and then 
local and systemic reactions occurring from day 0 to day 28 after each dose. All 
subjects are observed after each vaccination, and provided with a diary, to 
complete for 7 days. They are followed up after each vaccination, and at each visit 
they are questioned about the effects of the vaccine. The volunteers are always 
asked about a number of expected side effects related to vaccination – these are 
solicited adverse events, and may be local (related to the vaccination site) or 
systemic. Any other side effect or symptom is recorded as an unsolicited adverse 
event.   
 
Biological safety is also assessed by measuring the following, full blood count 
(FBC) and routine biochemistry - urea, potassium, sodium, ALT, total bilirubin, 
alkaline phosphatase, albumin, creatinine - one week and four weeks after each 
vaccination. 
 
The trials have an appointed Local Safety Monitor (LSM). The LSM is a local 
Consultant in Infectious Diseases, based on the Infectious Diseases ward adjacent 
to the study centre, who has a special interest in, and wide experience of malaria. 
He is independent from the research group. The LSM was consulted in order to Chapter 2 Vaccine Trials 
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assist in decisions about the safety of vaccine doses, and also in case of any 
uncertainty concerning volunteer safety, and is empowered to stop the study if 
necessary.  
 
2.6.5.1  Definitions 
An adverse event is any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not 
necessarily have a causal relationship with this treatment. An adverse event can 
therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding), for example, symptom or disease temporally associated with 
the use of a medicinal product, whether or not considered related to the medicinal 
product). 
 
A serious adverse event is any untoward medical occurrence that at any dose: 
results in death 
is life-threatening   
requires inpatient hospitalisation or prolongation of existing hospitalisation 
is a congenital anomaly/birth defect 
results in persistent or significant disability/incapacity 
 
Other non-serious events may be considered serious and reported immediately, 
i.e., events that required intervention to prevent one of the outcomes listed in the 
definition above. Any Serious Adverse Event (SAE) occurring from inclusion of the 
subject until the end of the study was also recorded. The relationship of any 
adverse event to the study vaccine is recorded by the Investigator, using the 
following definitions: definitely related, probably related, possibly related or not 
related. 
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2.6.5.2  Parameters 
The solicited clinical signs and symptoms are listed in  
Table 2.1. Volunteers are asked about these at each clinic visit, and also on the 








Documented fever (oral temperature > 37.5° C) General
Scaling/Pustules at site
Itch at the injection site
Warmth at the injection site
Swelling at injection site
Redness at the injection site









Documented fever (oral temperature > 37.5° C) General
Scaling/Pustules at site
Itch at the injection site
Warmth at the injection site
Swelling at injection site
Redness at the injection site
Pain at the injection site Local (injection site) 
Adverse events
 
Table 2.1: Adverse events 
Solicited local and general adverse events documented in the CRF. 
 
2.6.5.3  Method and Timing of Measurement 
The safety criteria are assessed during 30 minutes following the vaccination, and 
during the 28 following days. All volunteers are assessed by an Investigator 30 
minutes after the vaccination, and then again on day 2, day 7 and day 28 after 
vaccination. At each visit vital signs are measured together with any local 
reactions at the injection site. These include those signs listed in  
Table 2.1. All local reactions are considered causally related to the vaccination. 
The largest diameter of any redness is recorded in millimetres. The largest 
diameter site of local swelling is also recorded in millimetres. Severity of these 
local findings is graded using the scale provided in the following tables. Both 
measurements are taken as the largest diameter through one injection site, as on 
some occasions volunteers receive more than one injection for each dose of 
vaccine. 
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> 100 Grade 3 > 50 Grade 3
50 – 100 Grade 2 20 – 50 Grade 2
< 50 Grade 1 < 20 Grade 1






> 100 Grade 3 > 50 Grade 3
50 – 100 Grade 2 20 – 50 Grade 2
< 50 Grade 1 < 20 Grade 1







Table 2.2: Grading for swelling and redness 
Grading scales for swelling and redness. 
 
Study subjects are asked to indicate the maximum degree of pain they 
experienced at the injection site using a scale ranging from 0 to 3 as described in 
Table 2.3. 
 
Severe pain at rest (i.e. unable to use arm due to pain.) Grade 3
Painful when limb is moved (i.e. restriction in range of movement in arm, difficulty in carrying objects) Grade 2
Painful to touch, no restriction in movement of arms, able to work, drive, carry heavy objects as normal Grade 1
No pain at all Grade 0
Description Grade 
Severe pain at rest (i.e. unable to use arm due to pain.) Grade 3
Painful when limb is moved (i.e. restriction in range of movement in arm, difficulty in carrying objects) Grade 2
Painful to touch, no restriction in movement of arms, able to work, drive, carry heavy objects as normal Grade 1
No pain at all Grade 0
Description Grade 
 
Table 2.3: Grading pain 
Scale for grading pain 
At each visit subjects are requested to report local and general side effects they 
might have experienced since they last were seen. The Investigator assesses the 
severity of the solicited signs and symptoms using the key provided in Table 2.4. 
 
Serious, life-threatening:  Extreme limitation in activity, significant assistance required; significant 
medical intervention/therapy required, hospitalisation or hospice care probable
Grade 0
Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy 
required, hospitalisation possible
Grade 3
Moderate: Mild to moderate limitation in activity - some assistance may be needed; no or minimal 
medical intervention/therapy required
Grade 2
Mild: Transient or mild discomfort (< 48 hours); no medical intervention/therapy required Grade 1
None Grade 0
Description Grade 
Serious, life-threatening:  Extreme limitation in activity, significant assistance required; significant 
medical intervention/therapy required, hospitalisation or hospice care probable
Grade 0
Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy 
required, hospitalisation possible
Grade 3
Moderate: Mild to moderate limitation in activity - some assistance may be needed; no or minimal 
medical intervention/therapy required
Grade 2




Table 2.4: Grading other adverse events. 
Scale for grading severity of adverse events 
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Adverse events likely to be related to the vaccine, whether serious or not, which 
persist at the end of the trial are followed up by the Investigator where possible 
until their complete disappearance.  
 
The outcome of adverse event occurring within 30 days post-vaccination was 
assessed as: 
recovered/resolved 
not recovered/not resolved 
recovering/resolving 
recovered with sequelae/resolved with sequelae 
fatal (SAEs only) 
 
At visits 7 days and 28 days after each vaccination, volunteers provide a blood 
sample. This is sent for routine laboratory analysis, in order to demonstrate the 
biological safety of the vaccine. Any clinically significant deviations from the 
normal ranges are recorded as adverse events. 
 
2.6.6  Secondary Evaluation Criteria: Immunogenicity 
As well as assessing the safety of the vaccines in these studies, measuring their 
immunogenicity is also important. Although there is no defined immunological 
correlate of protection from malaria, a vaccine with only low levels of measured 
immunogenicity is less likely to be effective at preventing infection. 
 
2.6.6.1  Definition 
An assessment of the magnitude of the specific vaccine-induced cellular and 
humoral immune response was made in volunteers at baseline and following each 
vaccination. 
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2.6.6.2  Parameters 
The ex-vivo interferon gamma (IFN-γ) ELISPOT assay is performed to measure 
cellular responses to the vaccine insert at baseline and post-vaccine 
administration as detailed in the study protocol. These measurements are usually 
performed prior to vaccination and on day 7 and day 28 after vaccination. Antibody 
measurements, by ELISA may also be performed to assess any vaccine induced 
antibody response. 
 
2.6.6.3  Method and Timing of Measurement 
The ELISPOTs and ELISAs are performed according to standard operating 
procedures from the CCVTM laboratory. The detailed schedule of blood sampling 
was different for each study, and the timings can be found in the chapters relating 
to each trial. 
 
2.6.7  Tertiary Evaluation Criteria: Efficacy 
A detailed description of the challenge protocol can be found in chapter 7, but 
briefly, all volunteers are challenged with P. falciparum 14 days after the final 
vaccination. The challenges take place at Imperial College, London, as it contains 
a suitable insectary equipped to safely rear and store infected mosquitoes and to 
challenge human volunteers. The mosquitoes used for both studies described in 
this thesis were supplied by Captain Jack Williams of the Walter Reed Army 
Institute for Research. These were lab reared Anopheles stephensi mosquitoes 
infected with the 3D7 strain of P. falciparum parasites. Volunteers are taken into 
the insectary and each is provided with a cardboard carton, covered with netting, 
containing infectious mosquitoes. The carton is held over the arm of the volunteer, 
allowing mosquitoes to feed, until each volunteer has received a minimum of five 
bites from infectious mosquitoes. From the evening of day 6 following the 
challenge, volunteers attended clinic twice daily for a review of symptoms, vital 
signs monitoring (pulse, blood pressure and temperature) and withdrawal of 3mL 
of blood for thick film and PCR analysis. Field’s stain films were examined 
immediately by experienced microscopists for the appearance of parasitized red Chapter 2 Vaccine Trials 
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blood cells. A total of 200 high power fields were examined before a subject was 
declared slide negative. Subjects who reached day 15 without blood film evidence 
of malaria were monitored daily until day 21. All subjects were treated immediately 
with Riamet (artemether [20 mg], lumefantrine [120 mg]; Novartis) upon diagnosis 
of malaria. Subjects returned to clinic on two consecutive days for negative blood 
films post treatment. 
 
Follow-up after the challenge is important. Before volunteers can be challenged 
with malaria, they are required to provide detailed contact information for 
themselves and also for a close friend or relative who will know where they are for 
the duration of the follow up period. Volunteers that do not own mobile phones are 
issued with them, and all are given emergency alert cards to carry with them at all 
times. As the studies we conduct are performed on an out-patient basis, we also 
restrict recruitment to volunteers who live within a specific geographical area, so 
that any problems can be responded to quickly. A doctor is on call for the 
volunteers at all times to provide advice or assistance if required. 
 
If a vaccine is effective, volunteers will not develop malaria. A volunteer who has 
remained blood film negative by day 21 after the challenge is protected from 
disease. Any protected volunteers are treated with anti-malarial medication at this 
stage to prevent the theoretical possibility of malaria developing after that time. 
Provided volunteers attend visits as outlined in the protocol, the risk of developing 
any serious illness as a result of taking part is minimal. A review of the symptoms 
experienced by control volunteers taking part in studies such as this may be found 
in Chapter 7. 
 
These studies have their limitations; they identify vaccines that protect malaria 
naïve volunteers from Oxford against one particular strain of malaria. There are 
several reasons why a vaccine that works in these conditions might not be 
effective in the field. The ethnicity of the volunteers, which will in part determine 
the types of immune response they make, is different from that of most people 
living in endemic areas. The strain of malaria used, 3D7, has been found to be 
relatively dissimilar to strains that are currently causing infection around the world. 
This strain is used because it has been studied extensively in laboratories around Chapter 2 Vaccine Trials 
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the world, and is known to be sensitive to all antimalarial medications. If a vaccine 
is found to demonstrate efficacy in a study of this sort it may then be taken on to 
further Phase II and phase III studies in endemic areas. 
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Chapter 3   VAC027 
“A Phase I study to assess the safety and 
immunogenicity of the polyprotein malaria vaccine 
candidates “FP9-PP and MVA-PP” in healthy adults 




“Assessment of protection against malaria by 
sporozoite challenge of healthy adults vaccinated 
with the polyprotein malaria vaccines “FP9-PP, 




3.1  Introduction and Purpose 
VAC027 was planned as two clinical trials with separate protocols, VAC027.1 and 
VAC027.2. These two trials were planned to overlap, with some volunteers from 
one study going on to participate in the second. The main reason for dividing the 
vaccination protocol (VAC027.1) from the challenge protocol (VAC027.2) was 
historical, with previous trials having been carried out in this way, in the past 
allowing volunteers from several vaccination studies to be challenged at the same 
time under the same protocol. This is the last study that was divided in this way as, Chapter 3 VAC027 
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under the new Clinical Trials Regulations [166] introduced in 2004, it no longer 
made sense to separate the protocols for vaccination and challenge phases. 
 
Although most vaccine trials of pre-erythrocytic malaria vaccine candidates have 
included either the CS or TRAP antigen alone these represent but two of a large 
number of antigens expressed by sporozoites. The hypothesis behind the design 
of the vaccines to be used in this study was that using multiple antigens would 
broaden the target antigen range of vaccine induced immunity, increasing the 
number of potential epitopes available. This approach should also prevent the 
development of escape mutants by P. falciparum. 
 
The polyprotein vaccine used in this trial expresses six malaria antigens and its 
insert has previously been described by the acronym L3SEPTL [167]. This reflects 
the order of the six antigens in this insert: LSA3, STARP, Exp1, Pfs16, TRAP and 
LSA1.  
 
The amino-terminal three antigens of the polyprotein are clearly expressed by 
blood-stage parasites as well as sporozoites of P. falciparum. Despite its name, 
LSA3 (liver stage antigen 3) is expressed by blood-stage schizonts (initially named 
D260) [181], as well as sporozoites [182]. It is the target of HLA-B*53-restricted 
CTL in Gambians [88]. Importantly, LSA-3 has been shown to induce protective 
immunity by vaccination against sporozoite challenge in a chimpanzee model of P. 
falciparum infection [183] LSA-3 was administered to humans in a phase I plasmid 
DNA vaccine trial as part of a five plasmid DNA vaccine by the US Navy group 
(Richie et al. unpublished); there were no serious adverse events associated with 
vaccination and on sporozoite challenge there was no evidence of protection. 
 
STARP (sporozoite threonine and asparagine-rich protein) was described by 
Fidock et al. [184, 185], as a relatively conserved sporozoite antigen. Relatively 
low titres of antibodies against STARP seem to block sporozoite invasion [75]. It is 
also expressed by early ring-stage blood stage parasites but not by blood-stage 
schizonts. Gambians naturally exposed to malaria have CTL that target this 
antigen [82]. STARP has apparently not previously been administered to humans 
as part of a malaria vaccine candidate. Chapter 3 VAC027 
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Exp-1, exported protein-1 [186] is a sporozoite and blood stage antigen that is 
recognized by CTL in Gambians [82]. A study in Burkina Faso found that a positive 
antibody response to Exp-1 correlated with significantly lower risk of malaria 
during the subsequent transmission season [187]. The P. yoelii homologue of this 
protein induced protective immunity when used as a DNA vaccine in mice [188]. 
As a subunit protein vaccine, Exp-1 could induce protective immunity against 
blood-stage parasite challenge in squirrel monkeys [189]. This antigen has 
previously been administered to humans as part of a fusion protein with the central 
NANP repeat of the circumsporozoite protein (192 Nigerian school children were 
vaccinated, and all were protected from clinical malaria for a 12 week period) 
[190]. 
 
Pfs16 is expressed by sexual stage parasites and possibly also by sporozoites. 
Disruption of this gene in P. falciparum results in reduced gametocyte production 
[191]. Antibodies induced to this molecule by vaccine constructs were reported to 
inhibit sporozoite invasion of human hepatoma cells [192]. Pfs16 has not to our 
knowledge been used previously in humans as part of a human candidate malaria 
vaccine. 
 
The two antigens at the carboxyl-terminal, LSA1 and TRAP, are expressed only at 
the pre-erythrocytic stage of malaria infection. LSA1 was a component of the 
NYVAC-Pf7 candidate vaccine that was administered safely to about 32 subjects 
in the USA [168]. Thrombospondin-related adhesion protein (TRAP) was selected 
as it is well characterized and has a protective homologue in rodents [127]. TRAP 
was originally reported as a blood-stage antigen, but now is generally considered 
to be expressed on sporozoites only [193]. An antigen of particular interest is LSA-
1. This is expressed by liver-stage parasites but not sporozoites. It is the target of 
HLA-B*53 restricted cytotoxic T cell responses in Gambians [83], a population in 
which this HLA allele was associated with protection against severe malaria [87].   
 
Prieur et al. [167] have described L3SEPTL vaccines with this insert expressed in 
plasmid DNA, FP9 and MVA vectors. Immunogenicity of the viral vectors was 
greater than of the plasmid DNA vector. In heterologous prime-boost immunisation Chapter 3 VAC027 
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studies in mice strong CD8 T cell responses were induced. The expression of all 6 
antigens from the viral vector constructs was confirmed by immunogenicity studies 
in various strains of mice. Enhanced T cell responses were demonstrated with 
both FP9 priming and MVA boosting and the converse immunisation regime.  
 
This study examined the combination of these six malaria antigens in humans in a 
single vaccine construct. These were new vaccines to be tested for the first time in 
man, and so the study included a series of dose lead in groups (groups 1 – 5), 
who received one vaccination only, and were subsequently followed up for safety 
data collection. This was then followed by two prime-boost vaccination groups (6 & 
7), who received 3 doses of vaccine (either FFM, or MMF, depending on group). 
These volunteers were then invited to participate in the subsequent challenge 
study VAC027.2 in order to assess efficacy. For brevity the FP9-L3SEPTL and 
MVA-L3SEPTL constructs are hereafter referred to as FP9-PP and MVA-PP. 
 
3.2  Methods 
3.2.1  Objectives 
The primary objective of VAC027.1 was to assess the safety of the malaria 
vaccines FP9-PP and MVA-PP when administered individually and sequentially in 
a prime-boost strategy. The primary objective of VAC027.2 was to assess if 
volunteers from groups 6 and 7 of VAC027.1 (who received 2 doses of FP9-PP 
given 4 weeks apart followed by MVA-PP given another 4 weeks (± 1 week) later, 
or 2 doses of MVA-PP given 4 weeks apart followed by FP9-PP given 4 weeks (± 
1 week) later) were protected wholly or partially against malaria infection in a 
sporozoite challenge model. The secondary objective for both studies was to 
assess the cellular immune response generated by FP9-PP and MVA-PP when 
administered in a prime-boost regimen, and after challenge; and if there was 
evidence of partial or complete protection by the vaccinations, to explore 
immunological correlates of protective immunity. 
 
In the context of this thesis, both studies have been combined into one chapter, 
and therefore for ease of description, the objectives for both studies have been Chapter 3 VAC027 
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combined. As this study was testing new vaccines for the first time in man, safety 
remains the primary concern, and is therefore described as the primary objective 
throughout. Immunogenicity and efficacy are therefore both secondary objectives. 
 
Exploratory objectives for both studies included assessment of the humoral 
immune response generated by FP9-PP and MVA-PP when administered in a 
prime-boost regimen, by measuring anti-sporozoite antibodies; and assessment of 
the long term efficacy of FP9-PP and MVA-PP in a re-challenge of any volunteers 
protected at initial malaria challenge. 
 
3.3  Outcome Measures 
3.3.1  Primary Objective – Safety 
Safety was assessed by the collection of local and systemic adverse events. Each 
subject was observed for at least 30 minutes after vaccination, and underwent 
clinical review 2, 7 and 28 days after each vaccination for reporting of solicited and 
unsolicited adverse events. Subjects completed a diary card each day for the first 
7 days after each vaccination.  
 
Safety blood testing, including analysis of full blood count and biochemistry (urea, 
electrolytes, alanine aminotransferase, bilirubin, alkaline phosphatase, albumin) 
was also performed at intervals throughout the study (see figures 3.1 – 3.3 for 
details). 
 
3.3.2  Secondary Objective – Immunogenicity 
The immunogenicity of the vaccines was assessed primarily by measurement of 
ex-vivo and cultured IFN-γ ELISPOT responses to the polyprotein antigens before 
and after malaria infection.  
 
For the ex vivo IFN-γ ELISPOT freshly isolated PBMC are stimulated with malaria 
peptides, control peptides, recombinant antigens, or recombinant viruses 
expressing part or all of the L3SEPTL insert in ELISPOT plate (Millipore) wells Chapter 3 VAC027 
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coated with antibody specific for human IFN-γ (Mabtech). After 18-20 hours 
incubation the PBMC are washed away and biotinylated anti-IFN-γ added, 
followed by alkaline phosphatase-conjugated streptavidin (both from Mabtech). 
Capture of IFN-γ can then be visualized by adding chromogenic substrate (Bio-
Rad). The coloured spots are calculated with an ELISPOT reader (AID) and the 
results are expressed as spot forming units (SFU) per 1x10
6 PBMC. Peptides 
(Thermoelectron) were 20mers overlapping by 10, designed to cover the entire 
sequence of the polyprotein vaccine. Details of the sequences of the peptides, and 
the pools used in this study, may be found in Appendix 3. The sequence of TRAP 
used in the vaccine was from the T9/96 strain of falciparum malaria. The strain of 
malaria used in the subsequent challenge in the study VAC027.2 was 3D7 which 
has a slightly different TRAP sequence. ELISPOT responses to both sequences 
were therefore tested. 
 
3.3.3  Secondary Objective – Efficacy 
Protection against malaria infection was assessed using a P. falciparum 
sporozoite challenge model. To assess the efficacy of the vaccines all vaccinated 
subjects and six unvaccinated control subjects underwent experimental challenge 
with Plasmodium falciparum, fourteen days after the final vaccination. The details 
of the challenge method can be found in chapter 7.  From the evening of day 6 
subjects attended clinic twice daily for review of symptoms, vital signs monitoring 
(pulse, blood pressure and oral temperature) and withdrawal of 3 mL of blood for 
thick film and PCR analysis for parasite DNA. Field’s stain thick films were 
examined immediately by experienced microscopists for the appearance of viable 
parasites. A minimum of 200 high power fields were examined before a subject 
was declared slide negative. Subjects who reached day 15 without blood film 
evidence of malaria infection were followed up daily until day 21. All subjects were 
treated immediately with Riamet® (artemether 20mg, lumefantrine 120mg, 
Novartis) on diagnosis of malaria by the identification of a viable parasite on thick 
film. Subjects returned to clinic on two consecutive days for negative blood films 
post treatment. The pre-patent period was defined as the time to diagnosis, and 
efficacy was assessed by comparing this time period in vaccinated and 
unvaccinated subjects. Chapter 3 VAC027 
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The analysis for the primary objective was based on the number of hours between 
infectious challenge and blood stage parasitaemia. Each of the groups was 
compared with the other and with the control group using the Kaplan Meier 
method. Statistical significance of any differences observed was then assessed by 
the log rank test.  
 
Blood was taken daily for PCR analysis for parasite DNA. This was performed in 
real time, although the clinicians assessing the volunteers were blinded to the 
results. The method used is described in detail in [194]. The results of the PCR 
analysis were used to estimate parasite growth rates. A description of this method; 
and the reasons for choosing it over the other available methods for calculating 
parasite growth rates can be found in chapter 6 of this thesis. Chapter 3 VAC027 
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3.4  Investigational Plan 
3.4.1  Trial Plan 
The following two flow charts show the schedule of visits and procedures from 























Figure 3.1: Flow chart groups 1 – 5  
Summarising trial visits and procedures for groups 1 - 5. 
Group 1 to 5: lead-in dose regimen, 6 Visits, 1 Vaccination, Open, 90 Days duration/subject 
 
Visit Number  V1  V2  V3  V4  V5  V6 
Trial Timelines (Days,)  S  D0  D2  D7  D28  D90 
Time Windows (Days)      [±1 D]  [± 2D]  [±3 D]  [±14 D] 








Inclusion &  
Non Inclusion Criteria 
X           
Informed Consent  X           
Medical History  X           
Physical Examination  X           
β β β β-HCG urine test  X  X         
HCV, HIV, HBV tests  6mL           
HLA typing    3mL         
Contra-Indications Review    X         
Vaccination Doses    Vac1         
Immediate surveillance  
(30 min) 
  X         
Post-Dose Follow-Up  
(n Days) 
    2 days  7 days  28 days  90 days 
Vital signs    X  X  X  X  X 
Local & Systemic 
Events/Reactions 
  X  X  X  X  X 
Diary Cards Provided    DC1    DC2     
Diary Cards Collected        DC1  DC2   
Review of Diary Cards       X  X  X   










Biochemistry  3mL      3mL  3mL  3mL 
Haematology  2mL      2mL  2mL  2mL 
Antisporozoite Ab    10mL    10mL    10mL 
Exploratory Immunology    50mL    50mL    50mL 
Termination Record / 
Final 
          X 
Serious Adverse Events  to be reported at any time during the trial 
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Figure 3.2: Flow chart groups 6 & 7 
Summarising trial visits and procedures (VAC027.1, vaccination study) 
Group 6 and 7: prime-boost regimen, 12 Visits, 3 Vaccinations, Open, 150 Days duration/subject 
Visit Number  V1  V2  V3  V4  V5  V6  V7  V8  V9  V10  V11  V12 
Trial Timelines 
(Days,) 
S  D0  D2  D7  D28  D30  D35  D56  D58  D63  D84  D150 
Time Windows 
(Days) 
    ±1D  ±2D  ±10 D  ±1D  ±2D  +4wks/ 
-2wks 
±1D  ±2D  ±7 D  ±14 
D 




















Inclusion & Non 
Inclusion Criteria 
X                       
Informed 
Consent 
X                       
Medical History  X  X                     
Phys.  Exam.  X                       
β β β β-HCG urine test  X  X      X      X         
HCV, HIV, HBV 
tests 
6mL                       
HLA typing    3mL                     
Review Contra-
Indications  
X  X    X                 




  X      X      X         
Post-Dose 
Follow-Up (Days) 
    2  7  28  2  7  28  2  7  28  90 
Vital signs  X  X  X  X  X  X  X  X  X  X  X  X 
Local & Systemic 
Events/Reactions 
  X  X  X  X  X  X  X  X  X  X  X 
Diary Cards 
Provided 
  DC1      DC2      DC3         
Diary Cards 
Collected 
      DC1      DC2  DC    DC3     
Review Diary 
Cards 
    X  X  X  X  X  X  X  X  X   


















  75mL 
BS8 
Biochemistry  3mL      3mL  3mL    3mL  3mL    3mL    3mL 
Haematology  2mL      2mL  2mL    2mL  2mL    2mL    2mL 
Antisporozoite Ab    10mL                10mL    10mL 
Gene Expression    10mL                10mL    10mL 
Exploratory 
Immunology 
  50mL    50mL  50mL    50mL  50mL    50mL    50mL 
Termination 
Record  
                      X 
SAEs    to be reported at any time during the trial 
Trial phase    Primary Series  Booster series 
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816 741 657-681 613-654 612 544
5
4
1 470 Cumulative blood taken (vaccinees)
366 291 207-231 165-204 162 89
8
6 15 Cumulative blood taken (controls)
75 60 3x9 3x14 73 3
7
1 15 Blood drawn each time
10 (10†) 10
1
0 Gene expression study
10 10
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10 HBV, HCV, HIV serology
2 2 2 FBC incl. platelets
3 3 3 LFT / UE
5 HLA  typing (controls only)
Blood in ml needed for: 
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X X X X X X Interim history/Clinical assessment
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Figure 3.3 Flow chart for challenge study, VAC027.2 
Flow chart for challenge study for Groups 6 & 7 and unvaccinated control volunteers 
 
3.4.2  Trial Design 
This was a phase I/IIa, prospective, open partially-randomised clinical trial of a 
prime-boost malaria vaccination regimen using 2 different vaccine candidates. 
This began with five lead-in dose ranging groups of volunteers (groups 1 – 5) 
followed by two larger groups undergoing prime-boost vaccination. Subjects in 
these latter groups were subsequently invited to participate in a sporozoite 
challenge study (VAC027.2) to examine vaccine efficacy against malaria infection. Chapter 3 VAC027 
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Allocation of study subjects to groups 6 and 7 (but not groups 1 – 5) was 
randomised. 
 
During the dose lead-in phase of the study, interim safety data analyses were 
carried out before increasing the vaccine dose. This was carried after the day 7 
follow up visit had been completed for all volunteers in a given vaccine group. As 
this study was testing vaccines for the first time in human volunteers, the first 
doses of each vaccine were given to one volunteer only at a time (i.e. one 
volunteer in group 1 and one volunteer in group 2), with subsequent volunteers in 
those groups being vaccinated after a 24 hour period. 
 
Further analyses were carried out after vaccinations for groups 1 – 5 were 
completed to determine which doses were most appropriate to use during the 
prime-boost regimes subsequently used in groups 6 and 7. The vaccination and 
challenge schedule for volunteers in these groups is shown in Figure 3.4. 
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Sampling 
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3.4.3  Trial Calendar   
 
First visit first volunteer:   11th April 2006 
Last visit last volunteer:   12th January 2007 
Last vaccine given:  1st November 2006 
Challenge Dates:  14th and 15th November 2006 
Statistical Analysis:  Completed July 2007 
 
3.5  Vaccines 
3.5.1  Formulation of the MVA-PP Vaccine 
The vaccine, MVA-PP containing L3-SEPTL, was manufactured by a contract 
manufacturer (IDT, Germany) and provided in vials of 300 µL volume for 
intradermal injection at a concentration of 5 × 10
8 pfu/mL in 10mM Tris buffer. 
Vaccines were stored below -18° C in a freezer at the trial centre and allowed to 
thaw to room temperature by standing in the clinic room or by hand warming prior 
to administration. 
 
3.5.2  Formulation of the FP9-PP Vaccine 
The vaccine, FP9-PP containing L3-SEPTL, also manufactured under contract by 
IDT, was provided in vials of 300 µL volume for intradermal injection at a 
concentration of 3 × 10
8 pfu/mL in 10mM Tris buffer. Vaccines were stored below -
18° C in a freezer at the trial centre and allowed to thaw to room temperature by 
standing in the clinic room or by hand warming prior to administration. 
 
3.5.3  Selection of Doses 
Groups 1 – 5 were designed to assess safety and to gather immunogenicity data 
from escalating doses of the two vaccines FP9-PP and MVA-PP. Doses of up to 
1.5 × 10
8 pfu of similar viral vectored vaccines have been given in previous studies 
within this group with a good adverse event profile. 
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The doses of MVA-PP used in this study were: 
1 × 10
8 pfu (200 µL) for group 2,  
2 × 10
8 pfu (400 µL) for group 4, 
5 × 10
8 pfu (1000 µL) for group 5.  
 
The doses of FP9-PP used in this study were: 
1 × 10
8 pfu (330 µL) for group 1,  
2 × 10
8 pfu (660 µL) for group 3.  
 
The doses for groups 6 & 7 for each vaccine were determined by the investigators 
in conjunction with the Local Safety Monitor (LSM) after considering safety and 
immunogenicity data for the dose lead-in groups 1 – 5. The dose of MVA-PP used 
in groups 6 and 7 was 1 × 10
8 pfu for priming immunisations (i.e. first and second 
doses) and 2 × 10
8 pfu for boosting immunisations (i.e. third doses). The dose of 
FP9-PP used in groups 6 and 7 was 1 × 10
8 pfu for priming immunisations (i.e. 
first and second doses) and 2 × 10
8 pfu for boosting immunisations (i.e. third 
doses). The lower dose (1 × 10
8 pfu) was chosen for both vaccines for priming 
immunisations as no clear increase in post-prime immunogenicity was seen with 
the higher doses. The intermediate (2 × 10
8 pfu) was chosen for the boosting dose 
given that the safety profile was broadly similar to the low dose of each vaccine 
and that post-boost immunogenicity might be more reliant on dose than post-
prime.  
 
3.5.4  Preparation for Use 
The vaccines were supplied ready for injection. For groups requiring a larger 
volume of vaccine, multiple sterile syringes and needles were used to deliver up to 
six injections of up to 180 µL of vaccine each. All vaccine doses were divided 
equally between both arms, given as intradermal injections into the skin overlying 
the deltoid muscle of the upper arm. 
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3.6  Selection of the Trial Population 
3.6.1  Inclusion Criteria 
Healthy adults aged 18 to 55 years 
Resident in or near Oxford for the duration of the vaccination study 
Willingness to allow the investigators to access hospital and General Practitioner 
medical notes 
For females only, willingness to practice continuous effective contraception during 
the study and if participating, during the subsequent challenge study.  
Agreement to refrain from blood donation during the course of the study 
Written informed consent 
Willingness to undergo an HIV test  
 
3.6.2  Exclusion Criteria 
Any deviation from the normal range in biochemistry or haematology blood tests or 
in urine analysis as defined in Appendix 1 of the protocol. 
Prior receipt of an investigational malaria vaccine 
Use of any investigational or non-registered drug, vaccine or medical device other 
than the study vaccine within 30 days preceding dosing of study vaccine, or 
planned use during the study period 
Administration of chronic (defined as more than 14 days) immunosuppressive 
drugs or other immune modifying drugs within six months of vaccination. (For 
corticosteroids, this will mean prednisolone, or equivalent, ≥ 0.5 mg/kg/day. 
Inhaled and topical steroids are allowed.) 
History of malaria chemoprophylaxis with chloroquine within 5 months prior to the 
planned challenge, with Lariam within 6 weeks prior to the challenge, and Riamet 
within 2 weeks prior to the challenge 
Any history of malaria 
Travel to a malaria endemic country within the previous 6 months prior to the 
planned challenge 
Planned travel to malarious areas during the study period Chapter 3 VAC027 
  64 
Any confirmed or suspected immunosuppressive or immunodeficient condition, 
including human immunodeficiency virus (HIV) infection and asplenia 
History of allergic disease or reactions likely to be exacerbated by any component 
of the vaccine, e.g. egg products 
Evidence of cardiovascular disease  
History of cancer (except basal cell carcinoma of the skin and cervical carcinoma 
in situ) 
History of haemoglobinopathies: Sickle cell disease, thalassaemia, G6PD 
deficiency 
History of diabetes mellitus 
Chronic or active neurological disease  
Chronic gastrointestinal disease  
History of > 2 hospitalisations for invasive bacterial infections (pneumonia, 
meningitis) 
Suspected or known current alcohol abuse as defined by an alcohol intake of 
greater than 42 units every week 
Seropositive for hepatitis B surface antigen (HBsAg) 
Seropositive for hepatitis C virus (antibodies to HCV) 
Hepatomegaly, right upper quadrant abdominal pain or tenderness 
Evidence of serious psychiatric condition 
Any other on-going chronic illness requiring hospital specialist supervision 
Administration of immunoglobulins and/or any blood products within the three 
months preceding the planned administration of the vaccine candidate 
Pregnant or lactating female 
Female who is willing or intends to become pregnant during the study 
Any history of anaphylaxis in reaction to vaccination 
PI assessment of lack of willingness to participate and comply with all 
requirements of the protocol (including history or clinical evidence of iv drug 
abuse) 
Any other finding which in the opinion of the investigator would significantly 
increase the risk of having an adverse outcome from participating in this protocol 
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3.6.3  Randomisation Procedures 
Volunteers in groups 1-5 were not randomised but were enrolled sequentially into 
groups 1 – 5. Subjects were randomised into groups 6 or 7. To achieve equal 
numbers of volunteers in each group, restricted randomisation was performed as 
described in Kirkwood, Essentials of Medical Statistics (1st edition), page 185, 
using the random number tables in Appendix 10 of this book. 
 
3.7  Statistical Analysis 
3.7.1  Sample Size 
The primary objective of the study was descriptive – the safety of the vaccines. 
The numbers of volunteers were therefore chosen primarily for reasons of safety 
and practicality. The challenge  study aims to reveal potentially useful vaccine 
candidates so that they may be selected for further study, rather than demonstrate 
the eventual efficacy of a vaccine. The size of the study groups need to be 
adequate to demonstrate big differences between vaccinated volunteers and 
unvaccinated control volunteers. In this instance, the number of volunteers 
included (10 per vaccine group for the challenge study), would have 80% power to 
demonstrate a vaccine efficacy of 65% or greater.  
 
3.7.2  Statistical Methods 
The main objective of this study was assessment of safety, and it was therefore 
not powered to provide statistical comparisons between groups. Immunogenicity 
was assessed for each volunteer by summing the ELISPOT responses to each 
antigen across peptide pools. Immunogenicity was compared between groups 
using geometric mean and medians, with the significance of any differences 
observed calculated using Mann Whitney U test. 
 
Efficacy was assessed by calculation of the number of hours between infectious 
challenge and blood stage parasitaemia. Each of the groups of vaccinated 
volunteers that took part in the challenge was compared with the other and with Chapter 3 VAC027 
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the control group using the Kaplan Meier method. Statistical significance of any 
differences observed was then assessed by the log rank test.  
 
All data, including adverse event data collected on StudyBuilder™, was imported 
into and analysed using Microsoft® Excel or SPSS® statistics packages. 
 
3.8  Results 
Healthy malaria naïve adult subjects aged 18 – 50 years were recruited in the 
Oxford area and underwent medical screening as previously described [133]. All 
volunteers provided fully informed consent to participate in this study by signing a 
written consent form, prior to any study procedures being initiated. All vaccinations 
and follow up visits took place in the outpatients unit at the Centre for Clinical 
Vaccinology and Tropical Medicine, at the Churchill Hospital in Oxford. The 
malaria challenge was performed in the insectary in the Alexander Fleming 
Building, Imperial College, London. The study received ethical approval from the 
Oxfordshire Research Ethics Committee A. VAC027.1 received a favourable 
opinion on 8/10/2004, (COREC reference 04/Q1604/93), whilst the challenge 
study, VAC027.2 received a favourable opinion on 24/05/2006 (COREC reference 
06/Q1604/55). The study was performed in compliance with the requirements of 
the MHRA under a Clinical Trial Authorisation. It gained full regulatory approval 
from the MHRA; for VAC027.1 this was received on 14/3/2006, CTA number 
27454/0001/001-0001, Eudra CT Number 2004-002424-17. VAC027.2 was fully 
approved on 13/04/2006, with the CTA number 2754/0001/002-0001 and EudraCT 
number 2006-000629-67. An Independent Local Safety Monitor was appointed in 
Oxford. The trial was conducted according to GCP and in accordance with the 
current version of the declaration of Helsinki (52nd WMA General Assembly, 
Edinburgh, Scotland, October 2000). It was externally monitored by Appledown 
Clinical Research Ltd. 
 
Recruitment for this study began in April 2006, and the final visit of the final subject 
to the study site took place on 12th January 2007. The participant flow is shown in 
a CONSORT diagram in Figure 3.5.  Chapter 3 VAC027 
  67 








Assessed for eligibility (n=52) 
Excluded  (n= 18) 
 
Not meeting inclusion 
criteria (n= 11) 
 
Withdrew consent (n= 7) 




Excluded from analysis (n=0) 




Allocated to GROUPS 1-5  
(n= 15) 
Received allocated vaccinations 
(n= 15) 
Lost to follow-up (n= 0) 
 
Discontinued intervention (n= 3) 
Withdrew consent prior to challenge 
(n=1) 
Randomised to GROUP 7 MMF 
(n= 10) 
Received allocated doses (n= 8) 
Did not receive doses 2 and 3 (n= 1) 
(change in occupation) 
Did not receive dose 3 (n=1) 
(overseas travel) 
Entered MALARIA CHALLENGE 
(n=7) 
Analyzed   
 
Safety (n=10, 9, 8) 
(V1 n= 10, V2, n=9, V3 n=8) 
Efficacy (n=7) 




Randomised to GROUP 6 FFM 
(n=9) 
Received allocated doses (n=8) 
Did not receive dose 3 (n=1) 
(withdrew due to low mood) 
 
Entered MALARIA CHALLENGE 
(n= 8) 
Lost to follow-up  (n=0) 
  
Discontinued intervention   (n= 1)  











Figure 3.5: CONSORT flow chart 
CONSORT chart showing flow of participants through VAC027. 
 
In total, 52 subjects were screened, of whom 18 were excluded, 11 because they 
were ineligible, and 7 withdrew consent after screening. 34 volunteers were 
enrolled into the study, 15 into groups 1-5 (3 per group) and 19 into groups 6 and 
7. All volunteers in groups 1 to 5 received a single vaccine dose and attended 
follow up visits as planned in the protocol. 9 volunteers were randomised to group Chapter 3 VAC027 
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6 and 10 to group 7. Of these, one subject in group 6 withdrew from the study after 
the second vaccination. Two subjects in group 7 withdrew from the study. One 
volunteer withdrew after the first vaccine having taken on new work commitments 
rendering him unable to attend key clinic visits. A second volunteer withdrew after 
the second vaccination after deciding to travel abroad for an extended period of 
time during the follow up period. The volunteer attended for follow up at days 2 
and 7 following the second vaccination but declined further follow up. Available 
data has been included in the analysis. 
 
Of those volunteers who completed the course of vaccinations, all 8 volunteers in 
group 6 participated in the challenge, whilst only 7 of those from group 7 took part; 
one volunteer withdrew consent after the vaccination study. 6 volunteers were 
recruited to act as unvaccinated controls for the challenge phase. 
 
17 (50%) 17 (50%) 47.3 18.9 30.5 (8.9) 34 TOTAL 
COHORT
7 (70%) 3 (30%) 44.6 19.5 29.8 (7.5) 10 Group 7
3 (33.3%) 6 (66.7%) 47.3 20.6
32.2 
(10.5) 9 Group 6
2 (66.7%) 1 (33.3%) 45.1 18.9 29.5 
(13.8)
3 Group 5
3 (100%) 0 (0%) 42.1 21.5 28.8 
(11.5) 3 Group 4
1 (33.3%) 2 (66.7%) 40.0 34.7 34 (6.4) 3 Group 3
0 (0%) 3 (100%) 24.6 23.3 22.4 (2.8) 3 Group 2
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Table 3.1: Demographics 
Table demonstrating the demographic characteristics of volunteers by group. 
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3.8.1  Protocol Deviations 
Details of deviations from the protocol are given by study group: 
 
Group 2 
The physical examination was not performed during the screening visit for 
volunteer M1027554 due to the unforeseen unavailability of a clinician. This was 
instead carried out 6 days after the screening visit. The examination was normal 
and the volunteer was enrolled and vaccinated 9 days later.  
 
Volunteer M1027548 received a smaller dose of vaccine than intended (140µL 
instead of 200µL) due to an under filled vaccine vial. 
 
Group 5 
Volunteer M1027574 attended for the M+28 visit 8 days earlier than the window 
allowed due to travel plans unconnected with the trial. The subject attended the 
subsequent M+90 visit within window. 
 
Subject M1027572 revealed after receiving the second vaccination a history of low 
mood which predated the study but had not revealed this at screening and had not 
sought medical attention. The volunteer admitted finding committing to the trial 
procedures more difficult than expected and decided to withdraw from the study 
before being seen again. The volunteer did attend for day 2 and day 7 follow up 
visits and agreed to medical referral to the General Practitioner. A subsequent 
request for an update from the General Practitioner received no reply. As far as 
can be determined this volunteer would not necessarily have met exclusion criteria 
at screening if the full history had been divulged so data has been included for 
analysis. 
 
Subject M1027595 was unable to attend the FF+7 visit on time due to family 
problems but attended 7 days after the visit window. Safety data was collected at 
this visit, but blood was not taken or analysed for immunogenicity due to this 
delay. 
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Group 7 
Subject M1027585 failed to attend the MMF+28 visit due to academic 
commitments but did attend the final visit at MMF+90. 
 
Subjects M1027580 and M1027586 attended clinic on time for the FFM+28 visit 
but some records and procedures were not fully completed. These were 
completed subsequently 15 and 6 days after the visit window respectively. 
 
Subject M1027579 withdrew from the study after the first vaccine having taken on 
new work commitments rendering him unable to attend key clinic visits. The 
volunteer was able to attend for safety follow-up visits at 2, 7 and 28 days 
following vaccination but did not have blood collected for immunogenicity. 
Available data has been included in the analysis. 
 
Subject M1027575 withdrew after the second vaccination after deciding to travel 
abroad for an extended period of time during follow up. The volunteer attended for 
follow up at days 2 and 7 following the second vaccination but declined further 
follow up. Available data has been included in the analysis. 
 
3.8.2  Safety Results 
Eleven volunteers (32%) had at least one out of range blood result during the trial 
but none of these appeared vaccine related and only two (4%) warranted any 
further investigation. One was a mild iron deficiency anaemia associated with 
menorrhagia, and the other a persistent mildly raised bilirubin. Both volunteers 
were referred to their GPs for further investigation with their consent. 
 
 Both vaccines used were well tolerated and appeared safe in this small-scale 
phase I trial. All 15 volunteers (100%) in groups 1 – 5 completed the trial 
successfully. Of nineteen volunteers in groups 6 & 7, 1 (5%) withdrew following a 
worsening of a pre-existing problem and two (10%) withdrew from the trial for 
reasons unrelated to the study. 
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No serious adverse events (SAEs) occurred during the study. Reactions within 30 
minutes of vaccination were predominantly mild (96% mild, 4% moderate) and 
local (93%). Of 701 adverse events (AEs) recorded in total, 581 were judged 
probably or definitely related to vaccination and 568 of these (97.7%) were 
solicited adverse events. Severe AEs represent approximately 0.3% of all AEs and 
moderate AEs approximately 8%. All others were classed as mild. The following 
tables describe the local and systemic adverse events reported in the 28 days 
following each vaccination. No safety concerns were noted with these two novel 
vaccines during the course of the studies. 
 
18 16 18 Total (all grades)
0 3 15 0 1 15 0 2 16 Total
3 
(100%)
2 (67%) 3 
(100%)
Warmth










(100%) 1 (33%) 2 (67%) Redness







2 (67%) 3 
(100%)
Itch
Severe Mod Mild Severe Mod Mild Severe Mod Mild
Group 3: FP9-PP mid dose
No. volunteers (%)
(n = 3)
Group 2: MVA-PP low dose
No. volunteers (%)
(n = 3)




18 16 18 Total (all grades)
0 3 15 0 1 15 0 2 16 Total
3 
(100%)
2 (67%) 3 
(100%)
Warmth










(100%) 1 (33%) 2 (67%) Redness







2 (67%) 3 
(100%)
Itch
Severe Mod Mild Severe Mod Mild Severe Mod Mild
Group 3: FP9-PP mid dose
No. volunteers (%)
(n = 3)
Group 2: MVA-PP low dose
No. volunteers (%)
(n = 3)





Table 3.2: Local AEs groups 1 - 3 
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17 16 Total (all grades)
0 3 14 1 1 14 Total
3 (100%) 2 (67%) Warmth
2 (67%) 1 (33%) 1 (33%) 2 (67%) Swelling
3 (100%) 3 (100%) Scaling
1 (33%) 2 (67%) 3 (100%) Redness
2 (67%) 1 (33%) 2 (67%) Pain
3 (100%) 2 (67%) Itch
Severe Mod Mild Severe Mod Mild
Group 5: MVA-PP high dose
No. volunteers (%)
(n = 3)




17 16 Total (all grades)
0 3 14 1 1 14 Total
3 (100%) 2 (67%) Warmth
2 (67%) 1 (33%) 1 (33%) 2 (67%) Swelling
3 (100%) 3 (100%) Scaling
1 (33%) 2 (67%) 3 (100%) Redness
2 (67%) 1 (33%) 2 (67%) Pain
3 (100%) 2 (67%) Itch
Severe Mod Mild Severe Mod Mild
Group 5: MVA-PP high dose
No. volunteers (%)
(n = 3)





Table 3.3:Local AEs groups 4 & 5 
Tables 3.2 & 3.3: Groups 1 – 5, solicited local adverse events up to 28 days post-vaccination 
 
5 2 14 Total (all grades)
0 0 5 0 0 2 0 0 14 Total
1 (33%) 1 (33%) 3 (100%) Myalgia
2 (67%) Malaise
1 (33%) 1 (33%) 2 (67%) Headache
1 (33%) 2 (67%) Feverish
3 (100%) Fatigue
1 (33%) 1 (33%) Documented fever
1 (33%) 1 (33%) Arthralgia
Severe Mod Mild Severe Mod Mild Severe Mod Mild












5 2 14 Total (all grades)
0 0 5 0 0 2 0 0 14 Total
1 (33%) 1 (33%) 3 (100%) Myalgia
2 (67%) Malaise
1 (33%) 1 (33%) 2 (67%) Headache
1 (33%) 2 (67%) Feverish
3 (100%) Fatigue
1 (33%) 1 (33%) Documented fever
1 (33%) 1 (33%) Arthralgia
Severe Mod Mild Severe Mod Mild Severe Mod Mild













Table 3.4: Solicited systemic AEs groups 1 – 3 Chapter 3 VAC027 
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12 11 Total (all grades)
0 0 12 0 0 11 Total
1 (33%) 1 (33%) Nausea
2 (67%) 1 (33%) Myalgia
1 (33%) 2 (67%) Malaise
3 (100%) Headache
3 (100%) 2 (67%) Feverish
3 (100%) 2 (67%) Fatigue
1 (33%) Documented fever
1 (33%) Arthralgia
Severe Mod Mild Severe Mod Mild
Group 5: MVA-PP high dose
No. volunteers (%)
(n = 3)




12 11 Total (all grades)
0 0 12 0 0 11 Total
1 (33%) 1 (33%) Nausea
2 (67%) 1 (33%) Myalgia
1 (33%) 2 (67%) Malaise
3 (100%) Headache
3 (100%) 2 (67%) Feverish
3 (100%) 2 (67%) Fatigue
1 (33%) Documented fever
1 (33%) Arthralgia
Severe Mod Mild Severe Mod Mild
Group 5: MVA-PP high dose
No. volunteers (%)
(n = 3)





Table 3.5: Solicited systemic AEs groups 4 & 5 





0 9 36 0 7 38 0 6 41 Total
8 (89%) 7 (78%)
7 
(78%) Warmth


























6 (67%) 5 (56%)
7 
(78%) Itch
Severe Mod Mild Severe Mod Mild Severe Mod Mild
(n = 9) (n = 9) (n = 9)
No. volunteers (%) No. volunteers (%) No. volunteers (%)





0 9 36 0 7 38 0 6 41 Total
8 (89%) 7 (78%)
7 
(78%) Warmth


























6 (67%) 5 (56%)
7 
(78%) Itch
Severe Mod Mild Severe Mod Mild Severe Mod Mild
(n = 9) (n = 9) (n = 9)
No. volunteers (%) No. volunteers (%) No. volunteers (%)
Vaccine 3 Vaccine 2 Vaccine 1
Description
 
Table 3.6: Solicited local AEs group 6 
Group 6, solicited local adverse events up to 28 days post-vaccination. Chapter 3 VAC027 





0 12 32 1 6 42 0 3 51 Total
7 (78%) 7 (78%) 7 (70%) Warmth




(20%) 8 (80%) Swelling
6 (67%) 8 (89%)
10 
(100%) Scaling




(10%) 9 (90%) Redness
3 (33%) 5 (56%) 7 (78%) 8 (80%) Pain
7 (78%)
9 
(100%) 9 (90%) Itch
Severe Mod Mild Severe Mod Mild Severe Mod Mild
(n = 9) (n = 9) (n = 10)
No. volunteers (%) No. volunteers (%) No. volunteers (%)





0 12 32 1 6 42 0 3 51 Total
7 (78%) 7 (78%) 7 (70%) Warmth




(20%) 8 (80%) Swelling
6 (67%) 8 (89%)
10 
(100%) Scaling




(10%) 9 (90%) Redness
3 (33%) 5 (56%) 7 (78%) 8 (80%) Pain
7 (78%)
9 
(100%) 9 (90%) Itch
Severe Mod Mild Severe Mod Mild Severe Mod Mild
(n = 9) (n = 9) (n = 10)
No. volunteers (%) No. volunteers (%) No. volunteers (%)
Vaccine 3 Vaccine 2 Vaccine 1
Description
 
Table 3.7: Solicited local AEs group 7 












































Severe Mod Mild Severe Mod Mild Severe Mod Mild
(n = 9) (n = 9) (n = 9)
No. volunteers (%) No. volunteers (%) No. volunteers (%)













































Severe Mod Mild Severe Mod Mild Severe Mod Mild
(n = 9) (n = 9) (n = 9)
No. volunteers (%) No. volunteers (%) No. volunteers (%)
Vaccine 3 Vaccine 2 Vaccine 1
Description
 
Table 3.8: Solicited systemic AEs group 6 
Group 6, solicited systemic adverse events up to 28 days post-vaccination Chapter 3 VAC027 





0 2 34 0 0 11 0 0 34 Total
3 (33%)
1 
(11%) 1 (10%) Nausea
5 (56%)
2 
(22%) 6 (60%) Myalgia
5 (56%)
1 
(11%) 6 (60%) Malaise
6 (67%)
3 
(33%) 6 (60%) Headache
6 (67%)
1 
(11%) 5 (50%) Feverish
4 (44%)
2 
(22%) 5 (50%) Fatigue





(11%) 3 (30%) Arthralgia
Severe Mod Mild Severe Mod Mild Severe Mod Mild
(n = 9) (n = 9) (n = 10)
No. volunteers (%) No. volunteers (%) No. volunteers (%)





0 2 34 0 0 11 0 0 34 Total
3 (33%)
1 
(11%) 1 (10%) Nausea
5 (56%)
2 
(22%) 6 (60%) Myalgia
5 (56%)
1 
(11%) 6 (60%) Malaise
6 (67%)
3 
(33%) 6 (60%) Headache
6 (67%)
1 
(11%) 5 (50%) Feverish
4 (44%)
2 
(22%) 5 (50%) Fatigue





(11%) 3 (30%) Arthralgia
Severe Mod Mild Severe Mod Mild Severe Mod Mild
(n = 9) (n = 9) (n = 10)
No. volunteers (%) No. volunteers (%) No. volunteers (%)
Vaccine 3 Vaccine 2 Vaccine 1
Description
 
Table 3.9: Solicited systemic AEs group 7 
Group 7, solicited systemic adverse events up to 28 days post-vaccination. 
 
3.8.3  Immunogenicity 
Immunogenicity was measured by assessing cellular immune responses in an 
ELISPOT. Peripheral blood mononuclear cells (PBMC) were isolated from fresh 
ex-vivo human blood samples collected during the trial and either frozen and 
stored or assessed using the ex-vivo IFN-γ ELISPOT assay (figure 3.6). 
Responses to each antigen were calculated by summing responses to peptide 
pools across each antigen. 
 
3.8.3.1  Groups 1 – 5 
The following graphs show the responses in groups 1-5. These responses are low, 
as expected. Previous experience with these vaccines demonstrates that a single 
dose rarely results in a significant response [146]. Chapter 3 VAC027 
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The study was not powered to provide statistical comparison of the response 
between groups, and the data is from three individuals per group only. Geometric 
mean responses to the whole insert L3SEPTL one week after vaccination were as 
follows: 
Group 1: 62.1 sfu/million PBMCs 
Group 2: 186.1 sfu/million PBMCs 
Group 3: 30.5 sfu/million PBMCs 
Group 4: 135.5 sfu/million PBMCs 
Group 5: 18.7 sfu/million PBMCs 
 
However, comparison with the Mann-Whitney test using STATA™ software 
showed no significant difference in responses to the whole L3SEPTL insert at day 
7 in the following cases: when comparing FP9 and MVA vectors at low (p =0.13) 
and medium dose (p = 0.28); when comparing responses by vector regardless of 
dose (FP9 groups 1 & 3 v MVA groups 2, 4 and 5, p = 0.35); and when comparing 
different doses with the same vector (p = 0.13 to 0.83). 
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VAC027 IFN-γ γ γ γ ELISPOT responses
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VAC027 IFN-γ γ γ γ ELISPOT responses


































VAC027 IFN-γ γ γ γ ELISPOT responses





































Figure 3.6: IFN-γ ELISPOT responses groups 1-5 
ELISPOT responses to vaccine epitopes in groups 1 – 5 at baseline (D0) and 7 days after 
vaccination (V1+7). Horizontal lines show median response. Individual vaccine components 
are displayed along the x axis and response against the y axis, summed from multiple pools 
where applicable. The final data column represents the summed responses against the 
entire vaccine insert. 
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VAC027 IFN-γ γ γ γ ELISPOT responses


































Figure 3.7: IFN-γ ELISPOT responses to whole L3SEPTL insert groups 1–5 
Summed ELISPOT responses to whole L3SEPTL insert at baseline (D0) and 7 days after 
vaccination (V1+7). Horizontal lines show the median response. Responses are summed 
from multiple peptide pools. 
 
There is no clear relationship between dose of vaccine and the measured immune 
response in groups 1 to 5. There appears to be a trend towards an increased 
response following MVA at low or intermediate dose (groups 2 & 4) compared to 
FP9 at the equivalent doses (groups 1 & 3, see figure 3.7), however the high dose 
of MVA generates a response equivalent to the low or intermediate doses of FP9. 
 
3.8.3.2  Groups 6 & 7 
Figure 3.8 contains graphs showing the immune responses for groups 6 and 7. 
MVA induces a statistically significant priming response to the whole L3SEPTL 
insert in group 7 (p = 0.008) where FP9 fails to do so in group 6 (p = 0.68) when 
comparing responses at D0 with those at V1+7 (Wilcoxon signed rank test in 
STATA™). There is no significant rise in responses after the second vaccination (p 
= 0.31 for MVA and p = 0.67 for FP9 at V2+7 compared to V1+28). However MVA 
again induces a significant rise in responses to L3SEPTL at the final (boosting) 
dose (p = 0.04 for MVA in group 6, p = 0.67 for FP9 in group 7, comparing V3+7 
with V2+7 in each case). 
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The peak response (that obtained 7 days after the third vaccination) in these two 
groups was again low. Geometric mean response at V3+7 in group 6 was 100.8 
sfu/million PBMCs, and group 7 was 92.0 sfu/million PBMCs. 
 
 
VAC027 IFN-γ γ γ γ ELISPOT responses








































VAC027 IFN-γ γ γ γ ELISPOT responses








































Figure 3.8: IFN-γ ELISPOT responses groups 6 & 7 
ELISPOT responses to vaccine epitopes in groups 6 and 7 at baseline and following 
vaccination. Horizontal lines show the median response. Individual vaccine components are 
displayed along the x axis and response against the y axis, summed from multiple pools 
where applicable. The final data column represents the summed responses against the 
entire vaccine insert. For group 6, n=9 for time points D0, V1+7 and V1+28 but n=8 for time 
points V2+7 and V3+7. For group 7, n=10 for D0, n=9 for V1+7, V1+28 and V2+7 and n=8 for 
V3+7. 
 
 Chapter 3 VAC027 
  80 
VAC027 IFN-γ γ γ γ ELISPOT responses
Group 6 (n = 8 to 9)



























VAC027 IFN-γ γ γ γ ELISPOT responses
Group 7 (n = 8 to 10)



























Figure 3.9: IFN-γ ELISPOT responses to whole L3SEPTL insert groups 6 & 7 
Summed ELISPOT responses to whole L3SEPTL at baseline (D0) and following vaccination. 
Horizontal lines show the median response. The data shown represents the summed 
responses against the entire vaccine insert. For group 6, n=9 for time points D0, V1+7 and 
V1+28 but n=8 for time points V2+7 and V3+7. For group 7, n=10 for D0, n=9 for V1+7, V1+28 
and V2+7 and n=8 for V3+7. 
 
Analysis of responses 7 days after the first vaccine for volunteers in all groups (1 – 
7) by epitope shows that levels are significantly above baseline for LSA1 (p = 
0.001) but not for any other epitopes or the total L3SEPTL insert (p = 0.053). By 
the end of the trial (at V3+7), responses to the whole L3SEPTL insert were 
significantly higher than at baseline in group 7 (p = 0.01) but not in group 6 (p = 
0.94). This may in part be due to unexpectedly high baseline responses to the 
vaccine strain TRAP epitope (T996) in group 6 compared to group 7 (p = 0.003). 
 
The cellular immune response to vaccination was disappointingly poor. There was 
no clear relationship between vaccine dose and response in the dose-lead in Chapter 3 VAC027 
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groups or between vaccine vector and response at prime or boost in the prime-
boost groups. Group 7 achieved a modest but significant increase in overall 
responses by 7 days following final vaccination (p = 0.01 using Wilcoxon signed 
rank test). Disappointingly, however, group 6 responses at this time point were not 
significantly different from the relatively high baseline. 
 
3.8.4  Efficacy 
Mean time to parasitaemia for controls (n = 6) was 12.8 days (S.D. 1.4 days), 
compared to 11.6 days for group 6 (n = 8, S.D. 1.5 days), and 12.4 days for group 
7 (n = 7, S.D. 1.0 days). A Kaplan Meier plot of survival is shown in figure 3.10. All 
volunteers developed malaria during the follow up period. There is no significant 
difference in time to parasitaemia for volunteers in either vaccination group 
compared to controls (Log rank = 3.2, p = 0.2).  
 

































Figure 3.10: Kaplan meier plot  
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The mean rate of blood stage parasite growth were as follows: in group 6, 7.5 
parasites per ml per cycle (95% confidence intervals 3.9 – 11; standard deviation 
4.2), for group 7 this was 7.4 parasites per ml per cycle (95% CI 4.1 – 10.7; SD 
3.5) and for controls it was 9.1 parasites per ml per cycle (95% CI 7.4 - 10.8; SD 
1.6). There was no significant difference in growth rates between different groups 
of vaccinees, (Group 6 vs. Group 7, Mann Whitney U test, two tailed p = 0.95) or 
between control volunteers and those who received either vaccine regimen (Group 
6 plus Group 7 vs. Controls, Mann Whitney U, two tailed p = 0.19). 
 
As the vaccines used have both a liver stage and a blood stage component, as 
well as looking at the blood stage parasite growth rates, the numbers of infected 
hepatocytes are of interest. In group 6, the mean estimate of infected hepatocytes 
was 146, (95% CI, 60-232, SD 103), for group 7, the mean was 133 (95% CI, -3-
270, SD 148), whilst for control volunteers the mean was 109, (95% CI, 33-183, 
SD 71). There was no significant difference, either between group 6 and group 7 
(Mann Whitney U, two tailed p = 0.56), or between all vaccinated volunteers 
together and controls (Group 6 + Group 7 vs. Controls, Mann Whitney U, two 
tailed p = 0.76). 
 
3.9  Discussion 
This trial examined the safety and immunogenicity of a novel candidate malaria 
vaccine encoding a synthetic ‘polyprotein’ string of six pre-erythrocytic 
Plasmodium falciparum antigens [167]. In theory a broad response against 
multiple parasite epitopes might enhance the immune response to provide immune 
protection and also reduce the risk of parasite escape mutants arising.  
 
Preclinical work in mice suggested that a heterologous prime-boost immunisation 
regime employing poxvirus vaccines provided better immunogenicity than a 
homologous prime-boost regime or a heterologous regime incorporating a DNA 
vaccine, however it was not clear in which order the poxviruses should be 
employed as prime and boost. Strong responses were seen in splenocytes after 
intravenous vaccination when measured by the IFN-γ ELISPOT assay and by 
assessing the proportion of antigen-specific CD8+ T-cells by tetramer-staining. Chapter 3 VAC027 
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The immunogenicity following vaccination in all study groups was disappointing. 
Previous human trials of poxviruses encoding P. falciparum antigens have 
produced specific T cell responses of the order of 400 spot-forming units per 
million PBMC. The more effective prime-boost group in this trial (Group 7) 
achieved an increase in the summed response to the whole insert of just under 
100 spots per million PBMC at the peak time point (V1+7). 
 
The reasons for the poor immune responses generated by this vaccine in humans 
are not clear. The vaccine had been stored as recommended by the manufacturer 
and remained infectious when tested prior to use. The intradermal route has 
proved the most immunogenic in previous trials of poxvirus vaccines encoding 
malaria antigens in humans, but it is possible that this is not the optimal route for 
this vaccine in humans. The HLA type of the volunteers participating determines 
their capacity to generate responses to a specific antigen, however there was a 
good spread of different class I and class II types in volunteers in this study. In 
keeping with the low immunogenicity observed in these vaccines, no efficacy was 
demonstrated in the sporozoite challenge study. All volunteers succumbed to 
malaria infection by day 14.5 after the challenge.  
 
The clinical safety profile of this vaccine was good. 34 volunteers enrolled and 31 
(91%) completed the trial successfully. Only one of these withdrew due to an 
adverse event, which was judged to be unrelated to either vaccine or challenge. A 
total of 68 doses of vaccine were administered. Of 701 adverse events recorded, 
581 were judged probably or definitely related to vaccination and 568 of these 
(97.7%) were solicited adverse events. Only two adverse events were classed as 
‘severe’ – one related and solicited (swelling around the vaccine site) and one 
unrelated and unsolicited (a fractured coccyx). Severe adverse events represent 
approximately 0.3% of the total number, whilst approximately 8% were moderate. 
All others were classed as mild. No suspected unexpected serious adverse 
reactions (SUSARs) or serious adverse events (SAEs) occurred during this study.  
 
The safety profile of this vaccine provides further support for the ongoing program 
to develop effective vaccines against malaria, tuberculosis and HIV employing this Chapter 3 VAC027 
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approach and for exploring the use of other recombinant viral vectors to enhance 
immunogenicity. 
 
Further work is needed to determine whether other viral vectors or other P. 
falciparum antigens can deliver enhanced immunogenicity. This work is ongoing 
within the laboratory and clinic. If alternative vectors such as adenoviruses are 
found to be more immunogenic than the poxviruses used here, the multi-antigen 
approach used here would be worth reconsidering. However, there are no further 
plans for use of the polyprotein construct at present. 
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Chapter 4   VAC030 
‘Assessment of protection against malaria by 
sporozoite challenge of healthy adults vaccinated 
with the virosomal vaccine PEV3A and FP9-MVA 
ME-TRAP’ 
 
4.1  Introduction and Purpose 
This trial was the first to evaluate clinically the combined administration of two 
promising malaria vaccines targeting different life-cycle stages: FP9/MVA ME-
TRAP and PEV3A. Recent studies in murine malaria, assessing combinations of 
an anti-sporozoite vaccine and an anti-liver-stage vaccine [195], suggested that 
the observed outcome of combining these vaccines may be synergy. In this work, 
mice were vaccinated with recombinant viral vaccines FP9 and MVA expressing 
the P. berghei circumsporozoite protein, or a protein vaccine (CV-1866) consisting 
of hepatitis B core antigen particle containing two copies of the P. berghei CS B 
cell epitope DPPPPNPN (DP4), or a combination of the two. Mice were then 
challenged with P. berghei sporozoites to determine the protective efficacy of 
different vaccine regimens. The protein vaccine CV-1866 induced strong humoral 
immune responses that protected 12% animals from infection. The viral vectored 
vaccines, FP9 followed by MVA, induced strong T cell immunity that was partially 
protective (37% of animals) against the liver-stage of malaria. A mixture of the two 
vaccine types administered as a combination powerfully induced both types of 
immunity to the malarial antigen and afforded substantially higher levels of 
protection (combination; 90%) than either vaccine alone. Analysis of T cells and 
antibodies induced by the combination of vaccines revealed that both contributed 
to the enhanced levels of protection conferred by this regime.  
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For diseases such as malaria in which different potent immune responses are 
required to protect against different stages, using combinations of partially 
effective vaccines may offer a more rapid route to achieving deployable levels of 
efficacy than further development of individual vaccine strategies. This clinical trial 
was devised to test two currently available vaccine regimens in combination, with 
the hope that greater efficacy might be achieved by combining humoral and 
cellular immune responses.  
 
The viral vectors Fowl pox strain FP9 (FP9) and Modified vaccinia Virus Ankara 
(MVA) expressing the pre-erythrocytic antigen thrombospondin-related adhesion 
protein (TRAP), fused to a multi-epitope (ME) string, were developed in Oxford. 
When used in a prime boost regimen in malaria naïve individuals in Oxford, these 
vaccines induced good CD4 and CD8 T cell responses, and protected two 
individuals out of five completely from malaria in a sporozoite challenge. This 
protection persisted in one individual on two further challenges at 14 and 20 
months after vaccination [132].  
 
These encouraging data have led to the assessment of FP9-MVA ME-TRAP in a 
series of phase I studies in adults and in children in Gambia [148] and in Kenya. 
Good safety and strong T cell immunogenicity led to the initiation of a phase IIb 
efficacy trial of this vaccine against clinical malaria in 406 Kenyan children in 
March 2005. These studies have failed to replicate the results seen in Oxford. In 
both studies, immune responses in semi-immune adults in the Gambia, and 
particularly in children in Kenya, were lower than those seen in Oxford, and no 
efficacy against febrile malaria was observed in the Kenyan study of children living 
in an area of hyper-endemic malaria [150]. 
 
The ME string is a multiple epitope string including fourteen CD8+ T cell epitopes, 
one CD4+ T cell epitope, and two B cell epitopes from six pre-erythrocytic P. 
falciparum antigens. See table 4.1 for further details. It also contains two non-
malarial CD4+ T cell epitopes [145]. The ME string is fused in frame to the entire 
T9/96 strain of P. falciparum TRAP [127, 193, 196]. Of particular importance for 
this study, one of the B cell epitopes present in the ME string includes copies of 
the NANP sequence derived from the circumsporozoite protein, also used in UK39 Chapter 4 VAC030 
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in PEV3A. In addition, it contains three CD8+ and one CD4+ T cell epitopes also 
derived from the circumsporozoite protein, but no AMA-1 derived epitopes. 
 
Epitope Antigen Type HLA restriction
ls8 LSA1 CTL B35
cp26 CSP CTL B35
ls6 LSA1 CTL B53
tr42/43 TRAP CTL B8
tr39 TRAP CTL A2.1
cp6 CS CTL B7
st8 STARP CTL A2.2
ls50 LSA1 CTL B17
pb9 PbCS CTL mouse H2 -K d
tr26 TRAP CTL A2.1
ls53 LSA1 CTL B58
tr29 TRAP CTL A2.2
NANP CS B cell
TRAP AM TRAP Heparin binding 
cp39 CS CTL A2.1
la72 LSA3 CTL B8
ex23 Exp1 CTL B58
CSP CS T helper
BCG BCG T helper
TT TT T helper
Universal
epitopes
Epitope Antigen Type HLA restriction
ls8 LSA1 CTL B35
cp26 CSP CTL B35
ls6 LSA1 CTL B53
tr42/43 TRAP CTL B8
tr39 TRAP CTL A2.1
cp6 CS CTL B7
st8 STARP CTL A2.2
ls50 LSA1 CTL B17
pb9 PbCS CTL mouse H2 -K d
tr26 TRAP CTL A2.1
ls53 LSA1 CTL B58
tr29 TRAP CTL A2.2
NANP CS B cell
Epitope Antigen Type HLA restriction
ls8 LSA1 CTL B35
cp26 CSP CTL B35
ls6 LSA1 CTL B53
tr42/43 TRAP CTL B8
tr39 TRAP CTL A2.1
cp6 CS CTL B7
st8 STARP CTL A2.2
ls50 LSA1 CTL B17
pb9 PbCS CTL mouse H2 -K d
tr26 TRAP CTL A2.1
ls53 LSA1 CTL B58
tr29 TRAP CTL A2.2
NANP CS B cell
TRAP AM TRAP Heparin binding 
cp39 CS CTL A2.1
la72 LSA3 CTL B8
ex23 Exp1 CTL B58
CSP CS T helper
BCG BCG T helper




Table 4.1: Epitopes included in the ME-TRAP vaccine 
 
PEV3A was developed by Pevion Biotech in collaboration with the Swiss Tropical 
Institute. This vaccine uses virosomal technology; initially developed as a delivery 
system for hepatitis A vaccine [197]. Virosomes (immunopotentiating reconstituted 
influenza virosomes; or IRIVs) are small spherical vesicles, prepared by detergent 
removal from a mixture of natural and synthetic phospholipids and influenza virus 
surface glycoproteins. On their surface, they carry the influenza surface 
glycoproteins haemagglutinin (HA) and neuraminidase (NA). They have been 
shown to act as an efficient and highly effective means of enhancing the immune 
response to a variety of antigens [122]. The haemagglutinin membrane 
glycoprotein of influenza virus plays a key role in the mode of action of virosomes. 
As a major influenza viral antigen, it is a fusion-inducing component which 
facilitates antigen delivery to immunocompetent cells. In this vaccine, two synthetic 
P. falciparum peptide-PE conjugates are incorporated into the virosomes. These 
are derived from the circumsporozoite protein (CS) and the apical membrane 
antigen-1 protein (AMA-1) of P. falciparum. The peptide from the CS protein 
(UK39) is the major B cell epitope NANP in a specific conformation [198]. The Chapter 4 VAC030 
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peptide from AMA-1 (AMA-49) mimics the semi-conserved loop I of domain III and 
has been found capable of inducing antibodies that impairs the growth of P. 
falciparum blood-stage parasites [199]. These peptides are linked to a 
phospholipid (phosphatidylethanolamine) and this conjugate is then integrated into 
the virosomal membrane during the reconstitution process [198, 200]. A key 
feature of the synthetic peptides used here is that they are cyclised, and therefore 
they are displayed in a native-like state on the surface of the virosome. The 
sequences of both peptides used in this vaccine were derived from the K1 isolate 
of P. falciparum. The two components of this vaccine have been used individually 
and in combination in a Phase I study in Switzerland previously and found to be 
safe and immunogenic [201]. 
 
4.2  Methods 
4.2.1  Objectives 
The primary objective for this study was to assess protection against P. falciparum 
malaria infection following the virosomal vaccine PEV3A alone or in combination 
with FP9-MVA ME-TRAP vaccination. The secondary objective was to confirm the 
immunogenicity of PEV3A vaccination alone or in combination with FP9-MVA ME-
TRAP with measures of anti parasite immunity. These included assessment of the 
induced cellular and antibody immune responses. The third objective was to 
assess safety of the vaccines when administered alone and in combination. 
 
4.3  Outcome Measures 
4.3.1  Primary Objective - Efficacy 
Protection against malaria infection was the primary objective, and this was 
assessed using a P. falciparum sporozoite challenge model. To assess the 
efficacy of the vaccines all vaccinated subjects and six unvaccinated control 
subjects underwent experimental challenge with Plasmodium falciparum, fourteen 
days after the final vaccination. The details of the challenge method can be found 
in Chapter 7 of this thesis, but briefly, laboratory-reared Anopheles stephensi Chapter 4 VAC030 
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mosquitoes were infected with the 3D7 strain of P. falciparum parasites in an 
adapted model [202] as described before [146]. From the evening of day 6 
subjects attended clinic twice daily for review of symptoms, vital signs monitoring 
(pulse, blood pressure and oral temperature) and withdrawal of 3 mL of blood for 
thick film and PCR analysis for parasite DNA. Field’s stain thick films were 
examined immediately by experienced microscopists for the appearance of viable 
parasites. A minimum of 200 high power fields were examined before a subject 
was declared slide negative. Subjects who reached day 15 without blood film 
evidence of malaria infection were followed up daily until day 21. All subjects were 
treated immediately with Riamet® (artemether 20mg, lumefantrine 120mg, 
Novartis) on diagnosis of malaria by the identification of a viable parasite on thick 
film. Subjects returned to clinic on two consecutive days for negative blood films 
post treatment. The pre-patent period was defined as the time to diagnosis, and 
efficacy was assessed by comparing this time period in vaccinated and 
unvaccinated subjects. 
 
The analysis for the primary objective was based on the number of hours between 
infectious challenge and blood stage parasitaemia. Each of the groups was 
compared with the other and with the control group using the Kaplan Meier 
method. Statistical significance of any differences observed was then assessed by 
the log rank test.  
 
Blood was taken daily for PCR analysis for parasite DNA. This was performed in 
real time, although the clinicians assessing the volunteers were blinded to the 
results. The method used is described in detail in [194]. The results of the PCR 
analysis were used to estimate parasite growth rates. A description of this method; 
and the reasons for choosing it over the other available methods for calculating 
parasite growth rates can be found in Chapter 6 of this thesis. Briefly, it is based 
on a statistical model of parasite distribution, using a convolution of two probability 
density functions to estimate the numbers of parasites present in the blood at any 
time [203]. The model was coded into an Excel ™ spreadsheet, and the solver 
minimization routine was used to estimate the best solution by minimization of the 
squared difference between calculated and predicted values. Further analysis of Chapter 4 VAC030 
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parasite growth rates was undertaken using Mann Whitney U tests to compare 
groups.  
 
4.3.2  Secondary Objective - Immunogenicity 
The secondary objective was to assess the immunogenicity of the vaccines, when 
used in this way in combination. In order to quantify this, blood samples were 
taken from each volunteer at various time points during the study. A variety of 
methods were used to assess the magnitude and specificity of the induced 
immune response. Cellular immunity in the form of T cell responses to the 
vaccines were assessed using IFN-γ ELISPOT. ELISA was used to look for 
vaccine specific antibodies.  
 
ELISPOT was performed on PBMCs obtained from each volunteer at various time 
points (described in Section 4.3 Investigational Plan) as reported previously [204]. 
Anti-UK-39 and anti-AMA49-C1 antibodies were measured by ELISA. Briefly, 
ELISA polysorp microtiter plates (Nunc, Dr. Grogg, Stetten-Deiswill, Switzerland) 
were coated at 4° C overnight with 10 µg/ml AMA49-C1 (for PEV301) or UK-39 (for 
PEV302) in PBS, pH 7.4. Wells were then blocked with 5% milk powder in PBS for 
2 h at 37° C followed by three washes with PBS containing 0.05% Tween-20. 
Plates were then incubated with two-fold serial dilutions of human serum starting 
with 1:50 in PBS containing 0.05% Tween-20 and 0.5% milk powder for 2 h at 
37° C. After washing, the plates were incubated with horseradish-peroxidase-
conjugated goat anti-human IgG antibodies (KPL, Socochim, Lausanne, 
Switzerland) (1:2000 in PBS containing 0.05% Tween-20) for 1 h at 37° C and then 
washed. 1, 2-Diaminobezene substrate (OPD) (20 mg/tablet (Fluka, Sigma, 
Buchs, Switzerland)) in citrate-buffer (4 mg/ml OPD) + 0.01% H2O2 was added 
and incubated at room temperature. After 10 minutes the reaction was stopped by 
addition of sulphuric acid (final concentration 0.5M (Merck, Darmstadt, Germany)). 
The optical density (OD) of the reaction product was recorded at 492 nm using a 
microplate reader (SpectraMax plus, Bucher Biotech, Basel, Switzerland). Titration 
curves were registered using Softmax PRO software. Endpoint titres were 
calculated by comparing the ELISA OD of the test serum with the ELISA OD of a Chapter 4 VAC030 
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negative serum pool. The endpoint titre is the last serum dilution where the ODtest 
sera ≥ 2 x ODnegative serum. 
 
Avidity index (concentration of thiocyanate leading to the dissociation of 50% of 
the bound IgG in ELISA) was measured by adding serial dilutions of ammonium-
thiocyanate after serum incubation (triplicates at halfmax saturation), leading to 
partial dissociation of bound antibodies [205]. Western blotting with a lysate of P. 
falciparum (strain NF54) infected A. stephensi salivary glands, or a lysate of in 
vitro cultivated P. falciparum (strain K1; schizont stage) blood stage parasites, was 
performed to measure anti-CS protein or anti-AMA-1 IgG seroconversion at a 
serum dilution of 1:100. Immunofluorescent antibody assays (IFA) were used to 
measure anti-parasite IgG endpoint titres (defined as last serum dilution where a 
staining of the parasite is visible). IFA with a suspension of P. falciparum (strain 
NF54) infected A. stephensi salivary glands and IFA with a suspension of 
synchronised P. falciparum (strain K1; schizont stage) infected red blood cells, 
was used to assess anti-sporozoite and anti-blood stage endpoint titres, 
respectively. Western blotting and IFA are described in more detail in [199] (Okitsu 
et al., accepted). Positive and negative sera from a Phase 1 trial with PEV301 and 
PEV302 [123] were used as controls for ELISA, IFA and Western blotting.  
 
4.3.3  Tertiary Objective - Safety 
The third objective, safety and tolerability, is descriptive. It was assessed by 
collection of local and systemic adverse events. Each subject was observed for at 
least 30 minutes after vaccination, and underwent clinical review 2, 7 and 28 days 
after each vaccination for reporting of solicited and unsolicited adverse events. 
Subjects also completed a diary card every day for the first 7 days after each 
vaccination. Full blood count and biochemistry (urea, electrolytes, alanine 
aminotransferase, bilirubin, alkaline phosphatase, albumin) was performed at day 
0, 7, 28, 35, 56, 63, day of challenge (day 77), challenge + 7 days (day 84), 
challenge + 35 days (day 112) and challenge + 90 days (day 167). 
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4.3.4  Methods for Ancillary Analyses – Growth Inhibition Assay 
In order to quantify the ability of the induced antibodies to affect or modify parasite 
growth, Growth Inhibition Assays (GIA) were performed on plasma samples from 
each volunteer. Samples were shipped to Carole Long at the NIH for parasite 
Growth Inhibition Assay (GIA) analysis as described elsewhere [206]. Briefly, 
polyclonal IgG was purified from plasma, adjusted to a concentration of 
30.0mg/mL in incomplete RPMI 1640, and tested for biological activity against 
both the 3D7 and FVO strains of Plasmodium falciparum. Both strains are 
heterologous to those used in the construction of the vaccines – T9/96 in the ME 
TRAP construct, and K1 for PEV3A. A standardized GIA assay with samples from 
all volunteers on the day of challenge was performed and was compared with 
activity in samples from day 0. 
 
4.3.5  Methods for Ancillary Analyses – Parasite Sequencing 
One volunteer, M1030525, remained undiagnosed until day 20 after the challenge 
and then succumbed to malaria infection. The possibility that this could be an 
example of parasite immune escape was considered. Vaccination induced 
mutations in another Plasmodium antigen have been described in monkeys, after 
relatively short periods of infection [207]. Parasite DNA was extracted from a blood 
sample from volunteer 525 on day 20 as described [194]. Samples were prepared 
using the following method. 
 
Leukocytes were removed from the blood by filtration. Samples were centrifuged 
(5 minutes, 2,500 rpm, Beckman GS-6K centrifuge, Beckman Coulter, Inc., 
Fullerton, CA) and the sample volume marked on each tube. Plasma was removed 
and the cells were then resuspended with 1 mL sterile PBS and mixed by 
inversion.  The 24-well filter plate containing two layers of a glass-fibre based 
material (Whatman International, Clifton, NJ; product code 7700-9902) was 
positioned above a 24-well collection plate in a UniVac3 vacuum manifold (both 
from Whatman International) and samples added to each well. The vacutainer 
tubes were washed with 1 mL PBS, and this was poured into the corresponding 
sample well before drawing the sample through the filter by vacuum. Vacutainer Chapter 4 VAC030 
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tubes were washed again with 1 mL PBS and blood solutions filtered in the 
appropriate well. Filter wells were washed with 0.5 mL PBS, and this was filtered 
through. Samples were transferred back to their original vacutainer tubes, 
centrifuged (5 minutes, 2,500 rpm, (Beckmann GS-6K), and returned to the 
original blood sample volumes by removing excess supernatant. The blood 
samples were mixed by inversion, 0.5 mL was taken for immediate DNA 
extraction, and the remainder stored at –80° C. 
 
DNA extraction was then performed using the QIAamp DNA Blood Mini kit 
(QIAGEN, Crawley, UK) with some modifications to the standard protocol. The 
sample volume was 0.5 mL filtered blood. Volumes of protease, lysis buffer, and 
ethanol were 40 µL, 400 µL, and 400 µL, respectively, and wash buffer volumes 
increased to 750 µL. The second wash buffer allowed to soak on the DNA 
purification columns for 2 minutes before the vacuum was applied. Columns were 
transferred to collection tubes and centrifuged at 13,000 rpm for 4 minutes. DNA 
was eluted with 50 µL sterile 10 mM Tris, pH 8.0, incubating for 1 minute at room 
temperature before centrifugation (1 minute, 8,000 rpm) to collect the DNA 
sample.  
 
Primers were designed using primer design software (PrimerSelect, part of 
LaserGene from DNAStar, Madison, Wisconsin, USA) to produce a PCR product 
of 517 base pairs, from the AMA-1 gene of P. falciparum, 3D7 strain, from 998 – 




1: 517 bp product including PEV3A peptide 
Upper primer: 21 mer 5’ GAGTGCTTCGGATCAACCTAA 3’ 
Lower primer: 24mer 5’ TACTTCTGCCCTTCTTTCTACACA 3’ 
 
After optimization experiments, the PCR conditions were selected, and the Expand 
High Fidelity PCR system (Roche Applied Science) was chosen to produce PCR 
fragments for cloning. This system contains proof reading polymerase enzymes to 
correct transcriptional errors, minimizing the chance that any changes in sequence Chapter 4 VAC030 
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detected were as a result of the PCR itself. Two mixes were prepared containing 
the following components (volumes given are for one PCR reaction). 
 
20 Final reaction volume
0.75 Reverse primer (10 µM)
0.75 Forward primer (10 µM)
1.25 Nucleotide mix
17.25 PCR grade water
Volume (µL)
20 Final reaction volume
0.75 Reverse primer (10 µM)
0.75 Forward primer (10 µM)
1.25 Nucleotide mix
17.25 PCR grade water
Volume (µL)
 
Table 4.2: PCR mix 1 
 
25 Final reaction volume
0.75 Expand enzyme
5 Buffer
2.5 MgCl2 (25 µM stock)
16.25 PCR grade Water
Volume (µL)
25 Final reaction volume
0.75 Expand enzyme
5 Buffer
2.5 MgCl2 (25 µM stock)
16.25 PCR grade Water
Volume (µL)
 
Table 4.3: PCR mix 2 
 
One volume of each of mix 1 and 2 was added to each well for PCR reaction, and 
5 µL of template DNA was added. A positive control of a sample of 3D7 parasite 
DNA was included, and a negative control of water instead of sample DNA. Each 
reaction was overlaid with 25 µL mineral oil (Sigma Aldrich) to prevent 
evaporation. The PCR reactions were carried out on a Tetrad thermocycler (MJ 
Scientific) in 96 well microtitre plates. The PCR programme used was 2 minutes at 
94° C, followed by 35 cycles of 15 seconds at 94° C, 30 seconds at the specific 
annealing temperature (54° C) and 1 minute at 72° C. 
 
Agarose gel electrophoresis confirmed the bands were of the correct size. The 
band was cut from the gel, and DNA was isolated from using a MinElute Gel 
Extraction kit (Qiagen, Crawley, West Sussex, UK). Briefly, the gel section is 
placed in a 1.7 mL tube containing 750 µL solubilisation buffer, and heated in a Chapter 4 VAC030 
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water bath at 50° C until the gel had dissolved completely. The solution is then 
added to a MinElute column, and centrifuged at 13,000 rpm for one minute, the 
flow through is discarded. Any remaining solution is added to the column and 
again spun through.  The column is then washed with 750 µL PE wash buffer, and 
again centrifuged at 13,000 rpm for 1 minute. This spin is repeated to ensure all 
wash buffer is removed from the column. To elute the PCR fragment, 10 µL of 
water is then added to the column, and left to soak for 1 minute before another 
spin at 13000 rpm for 1 minute. 
 
The PCR fragments were then cloned using the pGEM-T Easy vector system 
(Promega) The following mix was prepared on ice, and then left at room 
temperature for two hours to ligate. 
 
10 Final volume




2 Purified PCR product
Volume (µL)
10 Final volume




2 Purified PCR product
Volume (µL)
 
Table 4.4: Cloning mix 
 
 
LB agar plates containing Ampicillin (100µg/mL), X-gal in DMF (60µg/mL) and 
0.1mM isopropyl-β-D-thiogalactopyranoside (IPTG) dissolved in 50% EtOH (Sigma 
Aldrich) were prepared. The ligated vector was transformed into MAX efficiency® 
DH5α™ chemically competent Escherichia coli cells (Invitrogen Ltd.) by adding 
10µL ligation mix to 100µL cells and incubating on ice for 30 minutes for the vector 
to bind to the surface. The cells were then placed in a water bath at 42° C for 45 
seconds to heat-shock the vector into the cells. The samples were placed 
immediately back on ice for 10 minutes before plating 20mL volumes onto the agar 
plates and incubating overnight at 37° C. 
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White colonies were picked from these plates and then purified using a QIAGEN 
Plasmid Mini kit (Qiagen Crawley, West Sussex, UK). Six colonies were selected 
and each was inoculated into a starter culture of 5mL LB medium containing 
Ampicillin (100µg/mL). These were incubated at 37° C with vigorous shaking for 16 
hours. Bacterial cells were harvested from 3 mL for each colony by centrifugation 
at 13200 rpm for 10 minutes. The bacterial pellet was then resuspended in 150 µL 
P1 buffer by vortexing. 300 µL P2 buffer was then added and mixed vigorously, 
samples were then incubated for 5 minutes at room temperature. 300 µL P3 buffer 
is then added to each tube, and again vigorously mixed, and incubated 
immediately on ice for 5 minutes. Samples were then centrifuged at 13200 rpm for 
10 minutes, the supernatant was then added to a pre-equilibrated Qiagen-Tip 20 
column, and allowed to drip through by gravity. Columns were washed with Buffer 
QC, and the DNA was then eluted from the column with 0.8mL of Buffer QF. DNA 
was then precipitated with 0.56mL of isopropanol and centrifuged at 13000 rpm for 
30minutes. Pellets were washed with 1mL 70% Ethanol and left to air dry. 
 
Restriction digests were then performed to confirm the plasmid identity (to check 
all selected clones contain an inserted sequence of the correct size). The 
















Table 4.5: Restriction digestion mix 
 
The digestion mix was incubated at 37° C for 2 hours, Loading dye was added to 
the digestion and samples were run on agarose gel to visualise the inserted 
sequence. Five out of six clones contained the inserted sequence, and the DNA 
was ethanol precipitated. DNA pellets were left to air dry, and were then sent to Chapter 4 VAC030 
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MWG-Biotech (Ebersberg, Germany) for sequencing with universal M13 forward 
and reverse primers. 
 
Subsequently, primers were also designed to cover the upstream region, including 
the promoter of AMA-1.  
 
 
2: 762 bp product 
Upper primer: 22mer 5’ TGCTTTTCCTCCAACAGAACCT 3’ 
Lower primer: 22mer 5’ ATGGGATGGGACAAAGCAGTAG 3’ 
 
3: 656bp product  
Upper primer: 26mer 5’ CGTATTATTATTGAGCGCCTTTGAGT 3’ 
Lower primer: 25mer 5’ TCATATTTCCTGCATGTCTTGAACA 3’ 
 
4: 636bp product 
Upper primer: 31mer 5’ GTGCTTCTTTTTTATTTCACTTTTGTTAGAG 3’ 
Lower primer: 28 mer 5’ ATGCGTGTTGTAATGTATTTTCGTCTTC 3’ 
 
These primers were used with both the Expand PCR high fidelity system and the 
Phusion High Fidelity DNA polymerase system (New England Biolabs, Ipswich, 
Massachusetts, USA). Multiple conditions and PCR programmes were tried with 
each system, it was not possible to amplify any PCR product from the sample from 
M1030525 using these primers. The positive controls worked, indicating that the 
primers themselves were binding to parasite DNA, however it is possible that there 
was insufficient good quality DNA remaining in the sample by this stage.  
 
4.3.6  Methods for Ancillary Analyses – Crisis Forms 
During the challenge phase of the study, microscopists detected the presence of 
morphologically abnormal parasites in films from volunteers pre-diagnosis. These 
differ from normal parasites in the staining of the nuclear material. While live 
parasites have nuclei that stain red/blue, these abnormal parasites stained only Chapter 4 VAC030 
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blue (see figure 4.1). We hypothesised that these were ‘crisis forms’ and that they 
might be an effect of vaccine-induced blood stage immunity. 
 
Figure 4.1: Crisis forms 
Morphologically normal parasite (left) and Crisis form (right). Note the difference in the 
parasite nuclear staining. 
 
Crisis forms were first described in 1944 by Taliaferro, WH and Taliaferro LG 
[208]. They are parasites whose intra-erythrocytic development has been retarded, 
resulting in morphologically abnormal parasites. These were initially found in 
Plasmodium brasilianum infection of Cebus monkeys undergoing a severe 
immunologic crisis. The crisis parasites appeared within erythrocytes at the same 
time as a rapid decrease in parasitaemia. They have since been described in 
mouse [209] and human malarias [210]. A study by Jensen et al. [211] 
demonstrated induction of crisis forms in cultured P. falciparum with human 
immune serum from Sudan. Intra-erythrocytic development was retarded, leading 
to the formation of crisis forms and parasite deterioration to some extent, by all 
sera that were tested in this study. They proposed two models to explain this intra-
erythrocytic, anti-parasitic action: 1) the presence in immune sera of a toxic 
cytokine, crisis form factor, 2) crisis forms result from oxidative stress generated 
during respiratory bursts associated with phagocyte activation, or indirectly by 
toxic products of lipid peroxidation produced by reactive oxygen species 
associated with phagocyte respiratory bursts. It has subsequently been shown that 
TNF alpha (a prime candidate for ‘crisis form factor’) does not induce crisis forms 
in cultured Plasmodium falciparum [212]. The exact mechanism for crisis form 
 Chapter 4 VAC030 
  99 
induction remains unknown; however their presence indicates an immunological 
intervention by the host in the course of infection. Thus, in these malaria naïve 
volunteers, they may represent evidence of blood stage immunity. Historically, 
these abnormal parasites have never been observed in studies at this centre 
before. 
 
In order to examine this phenomenon in more detail, blood films from volunteers 
taking part in this study were re-examined. Six slides were identified from each 
volunteer, the slide from the time of diagnosis, and those from the 5 time points 
preceding diagnosis. Films were also selected from some historical studies for the 
same analysis. Challenge studies VAC021.2 and VAC023.2 were chosen; and 6 
volunteers from each study – 3 vaccinees and 3 controls were included. The same 
6 slides were identified for each volunteer – the slide from the time of diagnosis, 
and those from the 5 time points preceding diagnosis.  
 
Each film was re-examined by one of the microscopists involved in the study, who 
were blinded to the group allocation of the volunteers. The whole film (1000 high 
power fields) from each time point was re-examined, and the number of normal 
and abnormal parasites was recorded. 
 
4.4  Investigational Plan 
4.4.1  Trial Plan 
Flow charts showing the schedules of visits and procedures to be performed at 
each visit follow. The first chart shows the procedures for the vaccination phase, 
whist the second shows the challenge phase.  Chapter 4 VAC030 
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Figure 4.2: Flow chart, vaccinations Chapter 4 VAC030 
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Figure 4.3: Flow chart, challenge phase 
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4.4.2  Trial Design 
This was a phase IIa prospective open partially-randomised clinical trial of a 
combination malaria vaccination regimen using 2 different vaccine regimens. This 
included 2 main study groups, receiving either the PEV3A vaccine alone, or the 
PEV3A vaccine in combination with the FFM ME-TRAP regimen. All vaccinations 
were given 4 weeks apart, and all volunteers were challenged with malaria 2 
weeks after the final vaccination. Figure 4.4 represents the trial layout. 
 
 
Figure 4.4: Vaccination and challenge plan 
 
4.4.3  Trial Calendar 
 
First visit first volunteer:   22nd August 2005 
Last visit last volunteer:   22nd February 2006 
Last vaccine given:  9th November 2005 
Challenge dates:  22nd & 23rd November 2005 
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4.5  Vaccines 
4.5.1  Formulation of FP9 and MVA ME-TRAP 
FP9 and MVA ME-TRAP were developed by Oxford University; and manufactured 
by a contract manufacturer (IDT, Germany). MVA and FP9 ME-TRAP were stored 
at –20° C and allowed to thaw prior to administration. The batch of FP9 ME-TRAP 
used in this study was 05 12 04, which was provided in vials of 225 µL volume at a 
concentration of 1.8 × 10
9 pfu/mL in 10 mM Tris buffer. The batch of MVA ME-
TRAP used was 05 12 04, which was provided in vials of 300 µL volume at a 
concentration of 5 × 10
8 pfu/mL in 10 mM Tris buffer. 
 
The potency of these vaccines was tested prior to the trial in a standardised assay 
on Balb/c mice, 14 days following administration of the vaccine; peptide specific 
ELISPOT responses were measured in splenic lymphocytes. Both vaccines were 
tested and found to be potent. 
 
4.5.2  Formulation of PEV3A 
PEV3A was manufactured by Pevion Biotech Ltd., Switzerland, and provided in 
vials of 0.5 mL containing 50 µg of PEV301 and 10 µg of PEV302 in phosphate 
buffered saline (pH 7.4) and stored at +2 to +8 ° C. The batch of PEV3A used was 
05PEV01. 
 
4.5.3  Selection of Doses 
The dose of FP9 ME-TRAP used in this study was 1.0 × 10
8 pfu, given 
intradermally in a volume of 60 µL. All doses of FP9 ME-TRAP were given into the 
right arm. The dose of MVA ME-TRAP used in this study was 1.5 × 10
8 pfu, given 
intradermally in a volume of 300 µL. All doses of MVA ME-TRAP were given into 
the right arm. These doses are the same as those used in previous studies using 
these vaccines, when they have been found to be safe and immunogenic. 
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The dose of PEV3A used in this study was 0.5 mL (PEV301 containing 50 µg 
AMA49, PEV302 containing 10µg UK39), given intramuscularly. All doses of 
PEV3A were administered into the left arm. This dose was selected following a 
preliminary phase I study, [123] in which it was shown to be most immunogenic for 
both antigens. 
 
4.6  Selection of the Trial Population 
4.6.1  Inclusion Criteria 
Healthy adults aged 18 to 50 years 
Written informed consent 
Resident in or near Oxford for the duration of the vaccination study 
For women only, willingness to practice continuous effective contraception during 
the study and (if participating) during the subsequent challenge study. 
Agreement to refrain from blood donation during the course of the study 
Willingness to undergo an HIV test 
 
4.6.2  Exclusion Criteria 
Any deviation from the normal range in biochemistry or haematology blood tests or 
in urine analysis as defined in Appendix A of the protocol 
Prior receipt of an investigational malaria vaccine 
Use of any investigational or non-registered drug, vaccine or medical device other 
than the study vaccine within 30 days preceding dosing of study vaccine, or 
planned use during the study period 
Administration of chronic (defined as more than 14 days) immunosuppressive 
drugs or other immune modifying drugs within six months of vaccination. (For 
corticosteroids, this will mean prednisolone, or equivalent, ≥ 0.5 mg/kg/day. 
Inhaled and topical steroids are allowed.) 
History of malaria chemoprophylaxis with chloroquine within 5 months prior to the 
planned challenge, with Lariam within 6 weeks prior to the challenge, and Riamet® 
within 2 weeks prior to the challenge 
Any history of malaria Chapter 4 VAC030 
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Travel to a malaria endemic area within the previous 6 months 
Planned travel to malarious areas during the study period 
Any confirmed or suspected immunosuppressive or immunodeficient condition, 
including human immunodeficiency virus (HIV) infection and asplenia 
History of allergic disease or reactions likely to be exacerbated by any component 
of the vaccine, e.g. egg products 
History of cancer (except basal cell carcinoma of the skin and cervical carcinoma 
in situ) 
History of haemoglobinopathies: Sickle cell disease, thalassaemia, G6PD 
deficiency 
History of diabetes mellitus 
Chronic or active neurological disease including seizures 
History of > 2 hospitalisations for invasive bacterial infections (pneumonia, 
meningitis) 
Suspected or known current alcohol abuse as defined by an alcohol intake of 
greater than 42 units every week 
Seropositive for hepatitis B surface antigen (HBsAg) or hepatitis C virus 
(antibodies to HCV) 
Hepatomegaly, right upper quadrant abdominal pain or tenderness 
Evidence of serious psychiatric condition 
Any on-going chronic illness requiring hospital specialist supervision 
Administration of immunoglobulins and/or any blood products within the three 
months preceding the planned administration of the vaccine candidate 
Pregnant or lactating woman 
Any woman who is willing or intends to become pregnant during the study 
Any history of anaphylaxis in reaction to vaccination 
Principal Investigator assessment of lack of willingness to participate and comply 
with all requirements of the protocol 
History or clinical evidence of intravenous drug abuse  
Any other finding which in the opinion of the Investigator would significantly 
increase the risk of having an adverse outcome from participating in this protocol. 
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4.7  Statistical Analysis 
4.7.1  Sample Size 
This study aimed to provide both an initial estimate of the efficacy of the vaccines 
used in combination and to compare this with the single vaccine PEV3A. Prior to 
this trial, it was difficult to estimate the potential size of any beneficial effect of 
PEV3A. The analysis of overall efficacy in the 24 vaccinated volunteers had 80% 
power to detect a significant difference from the six controls in rate of sterile 
protection if 60% efficacy was achieved. Volunteers were allocated to groups by 
the investigators. Neither volunteers nor the investigators performing the study 
were blinded to the intervention given. 
 
4.7.2  Statistical Methods 
The analysis for the primary objective was based on the number of hours between 
infectious challenge and blood stage parasitaemia. Each of the groups was 
compared with the other and with the control group using the Kaplan Meier 
method. Statistical significance of any differences observed was then assessed by 
the log rank test.  
 
Immunogenicity was assessed by comparing the sum of the interferon-γ ELISPOT 
responses to malaria peptides, the geometric mean and 95% confidence intervals 
of the antibody titres determined by ELISA and IFA in the two different vaccination 
groups. The statistical significance of the effect of combined vaccine delivery was 
determined using a Mann-Whitney U test to compare ELISA and IFA titres 
between the two vaccination groups. The impact of co-administration of vaccines 
on antibody avidity was calculated with a two-tailed unpaired t test comparing 
avidities after first, second, and third immunization. The statistical significance of 
the difference in number of responders after three vaccinations in the two groups 
was calculated with a Fisher’s exact test. To assess the statistical significance of 
titre increases (ELISA, IFA) after sporozoite challenge we used a Wilcoxon signed-
rank test to compare titres before and after sporozoite challenge. Results were 
analysed for correlation to any delay in parasitaemia. All data, including adverse Chapter 4 VAC030 
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event data collected on StudyBuilder, was imported into and analysed using 
Microsoft Excel or SPSS statistics packages. All statistical analyses and graphs of 
ELISA, IFA and avidity results were made using GraphPad Prism version 4.03 for 
Windows, GraphPad Software, San Diego California USA. 
 
4.8  Results 
Healthy malaria naïve adult subjects aged 18 – 50 years were recruited in the 
Oxford area and underwent medical screening as previously described [133]. All 
volunteers provided fully informed consent to participate in this study by signing a 
written consent form, prior to any study procedures. All vaccinations and follow up 
visits took place in the outpatients unit at the Centre for Clinical Vaccinology and 
Tropical Medicine, at the Churchill Hospital in Oxford. The malaria challenge was 
performed in the insectary in the Alexander Fleming Building, Imperial College, 
London. The study received ethical approval from the Oxfordshire Research Ethics 
Committee A on 10/6/2005, (COREC reference 05/Q1604/69). The study was 
performed in compliance with the requirements of the MHRA under a Clinical Trial 
Authorisation. It gained full regulatory approval from the MHRA on 23/5/2005, 
Eudra CT number 2005-001041-42. An Independent Local Safety Monitor was 
appointed in Oxford. The trial was conducted according to GCP and in accordance 
with the current version of the declaration of Helsinki (52nd WMA General 
Assembly, Edinburgh, Scotland, October 2000). It was externally monitored by 
Appledown Clinical Research Ltd. 
 
Recruitment for this study began in August 2005, and the final visit of the final 
subject to the study site took place on 22nd February 2006. In total, 44 subjects 
were screened, of whom 13 were excluded, 7 because they were ineligible 
(previous history of intravenous drug use (IVDU), history of psychiatric illness, a 
new finding of heart murmur, recent travel to endemic areas), and 6 withdrew 
consent after screening. 30 volunteers were initially enrolled into the study.  One of 
those enrolled into group 2 had an undisclosed history of IVDU; this subject was 
withdrawn as soon as this was revealed to the investigator, shortly after the first 
vaccination. Data concerning the safety of one dose of vaccine was collected from 
this volunteer, but they were otherwise excluded from the analysis. One extra Chapter 4 VAC030 
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volunteer who had been screened but initially not enrolled was then allocated to 
group 2 to replace this subject. In total, 24 volunteers received all three 
vaccinations in groups 1 and 2. Demographic characteristics of volunteers in each 
group are provided in Table 4.6. All of these volunteers subsequently took part in 
the malaria challenge, and completed all follow up. 6 of the enrolled volunteers 
were recruited to act as unvaccinated controls for the challenge phase. One of 
these subjects was withdrawn from the challenge early and treated; this was a 
result of an unforeseen change in personal circumstances unrelated to the trial. 
This volunteer subsequently completed all follow up. These two volunteers 
accounted for the two protocol deviations that were recorded during the trial. The 
participant flow is shown in a CONSORT diagram in figure 4.5. 
 
17 (54) 14 (45) 44 21 31 TOTAL COHORT
3 (50) 3 (50) 40 23 30 (7.5) 6 Controls
8 (62) 5 (38) 44 23 29.5 (5.3) 13 Group 2
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Table 4.6: Demographics 
Demographic characteristics of volunteers by group 
 
24 volunteers were enrolled into the study, with an additional 6 unvaccinated 
controls for the malaria challenge. Group 1 volunteers received three doses of 
PEV3A 0.5mL (P) given intramuscularly at baseline, 4 weeks later and 8 weeks, 
while those in Group 2 received a combination of PEV3A 0.5mL given 
intramuscularly (P) and FP9 ME-TRAP 1 x 10
8 plaque forming units (pfu) given 
intradermally (F), at baseline; (P) and (F) 4 weeks later; and (P) and MVA ME-
TRAP 1.5 x 10
8 pfu given intradermally (M) at 8 weeks. Intramuscular injections 
were given into the left deltoid; intradermal injections were administered into the 
skin over the right deltoid. Up to 80 mL of blood was drawn at day 0, 7, 28, 35, 56, 
63, day of challenge (day 70), challenge + 7 days (day 77), challenge + 35 days 
(day 105) and challenge + 90 days (day 160) for safety assessment and 
measurement of immunogenicity. 
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Assessed for eligibility (n=44) 
Excluded  (n= 13) 
 
  Not meeting inclusion criteria 
(n= 7) 
  Refused to participate 
(n= 6) 
   
Analyzed (n=12) 
 
Excluded from analysis (n=0) 




Allocated to GROUP 1 'PPP' 
(n= 12) 
Received allocated vaccinations 
(n= 12) 




Allocated to GROUP 2 'PFPFPM' 
(n= 13) 
Received allocated vaccinations 
(n= 12) 
Did not receive doses 2 and 3 
(n= 1)  Withdrawn after 1 
vaccination, history of IVDU 
Analyzed (n=12) 
 
Excluded from analysis (n=1) 
Subject withdrawn after 1 
vaccination following  
information about previous IVDU 
Enrollment 
Allocated to intervention 
CONTROLS 
(n=6) 
Entered malaria challenge 
(n= 6) 
Did not receive allocated 
intervention 
(n=0) 
Lost to follow-up  (n=0) 
  
Discontinued intervention 
    (n= 1) Treated early after 
malaria challenge because of a 
change in personal circumstances. 
Analyzed (n=5) 
 
Excluded from analysis (n=1) 
Subject did not complete 






Figure 4.5: CONSORT flow chart 
CONSORT flow chart demonstrating participant flow through VAC030. 
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4.8.1  Efficacy 
Mean time to parasitaemia for controls (n = 5) was 11.8 days (S.D. 1.6 days), 
compared to 12.8 days for group 1 (n = 12, S.D. 2.68 days), and 12.1 days for 
group 2 (n = 12, (S.D. 0.96 days). A Kaplan Meier plot of survival is shown in 
figure 4.6. One volunteer in group 1 was not diagnosed until day 20, however, 
there is no significant difference in time to parasitaemia for volunteers in either 
















Figure 4.6: Kaplan meier plot 
A survival plot showing time to diagnosis of malaria infection for each group of volunteers. 
Although no sterile protection was seen following the sporozoite challenge, we 
observed some evidence of blood stage protection for the first time in humans in a 
challenge study. Examples of estimated parasite densities based on PCR data are 
shown in figures 4.7 and 4.8. Most volunteers showed an exponential increase in 
parasite densities starting at day 7 after challenge (Figure 4.7). However, a 
number of subjects (525 and 529 in group 1 and 513 and 532 in group 2), had 
unusual PCR results (Figure 4.8). In these volunteers PCR for parasite DNA was 
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negative before becoming positive again, at least once, before rising up to the 
point of diagnosis. 
 



























Figure 4.7: PCR results 
Three volunteers selected to demonstrate expected pattern of PCR results: an exponential 
increase in the numbers of parasites over time, with some cycling seen as parasites are 


























































Figure 4.8: PCR results 
This figure shows data from all 4 volunteers who had unusual PCR results. Up to 150 
parasites/mL are detected, and are subsequently undetectable for one or more time points, 
before they are measured again. This pattern occurs several times, up to a maximum of 5 
times in volunteer 525. Chapter 4 VAC030 
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Parasite growth rates were calculated. The mean rate of blood stage parasite 
growth in volunteers in group 1 was 5.7 parasites per ml per cycle (95% 
confidence intervals 4.1 - 7.3; standard deviation 2.6), for group 2 was 6.3 (95% CI 
4.0 - 8.5; SD 3.5) and for controls it was 8.7 (95% CI 7.2 - 10.2; SD 1.2). 
Comparing the growth rates of vaccinated volunteers, those in group 1 are not 
significantly different to those of volunteers in group 2 (Mann Whitney U test; two 
tailed  p=0.63). Comparing group 1 to controls, growth rates are significantly lower 
in group 1 volunteers than in controls (Mann Whitney U; two tailed p = 0.02). For 
group 2 versus controls, there is again a significant difference (Mann Whitney U; 
two tailed p = 0.02). 
Grouping all vaccinated volunteers together, and comparing them to controls, 
there is again a significant reduction in parasite growth rates; (Mann Whitney U; 
two tailed p = 0.012). More detailed analysis of these results can be found in 
Chapter 6 of this thesis. 
 
Compared to the control group the estimated number of infected hepatocytes was 
1.8 times lower in the PEV3A group and 2.3 times lower in the combination group 
respectively. Statistical analysis of these estimates showed no significant 
difference between group 1 and group 2 (Mann Whitney U test, p = 0.6), or 
between either group of vaccinated volunteers and controls (group 1 versus 
controls, Mann Whitney U test, p = 0.3, group 2 versus controls, p = 0.4; all 
vaccinated volunteers versus controls, Mann Whitney U, p = 0.3). The details of 
this analysis can be found in Chapter 6 of this thesis. 
 
4.8.2  Immunogenicity 
Immunogenicity was assessed by measurement of vaccine induced T cell 
responses and antibodies at multiple points during the trial. 
 Chapter 4 VAC030 
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4.8.2.1   Antibody Responses  
Anti-AMA49-C1 antibodies were induced at high levels in all volunteers following 
immunization with PEV3A (See figure 4.9A). One immunization was sufficient to 
produce 100% seroconversion in both groups. No increase in anti-peptide titres 
was observed after sporozoite infection. Unvaccinated controls did not show any 
increase in anti-AMA49-C1 antibody titres. Co-administration of FFM ME-TRAP 
led to an increase of anti-peptide IgG titres, which became significant after the 
third immunization (p = 0.03). The avidity of this anti-peptide response increased 
following every vaccination (Figure 4.9B). The mean avidity index did not differ 
between the two vaccination groups at any time point (data not shown) but a 
stronger increase of the mean avidity observed in the PEV3A group became 
statistically significant after the third immunization (two-tailed unpaired t test p = 
0.04). Sporozoite challenge led to a decrease of avidity in group 1 (two-tailed 
paired t test p = 0.004), whereas no significant change was observed in the group 
receiving a combination of the two vaccines (two-tailed paired t test p = 0.6). 
Antibody cross-reactivity with blood-stage parasites was assessed by IFA with P. 
falciparum (strain K1) blood stage parasites (figure 4.10). Three immunizations 
with PEV3A led to an increase of IgG titres in 4 out of 12 volunteers in group 1 and 
in 3 out of 12 volunteers in group 2. Mean IgG titres in IFA after three 
immunizations did not significantly differ between the two groups (Mann-Whitney U 
two-tailed p = 0.49). There was no evidence of a difference in number of 
responders after three vaccinations between group 1 and 2 (Fisher’s exact test p = 
0.64). Although not statistically significant, there appeared to be an increase in 
parasite-binding antibodies in IFA after sporozoite challenge. 78% (7/9) of all 
volunteers who were IFA positive after challenge (both groups) had an increased 
endpoint titre after sporozoite infection. Unvaccinated controls did not produce 
detectable levels of blood-stage parasite-binding antibodies (data not shown). 
Generally, interpretation of IFA results with blood stage parasites was very difficult 
due to non-specific background staining. As only clearly positive results were 
included in the analysis, parasite-binding antibody responses in some volunteers 
may have been missed. Western blot analysis with sera from immunized 
volunteers (after three vaccinations) showed specific recognition of parasite-
derived AMA-1 in 16 out of 24 volunteers at a serum dilution of 1:100 (data not Chapter 4 VAC030 
  114
shown) supporting the notion that some parasite cross-reactive responses in IFA 
were missed. 
 
High levels of anti-UK-39 antibodies were detected after vaccination with PEV3A 
(Figure 4.9A). Two immunizations were required to achieve 100% seroconversion 
in both vaccination groups. Co-administration of FFM ME-TRAP had no impact on 
the magnitude of mean anti-UK-39 titres at any time-point (Mann-Whitney U two-
tailed p = 0.95 after 3rd vaccination). Sporozoite challenge led to an increase in 
anti-peptide titres in the combination group (Wilcoxon sign-rank p = 0.03), whereas 
no change in titre was seen in the PEV3A group after infection (Wilcoxon sign-rank 
p = 0.64), (Figure 4.9A). No anti-UK-39 IgG was detected in unvaccinated controls. 
The avidity of anti-UK-39 IgG increased following every immunization (Figure 
4.9B). Although there was a higher mean avidity index in group 1 compared to 
group 2 after second and third immunization (two-tailed unpaired t test p = 0.001 
after second and p = 0.008 after third vaccination) (data not shown) we did not 
observe any difference in avidity increase between the two vaccination groups or a 
significant change in avidity after sporozoite challenge (two-tailed paired t test 
group 1 p = 0.64; group 2 p = 0.44). Immunization with PEV3A alone induced 
parasite cross-reactive antibodies in all volunteers after two vaccinations, as 
observed in IFA with P. falciparum sporozoites (Figure 4.10). The number of 
volunteers with parasite-binding antibodies in the combination group increased 
with every immunization reaching 82% (9/11) after the third immunization. There 
was no evidence for a difference in number of responders after three vaccinations 
between group 1 and 2 (Fisher’s exact test p = 0.22). Higher mean IFA titres 
induced by immunization with PEV3A alone compared to combined vaccination 
became significant after three vaccinations (Mann-Whitney U two tailed p = 0.02). 
A boost of the vaccine-induced response after infection was observed in 33% 
(4/12; group 1) and 75% (9/12; group 2) of the volunteers as detected by 
increased IFA titres after sporozoite challenge. The observed increase of IFA titres 
after infection was significant only for the group receiving both vaccines (Wilcoxon 
sign-rank p=0.04). No sporozoite-binding antibodies were detected in 
unvaccinated controls after sporozoite challenge (data not shown). Staining of a 
CSP characteristic double band was found in Western blot with 13 out of 23 sera Chapter 4 VAC030 
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after three vaccinations at a dilution of 1:100 (data not shown). There was no 
correlation in levels of any induced antibodies with time to infection. 
 
 
Figure 4.9: Anti-peptide responses  
A: (Upper panel) Geometric mean anti-AMA49-C1 (PEV301) and anti UK-39 (PEV302) 
endpoint-titres (log10) with 95% confidence intervals for group 1 (PEV3A), group 2 (PEV3A + 
ME-TRAP) and unvaccinated controls. 
B: (Lower panel) Mean avidity increase (relative to avidity index after first immunization) 
with 95% confidence intervals.  
Arrows along the x axis represent the timing of each vaccination, and the asterisk denotes 
the challenge. Chapter 4 VAC030 
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Figure 4.10: Antibody reactivity with P. falciparum 
A: (Upper panel) IgG endpoint titres measured in IFA with P. falciparum (K1) blood stage 
parasites  
B: (Lower panel) IgG endpoint titres measured in IFA with P. falciparum (NF54) sporozoites. 
 
Individual titres are shown, with the geometric mean for every time point on a log scale. 
 
4.8.2.2   T cell Responses 
There were low level background responses to ME-TRAP in group 1 (summed 
response at peak time point was 13.3 SFU/10
6 PBMC). Responses in group 2 
were significantly higher than those in group 1- the geometric mean summed 
responses to ME and T996 TRAP pools at peak time point was 49.8 SFU/10
6 
PBMC (two tailed t test on log converted data p = 0.001). However these 
responses were low compared to those seen in previous trials with this vaccine 
(previously, a geometric mean summed response to ME-TRAP of 454 SFU/10
6 
PBMC was observed at the peak time point). Figure 4.11 illustrates the median 
responses by group, before vaccination, at the peak time point (third vaccination 




































Figure 4.11: Median ELISPOT response by group  
 
4.8.3  Safety  
There were no clinically significant changes in haematological (full blood count) or 
biochemical (sodium, potassium, urea, creatinine, ALT, alkaline phosphatase, 
albumin, bilirubin) parameters throughout the study. No serious adverse events 
occurred during this study. One volunteer developed an enlarged right 
supraclavicular lymph node following the first vaccination with FP9 ME-TRAP. The 
maximum recorded size of this lymph node was 1.3cm. It increased in size again 
following subsequent vaccinations in the right arm. This node was still present at 
study close out. The volunteer was referred to their General Practitioner for 
assessment and investigation, who has indicated no further follow up is required. 
Adverse events following vaccination followed a profile similar to that seen before 
with these vaccines, [123], [133]. The frequency of vaccination site pain, swelling, 
redness, warmth, itch and scaling was, as expected, higher following FP9 and 
MVA ME-TRAP than PEV3A. One volunteer (514) reported severe pain following 
the third vaccination with PEV3A. This was recorded as starting on the evening of Chapter 4 VAC030 
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the third vaccination, and lasting 6 days. It was recorded as intensity 3 (severe 
pain at rest) for two days, and then subsided to intensity 2 (pain on movement) for 
a further two days. For the final two days it was recorded with a score of 1 (pain on 
touch). After this period it had completely resolved, with no long term effects. The 
frequency of general symptoms in group 1 was also lower than that in group 2. In 
group 1, 50% of volunteers experienced at least one systemic side effect (5/12 = 
41% after dose 1, 1/12 = 8% after dose 2, and 2/12 = 17% after dose 3), whilst 
83% (10/12) in group 2 experienced at least one (6/13 = 46% after dose 1, 7/12 
=58% after dose 2, 9/12 = 75% after dose 3). This is slightly different to previously 
reported studies using similar virally vectored vaccines, where general symptoms 
seemed to be attenuated following second and subsequent doses [133]. See the 
following tables for details of adverse events considered related to vaccination. 
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100 12 - 0 - 0 Scaling  
67 8 - 0 - 0 Itch  
83 10 - 0 - 0 Warmth  
100 12 - 0 8 1 Swelling  
100 12 17 2 17 2 Redness  
100 12 67 8 67 8 Pain  
% n % n % n
MVA ME-TRAP i.d. PEV3A i.m. PEV3A i.m.
Group 2, n = 12 Group 1, n = 12 VACCINE
DOSE 3
58 7 0 0 0 0 Scaling  
42 5 0 0 0 0 Itch  
8 1 0 0 0 0 Warmth  
92 11 0 0 8 1 Swelling  
100 12 0 0 17 2 Redness  
75 9 58 7 42 5 Pain  
% n % n % n
FP9 ME-TRAP i.d. PEV3A i.m. PEV3A i.m.
Group 2, n = 12
Group 1, n = 12
VACCINE 
DOSE 2
54 7 0 0 0 0 Scaling
31 4 8 1 0 0 Itch
23 3 0 0 0 0 Warmth
85 11 8 1 17 2 Swelling
100 13 15 2 17 2 Redness
46 6 23 3 25 3 Pain
% n % n % n
FP9 ME-TRAP i.d. PEV3A i.m. PEV3A i.m.
Group 2, n = 13
Group 1, n = 12
VACCINE 
DOSE 1
100 12 - 0 - 0 Scaling  
67 8 - 0 - 0 Itch  
83 10 - 0 - 0 Warmth  
100 12 - 0 8 1 Swelling  
100 12 17 2 17 2 Redness  
100 12 67 8 67 8 Pain  
% n % n % n
MVA ME-TRAP i.d. PEV3A i.m. PEV3A i.m.
Group 2, n = 12 Group 1, n = 12 VACCINE
DOSE 3
58 7 0 0 0 0 Scaling  
42 5 0 0 0 0 Itch  
8 1 0 0 0 0 Warmth  
92 11 0 0 8 1 Swelling  
100 12 0 0 17 2 Redness  
75 9 58 7 42 5 Pain  
% n % n % n
FP9 ME-TRAP i.d. PEV3A i.m. PEV3A i.m.
Group 2, n = 12
Group 1, n = 12
VACCINE 
DOSE 2
54 7 0 0 0 0 Scaling
31 4 8 1 0 0 Itch
23 3 0 0 0 0 Warmth
85 11 8 1 17 2 Swelling
100 13 15 2 17 2 Redness
46 6 23 3 25 3 Pain
% n % n % n
FP9 ME-TRAP i.d. PEV3A i.m. PEV3A i.m.
Group 2, n = 13




Table 4.7: Frequency of solicited local symptoms 
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8 1 - 0 Nausea/vomiting
42 5 17 2 Myalgia
25 3 - 0 Headache
25 3 8 1 Arthralgia
42 5 8 1 Malaise
33 4 8 1 Symptoms of feverish
8 1 8 1 Documented Fever >37.5
% n % n
Group 2, n=12 Group 1, n=12 VACCINE
DOSE 3
8 1 - 0 Nausea/vomiting
50 6 25 3 Myalgia
25 3 - 0 Headache
8 1 8 1 Arthralgia
42 5 8 1 Malaise
33 4 8 1 Symptoms of feverish
- 0 - 0 Document. Fever >37.5
% n % n
Group 2, n=12 Group 1, n=12 VACCINE
DOSE 2
- 0 - 0 Nausea/vomiting
38 5 83 5 Myalgia
31 4 - 0 Headache
15 2 17 2 Arthralgia
31 4 - 0 Malaise
31 4 17 2 Symptoms of feverish
- 0 8 1 Documented Fever >37.5
% n % n
Group 2, n=13 Group 1, n=12 VACCINE
DOSE 1
8 1 - 0 Nausea/vomiting
42 5 17 2 Myalgia
25 3 - 0 Headache
25 3 8 1 Arthralgia
42 5 8 1 Malaise
33 4 8 1 Symptoms of feverish
8 1 8 1 Documented Fever >37.5
% n % n
Group 2, n=12 Group 1, n=12 VACCINE
DOSE 3
8 1 - 0 Nausea/vomiting
50 6 25 3 Myalgia
25 3 - 0 Headache
8 1 8 1 Arthralgia
42 5 8 1 Malaise
33 4 8 1 Symptoms of feverish
- 0 - 0 Document. Fever >37.5
% n % n
Group 2, n=12 Group 1, n=12 VACCINE
DOSE 2
- 0 - 0 Nausea/vomiting
38 5 83 5 Myalgia
31 4 - 0 Headache
15 2 17 2 Arthralgia
31 4 - 0 Malaise
31 4 17 2 Symptoms of feverish
- 0 8 1 Documented Fever >37.5
% n % n
Group 2, n=13 Group 1, n=12 VACCINE
DOSE 1
 
Table 4.8: Frequency of solicited general symptoms 
 
4.8.4  Ancillary Analyses – Growth Inhibition 
No significant GIA activity was seen in any sample relative to day 0 activity. 
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4.8.5  Ancillary Analyses – Sequencing 
No changes were identified in the DNA sequence of DNA extracted from parasites 
from the sample on day 20. Unfortunately we failed to amplify DNA from the 
upstream region, so are unable to exclude another mutation for example in the 
promoter, which might have resulted in a shift in the open reading frame. This 
failure is likely to have been due to a problem with the quality of the sample DNA. 
This could have been caused by multiple freeze-thaws leading to degradation of 
the DNA, but it may just reflect the difficulty of designing suitable primers for use 
with the relatively A and C rich parasite DNA. The sample was amplified using a 
whole genome amplification technique called GenomiPhi™ (GE Healthcare Life 
Sciences), however, using this amplified DNA still did not result in any PCR 
product. 
 
4.8.6  Ancillary Analyses – Crisis Forms 
Morphologically abnormal parasites were seen in films from every vaccinated 
volunteer (n = 24) in this study. They were identified in the films of significantly 
fewer (two out of the six) controls (Fisher’s exact test, p value=0.001). The 
proportion of crisis forms as a percentage of total number of parasites for each 
participant was been calculated. For volunteers in group one, the average 
proportion of crisis forms was 66% (95% CI, 54-78, SD 19), for those volunteers in 
group two, the proportion was 55% (95% CI, 41-69, SD 22) and for controls the 
proportion was 13% (95% CI -11-37, SD 23). There was a significant difference 
between the proportion of crisis forms among all detected parasites in vaccinated 
volunteers and controls (Mann Whitney U, p = 0.001). No crisis forms were 
detected in the blood films that were reviewed from previous challenge studies. Chapter 4 VAC030 
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4.9  Discussion 
This trial is the first to provide evidence of vaccine-induced blood stage parasite 
activity and partial protection in a healthy volunteer challenge study. Two 
observations are indicative of a parasite inhibitory effect, the first (I) of which may 
be divided into three components. (I.i) One volunteer was not diagnosed until day 
20 after infection, this being a substantial delay in time to diagnosis. In 52 non-
vaccinated control volunteers involved in identical challenge studies at the centre 
over the last six years, none have remained parasite free on microscopy beyond 
day 14 post challenge. (I.ii) The same volunteer, along with three others, had 
fluctuations in PCR-measured parasite densities that are consistent with a blood 
stage inhibitory effect on parasite growth. (I.iii) There was a significant difference 
in the parasite growth rates in vaccinated volunteers versus controls. This is 
observed in both groups of vaccinated volunteers, and is therefore likely to be 
related to vaccination with PEV3A. (II) The presence of morphologically abnormal 
parasites suggests a vaccine-induced immune response against the parasites. 
However, as they were also observed in the blood of two of six control volunteers, 
their presence is not necessarily vaccine related. 
 
The volunteer in whom diagnosis was delayed until day 20 developed high levels 
of anti AMA49 and UK39 antibodies (peak AMA49 response end point titre 33779, 
UK39 end point titre 18102). Positive IFA results were obtained with sporozoites, 
but not with blood stage parasites. ELISPOT responses were negligible, with 
AMA-1 and NANP responses all remaining <10 sfu/million PBMCs throughout the 
study. No detectable GIA activity was measured. The mechanism of partial 
protection in this volunteer, therefore, appears to be something other than that 
which we have directly measured. 
 
Taken together these results suggest that PEV3A has induced a protective 
immune response against blood stage parasites. However this was not enough to 
prevent patent infection in malaria naïve individuals, in the stringent challenge 
model used that involves high numbers of sporozoites for infection.  Blood stage 
protection might be enhanced by targeting several blood stage antigens with a Chapter 4 VAC030 
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multivalent subunit vaccine and this is technically feasible with the virosomal 
vaccine approach.  
 
This study was designed to search for a possible synergistic effect of combining 
two potentially complimentary vaccine strategies. The idea that combining 
induction of anti-sporozoite antibodies by the CS component of PEV3A and anti-
liver-stage T cell responses by recombinant viruses would lead to a synergistic 
enhancement of protection was suggested by experiments in a mouse model 
[195]. In this model, viral vectors appeared to act as an adjuvant to a protein 
vaccine, enhancing the magnitude of the antibody response. The best results (i.e. 
highest levels of protection from a subsequent malaria challenge) were obtained 
when the vaccines were mixed physically in the same syringe and administered at 
the same site. Both T cells and antibodies were shown to be important in 
mediating this protection. In this first phase I/IIa trial, we elected to administer the 
vaccines at the same time, but at separate sites rather than mixed in the same 
syringe. This was in order to reduce the potential risk of interference of the two 
vaccines. The vaccines used were safe when administered concurrently, in 
opposite arms, and the PEV3A virosomes were immunogenic. High levels of anti 
AMA49-C1 and anti UK-39 antibodies were measured post vaccination in all 
volunteers. A high proportion of these antibodies were able to bind to the native 
parasite proteins in vitro in IFA suggesting they are likely to be functional.  
 
There is a clear discrepancy between the number of vaccinees who were IFA 
positive (only 25%), while AMA-1 was recognized by a much higher percentage of 
vaccinees in Western blot analysis. This discrepancy appears to be related to the 
fact that the background staining in the IFA with blood stage parasites was already 
high at day 0 in many volunteers. It is most likely that this background staining is 
caused by cross-reactive antibodies induced by other pathogens such as 
toxoplasma. While pre-immune sera (from day 0) showed no staining of the 
83/66KDa AMA-1 bands in Western blot analysis, these bands were shining up 
with most immune sera (from after the third vaccination - see Figure 4.12). Many 
pre-immune sera yielded background staining with different sets of unrelated 
proteins; these antibody titres were not boosted by the vaccination. However, Chapter 4 VAC030 
  124
these antibodies are apparently responsible for high and variable IFA background 




Figure 4.12: Western blot analysis. 
Sera of the vaccinees were used to analyse blood-stage-lysates of P. falciparum as 
indicated as numbers above the lanes. For all probands the Western blot was developed 
using the pre-immune (left lanes) serum and the serum obtained after the 3rd immunization 
(right lanes for each proband). As controls for AMA-1-staining the monoclonal antibody 
DV11a was used. The arrows mark the size of the two AMA-1-processing products. 
 
The criteria for IFA were fairly stringent: a serum was only considered IFA positive 
when a vaccination-associated emergence of an AMA-1 characteristic punctuate 
staining pattern was observed.  
 
AMA49 has been designed and optimized to induce antibodies binding to the 
parasite. This has been proven by immunization of mice that had no parasite 
cross-reactive pre-immune antibodies [199]. The analysis clearly showed the 
importance of a critical length of the peptide to induce parasite interacting 
antibodies and parasite-binding mAbs generated after immunization with the 
virosomes primarily recognized discontinues epitopes of the loop. Furthermore, 
virosomes have proven to present peptide epitope in a native like three 
dimensional structure compared to the same structures adsorbed to alum[198]. 
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The high background staining caused by cross-reactive antibodies in combination 
with the stringency of the interpretation of IFA results are likely to be responsible 
for the observed discrepancy between IFA and Western blot positivity.  
 
The induced ELISA titres were comparable with those from a previous Phase I 
study using this vaccine [123]; Okitsu et al. submitted). Co-administration of FFM 
ME-TRAP did boost the magnitude of the anti-AMA49-C1 antibody response but 
not the anti-UK-39 response. However, whereas in the animal model, good T cell 
induction was achieved by the viral vectored vaccines this was reduced about 10-
fold in this study compared to previous trials. Co-administration of vaccines could 
have led to antigenic competition or interference, which might account for this low 
immunogenicity. Both FP9 and MVA ME-TRAP were tested for potency in mice 
prior to the study, and were found to be potent, and if anything more immunogenic 
than previously used batches of this vaccine (data not shown). Estimated numbers 
of P. falciparum infected hepatocytes were similar between both groups of 
vaccinated volunteers, leading to the conclusion that there was no clear evidence 
of any liver stage effect by FFM ME-TRAP, in keeping with the low T cell 
immunogenicity observed. 
 
Another important observation in this study was an increase in parasite reactive 
antibodies after sporozoite challenge. While anti-peptide titres did not markedly 
change, titres measured in IFA with P. falciparum blood stage parasites and 
sporozoites were boosted by infection. This indicates that PEV3A-induced immune 
responses can be boosted and skewed towards parasite-binding antibody 
populations by sporozoite infection. Results from in vitro sporozoite inhibition 
assays in a phase 1 trial with the same vaccine have shown inhibition of 
sporozoite migration and invasion in the presence of anti-UK-39 IgG (Okitsu et al., 
submitted). Although statistically not significant, we found a trend towards reduced 
numbers of infected hepatocytes in both vaccination groups compared to 
unvaccinated controls, possibly suggesting a role for anti-UK39 antibodies in the 
reduction of infected hepatocytes, but there was little power in this inter-group 
comparison.  
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Reduced parasite growth rates and the presence of crisis forms in the blood of all 
vaccinated volunteers who took part in this trial provide evidence that the immune 
response to the vaccine PEV3A is exerting an anti-blood stage protective effect. 
Murine monoclonal antibodies against AMA49-C1 are capable of inhibiting blood 
stage parasite growth in vitro [199], which is at least in part due to inhibition of 
intra-erythrocytic parasite development (unpublished observation).  
 
The interpretation of these results is complicated by the fact that AMA-1 is 
expressed by both sporozoites and merozoites [213], and so it is possible that 
antibodies to this antigen induced by the virosome might have contributed to any 
pre-erythrocytic effect. The non significant trend to reduced numbers of parasites 
emerging from the liver of all vaccinated volunteers may reflect this effect. 
 
It might be argued that some of these observations of blood stage immunity 
(reduction in growth rates, presence of crisis forms etc.) may rather be related to 
the potential pre-erythrocytic action of PEV3A. However, in previous challenge 
studies, the number of parasites emerging from the liver of unvaccinated control 
volunteers has been shown to vary as much as five fold [214]. Despite this 
variation, rates of parasite growth in these volunteers were similar. Equally, crisis 
forms have never been observed historically in our studies of pre-erythrocytic 
vaccine candidates. Indeed, following their observation in this study, the same 
slide reader went back to examine a selection of blood films from vaccinated and 
control volunteers in two previous studies where some evidence of pre-erythrocytic 
efficacy has been observed (VAC021 [215] and VAC023 [216]). The slide reader 
was blinded to the group allocation of the volunteers. In total 72 slides were 
selected for re-examination (6 slides each from 6 volunteers from each study, 3 
vaccinees plus 3 controls) and no crisis forms were observed. It seems likely 
therefore, that the differences observed here are indeed related to vaccine 
induced blood stage immunity. 
 
The current challenge was a heterologous one with 3D7 parasites, rather than the 
K1, or T9/96 strains, used in the generation of PEV3A or the ME-TRAP vaccines 
respectively. PEV301 targets the semi-conserved sequence AMA-1446-490, which 
contains only three dimorphic positions (D/N448, M/K451 and K/I485) at its C and Chapter 4 VAC030 
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N terminus, respectively. The elicited antibody responses are focussed on the 
conserved central portion of this sequence stretch and all murine vaccine-induced 
monoclonal antibodies tested were cross-reactive with P. falciparum strains 
expressing natural sequence variants of AMA-1446-490 [199]. In contrast to 
results with monoclonal antibodies, growth inhibition assays performed with sera 
of the volunteers immunized in this trial were negative. Further data will be 
required to assess the utility and sensitivity of this assay for predicting blood stage 
vaccine efficacy, but these trial results suggest caution in the exclusive use of this 
assay as an in vitro predictor of blood-stage vaccine efficacy. 
 
An effective malaria vaccine may need to target multiple parasite antigens from 
different stages of the life cycle.  Several vaccine candidates have previously 
provided evidence of pre-erythrocytic stage efficacy in Phase IIa trials [113, 116, 
132, 217]. Here we have shown evidence for a vaccine-induced blood stage 
protection for the first time in a challenge study. This study also shows that 
protective efficacy at the blood-stage level can be observed using sporozoites 
rather than blood stage parasites [109] for challenge studies. Moreover, 100% 
seroconversion induced by virosomally-formulated peptides and the observed 
boost of this response by sporozoite infection support the potential of further 
development of the virosome system as a malaria vaccine. 
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Chapter 5   Lab work 
5.1  Introduction and Literature Review 
The multiple stages in the life cycle of P. falciparum make it a difficult target for 
vaccine developers, as largely different sets of antigens are expressed in each of 
the various stages. The observation, described in Chapter 1, that protection 
against malaria infection can be induced by immunisation with radiation attenuated 
sporozoites has led to a focus on the liver stage of P. falciparum, in the hope of 
identifying the antigens involved. A variety of liver stage antigens have been 
investigated; indeed, the vaccine which is currently the most well developed, 
RTS,S, is derived from the circumsporozoite protein.  
 
Of the nearly one million people who die each year from malaria, over 75% are 
children under 5 [4]. While the majority of the burden of malaria morbidity and 
mortality falls on young children, adults living in malaria endemic areas develop 
immunity to infection. Even with repeated infections, this protective immunity is 
incomplete; individuals are protected from clinical disease, without being protected 
from parasitaemia. This appears to be age dependent and results in a lower 
incidence of clinical malaria in these individuals [60]. There is evidence for a 
genetic basis for antibody and cellular responses to malaria proteins [30].  
 
Identification of specific immunologic determinants of protection will lead to 
development of the most promising vaccine candidates, including multistage 
vaccines. Thus examining the antigen specific immune responses to the liver 
stages of individuals in endemic areas may help in the development of new 
malaria vaccines. 
 
This study set out to examine the responses to various liver stage antigens in 
individuals from endemic areas. The antigens chosen were selected on the basis 
of previous immunological studies in malaria endemic areas, and the studies of 
volunteers immunized with radiation-attenuated sporozoites [85,88,218]. They Chapter 5 Lab Work 
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were selected for inclusion in a new candidate malaria vaccine, which showed 
promising results in preclinical work, described by Prieur [167]. The clinical trial 
that was planned using this vaccine is described in Chapter 3. A detailed 
description of the individual antigens included may be found there. In the order 
that they are expressed in the insert, they are: 
 
LSA - 3, Liver stage antigen 3 is expressed by blood-stage schizonts as well as 
sporozoites [181].  
STARP, Sporozoite threonine and asparagine-rich protein was described by 
Fidock et al. as a relatively conserved sporozoite antigen [185].  
Exp-1, Exported protein-1 was originally described by Hope et al. [186] as a 
sporozoite and blood stage antigen.  
Pfs 16 is an antigen found in sexual stage parasites [192] and possibly also in 
sporozoites. 
TRAP, Thrombospondin-related adhesion protein is well characterized and has a 
protective homologue in rodents.  
LSA-1, Liver Stage Antigen 1 is expressed solely in the pre-erythrocytic stage, first 
described in 1987 by Guerin-Marchand et al. [219].  
 
5.2  Methods 
The primary objective of this work was to examine immune responses to the pre-
erythrocytic antigens described, in adults from endemic areas. Both humoral and 
cellular responses to these antigens were examined, using ELISA and ELISPOT 
techniques. These assays are sensitive methods for the detection of cytokines. 
The data obtained was then analysed to see if there was any link between then 
magnitude of any individual immune response, and whether that individual 
developed malaria infection or not. As described in reference [60], this is a crude 
method to identify immune responses that may be important in protecting from 
malaria infection. 
 
Two malaria vaccine studies that took place in The Gambia (VAC020 [220] and 
VAC029 [221]) were selected. VAC020 was a Phase IIb study testing the 
heterologous prime-boost vaccination regimen of two doses of DNA ME-TRAP Chapter 5 Lab Work 
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followed by one dose of MVA ME-TRAP. The main objectives of this study were to 
evaluate vaccine safety and efficacy in semi-immune adults in the Gambia. 
VAC029 was a study designed to evaluate the use of daily real time PCR to detect 
parasites, in the field, for evaluation of pre-erythrocytic malaria vaccines. 
Volunteers were vaccinated with the candidate malaria vaccines MVA and FP9 
ME-TRAP in the course of this study. Control volunteers were included in both of 
these studies, and they received a rabies vaccine rather than a candidate malaria 
vaccine. Importantly, a follow up period to detect malaria infection was included in 
each study. Samples from these volunteers were identified for further analysis.  
 
These malaria vaccine studies were performed in The Gambia between 2002 and 
2004, and written consent was obtained from all participating volunteers prior to 
their inclusion. Although this consent included permission to store samples taken 
during the study, specific consent to use these stored samples was not sought at 
the time. Permission was therefore obtained from the Oxfordshire Research Ethics 
Committee (reference number 061/Q1606/123) for these and other samples to be 
used for further analysis of immune responses to malaria infection. 
 
Cellular samples were obtained from VAC020. In this study volunteers were 
vaccinated with either a candidate malaria vaccine or rabies vaccine, and 
subsequently followed for 11 weeks; samples of peripheral blood mononuclear 
cells were obtained at 12 weeks. During the follow up period blood smears were 
taken weekly, or if volunteers developed symptoms of malaria, to detect parasites. 
The primary endpoint was time to first infection with asexual P. falciparum 
parasites (i.e. first seen on blood smear – not time to clinical malaria). All 
volunteers were treated with effective antimalarial medication as soon as parasites 
were detected. 
 
Serum samples were from VAC029. Again, volunteers received either a malaria 
vaccine or a rabies vaccine, and one week after the final vaccination (of three) 
serum samples were obtained. From 14 days after the final vaccination, volunteers 
were followed for a 28 day period, with daily finger prick samples of blood taken for 
parasite PCR. Blood smears were performed only if volunteers developed 
symptoms of malaria. Only 12 volunteers out of a total of 103 developed malaria Chapter 5 Lab Work 
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during the follow up period, so for this analysis of a subsection of control 
volunteers, PCR positivity was used as a surrogate for clinical malaria. 
 
Immune responses to the malaria antigens described were measured using 
ELISPOT and ELISA techniques. These were chosen to identify both cellular and 
antibody mediated immune responses in these individuals. 
 
5.2.1  ELISPOT 
The ELISPOT (enzyme-linked immunospot) technique detects T cells that secrete 
a given cytokine (e.g., gamma interferon [IFN-γ]) in response to an antigenic 
stimulation. T cells and antigen presenting cells (present in the isolated PBMC) are 
cultured in wells which have been coated with anti-IFN-γ antibodies. The secreted 
IFN-γ is captured by the coated antibody and then revealed with a second 
antibody coupled to a chromogenic substrate. Thus, locally secreted cytokine 
molecules form spots, with each spot corresponding to one IFN-γ-secreting cell. 
The number of spots allows one to determine the frequency of IFN-γ-secreting 
cells specific for a given antigen in the analyzed sample. Cells secreting as few as 
100 molecules can be detected by taking advantage of the high concentration of 
cytokines in the immediate environment of the activated T cells. However, the 
ELISPOT assay detects preferentially effector T cells. The amount of secreted 
cytokine is not determined in ELISPOT assays. 
 
Interferon gamma ELISPOTs were performed on frozen PBMCs collected during 
the study (VAC020). These cells were isolated from heparinised blood samples 
using Lymphprep (Nycomed) gradient centrifugation, frozen in 10% DMSO-FCS 
(Sigma-Aldrich) and stored in liquid nitrogen.  
 
Cells were thawed and re-suspended in RPMI 1640 (Sigma-Aldrich) containing 
1000U/mL penicillin-streptomycin (Invitrogen Life Technologies), 20mM L-
Glutamine (Sigma-Aldrich), and 10% heat-inactivated fetal calf serum (Sigma-
Aldrich) (R10) at a concentration of 8 x 10
6 cells/mL. In the thawing procedure, 25 
U/mL Benzonase nuclease (Novagen) was added to avoid cell clumping. Cells 
were counted with an automated cell counter (CasyCounter TT Schärfe System).  Chapter 5 Lab Work 
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The ELISPOT assay was performed using MultiScreen Immobilon-P 96-well 
filtration plates (MAIP S45; Millipore), IFN-γ ELISPOT kits (Mabtech) and alkaline 
phosphatase substrate (Bio-Rad). Cells were stimulated (in duplicate wells) with 
10 µg/ml/peptide of pools of 20-mer peptides overlapping by 10 aa, for a 18-20 
hours at +37° C, 5%CO2. Spots were counted with an ELISPOT reader (AID). The 
peptides used in these assays were ordered from Thermoelectron, and were 
20mers overlapping by 10 amino acids. They covered each of the antigens 
outlined in the introduction, and are listed in Appendix 3. Antigen specific cells per 
10
6 PBMC were calculated by subtracting spot numbers in media only wells from 
spot numbers in peptide-containing wells. Each pool of peptides contained 
approximately 20 peptides, and so the total response for each antigen was 
calculated by summing the response for each peptide pool.  
 
5.2.2  ELISA 
ELISA (Enzyme-Linked Immuno Sorbent Assay) is a specific and highly sensitive 
method for quantitative measurements of antibodies, or cytokines in solutions. For 
detection of antibodies to specific antigens, the antigen of interest is coated on a 
micro titre plate. An anti-human IgG monoclonal antibody (mAb) is used for 
detection of any antibody that has bound to antigen on the plate. The detection 
mAb is labelled with biotin, which allows subsequent binding of a streptavidin-
conjugated enzyme. Any unbound reagents are washed away. When substrate is 
added, a colour reaction will develop that is proportional to the amount of bound 
antibodies. The concentration of antibody can then be determined by comparison 
with a standard curve with known concentrations of antibody. Unfortunately in this 
case, no solutions of antibody of known concentration were available. A sample of 
serum from a malaria naïve individual was used as a negative control. Arbitrarily, 
an endpoint titre cut off optical density of >0.2 was chosen as a positive result.  
 
Antibodies against five of the six antigens of interest were examined, it was not 
possible to source recombinant protein for Pfs 16, and so this antigen was not 
included. Protein for these ELISAs was obtained from various sources, as shown 
in table 5.1. 
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824mcg/mL David Lanar, WRAIR, Maryland, USA. LSA1 
160mcg/mL Joe Cohen at Glaxo Smith Kline, 
Rixensart, Belgium.
TRAP 
4.22mg/mL David Lanar, WRAIR, Maryland, USA. Exp1 
500mcg/mL Pierre Druihle, Institut Pasteur, Paris. STARP 
600mcg/mL LSA3 GST 729 
550mcg/mL LSA3 GST PC 
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160mcg/mL Joe Cohen at Glaxo Smith Kline, 
Rixensart, Belgium.
TRAP 
4.22mg/mL David Lanar, WRAIR, Maryland, USA. Exp1 
500mcg/mL Pierre Druihle, Institut Pasteur, Paris. STARP 
600mcg/mL LSA3 GST 729 
550mcg/mL LSA3 GST PC 





Table 5.1: ELISA antigens  
 
The recombinant proteins LSA3 GST 729, GST NN and GST PC were designed to 
cover 95% of the LSA-3 antigen. GST 729: GST (glutathione-S-transferase)-fused 
protein encoded by the DG729 insert (aa 1’-150’), GST NN: GST-fused protein (aa 
369-447), and GST PC: GST-fused protein (aa 869-1786) (see reference [183] for 
details). The following figure demonstrates the gene for LSA3 and the relative 
positions of recombinant proteins used. 
 
 
Figure 5.1: LSA3 gene map  
LSA3 map showing the positions of the three separate antigens used for the detection LSA3 
antibodies. 
 
All proteins were resuspended in carbonate bicarbonate buffer, 0.05M, pH 9.6 
(Sigma Aldrich) at a concentration of 1 µg/mL.  
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NUNC-Immuno 96 well plates (Nunc) were coated at 4° C overnight with these 
antigens. Wells were then blocked with 1% Bovine Albumin in PBS containing 0.05 
% Tween-20 (Sigma Aldrich) for 2 h at 37° C followed by three washes with PBS – 
Tween. Plates were then incubated with serial dilutions of human serum, starting 
with 1:50, down to 1:6400, in PBS containing 0.05% Tween-20 and 0.2 % Bovine 
albumin, at 37° C for 2 h. Samples were performed in duplicate. After washing, 
plates were then incubated with anti-human IgG at 0.25µgml (Promega) for 30 
mins at 25° C and then washed again. 100 µL of p-Nitrophenyl phosphate 
substrate (pNPP) (20mg/ tablet, Sigma Aldrich) dissolved in 5mL 0.2M TRIS (pH 
9.8) was added and incubated at 25° C for 25 minutes. The optical density (OD) of 
the reaction product was recorded at 405 nm using a microplate reader (Dynex 
Technologies MLX 96 Well Plate Luminometer and Dynex Revelation 4.22 
software). A cut off OD of 0.2 was used to determine positive samples, and the 
end point titre was calculated based on the serial dilutions. Data was analysed 
using Microsoft Excel to determine the endpoint titre for each sample. 
 
5.3  Results 
5.3.1  ELISPOT Results 
Individuals from the Gambia had evidence of T cell responses to peptides from 
LSA3 STARP, Exp1, TRAP and LSA1 detectable by interferon gamma ELISPOT 
assay. A total of 33 volunteers were selected for analysis. Volunteers were divided 
into those who developed malaria during the follow up period (n=20) and those 
who did not (n=13), and mean numbers of spot forming units for each antigen 
were calculated. The results are shown in the following graphs. 



































































































































































































Figure 5.2: ELISPOT results for each antigen by malaria outcome.  
Summed number of spot forming units per 10
6 PBMCs. YES = positive diagnosis of malaria 
during follow up period. NO = not diagnosed with malaria. Two tailed t tests were used 
compare ELISPOT responses in those who did or did not develop malaria, and the following 
p values were calculated: LSA3, p = 0.08; STARP, p = 0.09; TRAP, p = 0.34; LSA1, p = 0.49. 
 
Those that did not develop malaria in the subsequent follow up period had a trend 
to  higher T cell responses to LSA3 and STARP (as measured by IFN gamma 
ELISPOT) than those who succumbed to infection during that period. There was a 
correlation between the magnitude of the ELISPOT response and the time of 
diagnosis for LSA 3 (Spearman’s Correlation, p = 0.03), and LSA 1 (Spearman’s 
correlation coefficient, p = 0.006), but not for responses to STARP (Spearman’s 
correlation coefficient, p = 0.9) or TRAP (Spearman’s correlation coefficient, p = 
0.9). This is demonstrated in the following graphs. Chapter 5 Lab Work 
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Figure 5.3: ELISPOT response to LSA3 vs. time to diagnosis. 
A scatter plot of ELISPOT response to LSA3 against week of diagnosis demonstrates a 
positive correlation. Spearman’s correlation coefficient p = 0.03 







































Figure 5.4: ELISPOT response to LSA1 vs. time to diagnosis.  
A positive correlation is again demonstrated. Spearman’s correlation coefficient p = 0.006 Chapter 5 Lab Work 
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The time to malaria infection was significantly longer in those with higher T cell 
responses to all antigens apart from STARP (Kaplan Meier survival analysis of 
summed LSA3 response, Log rank p < 0.0005; for TRAP, p <0.0005 and LSA 1, p 
= 0.001, for STARP log rank p = 0.17) data not shown. 
 
5.3.2  ELISA Results 
 
The protein antigens provided were initially checked for purity by gel 
electrophoresis. This showed fragments of the expected molecular weight for each 






































































































































Figure 5.5: Gel electrophoresis  
Gel showing the recombinant proteins used in the ELISA experiments. Chapter 5 Lab Work 
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Samples were chosen from 23 volunteers who participated as control volunteers in 
the malaria vaccine study, and follow up data was not made available until after all 
ELISA assays had been performed. Unfortunately, 5 of the volunteers chosen 
were lost to follow up during the subsequent period, and so information concerning 
malaria infection was not collected.  
 
Antibodies to all the antigens selected were detected at varying levels in the 
samples chosen. Antibodies to Exp 1 were detected at only very low levels in a 
few samples, and this antigen was therefore not used in any subsequent analysis. 
The endpoint titres for each antigen for all 23 volunteers are shown in the following 
table. 
 
0 266 1396 2046 265 0 1782 51
89 93 7893 514 224 140 150 74
0 59 218 303 203 0 100 71
198 2923 1414 3459 2469 300 691 67
81 0 104 530 357 0 173 66
655 468 18880 22613 7270 6600 8743 48
182 13867 9143 7319 4577 1581 1160 45
166 286 3200 5473 2318 2732 424 39
336 183 7529 21323 9452 4509 7362 35
95 173 6784 9600 5967 2624 1010 32
436 2629 7400 16488 5881 2607 8000 21
114 91 2473 1646 1067 357 223 18
140 1294 8457 5758 2667 1507 1584 63
66 0 92 4269 162 3938 168 110
184 141 1538 3858 347 2936 575 107
127 354 14629 38824 1328 36800 696 101
76 92 369 3850 693 2720 436 94
100 135 1635 3294 990 1394 910 91
85 120 16800 658 120 314 224 86
0 0 0 144 0 0 144 85
70 0 314 907 246 120 541 84
196 149 826 1029 236 98 695 83
70 114 571 795 429 156 209 115
LSA 1 TRAP STARP LSA 3 
TOTAL
LSA 3 NN LSA 3 PC LSA 3 729 VOLUNTEER NO.
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Table 5.2: Endpoint titres 
The endpoint titre for each antigen is shown by volunteer. LSA 3 Total is the sum of the 
titres for the 3 individual recombinant proteins covering LSA 3. 
 Chapter 5 Lab Work 
  139
Combining this data with the information concerning malaria infection, it can be 
seen that rather than there being a correlation between high antibody levels and 
protection from infection, rather the converse appears to be true. The graphs in 
figure 5.6 describe this data in more detail. 
 
When volunteers are divided into those who did became PCR positive for malaria 
during the follow up period (n=10) and those who did not, (n = 8) it can be seen 
that there is no significant difference in endpoint titre between the two groups. The 
data is summarised in the table 5.3, and figure 5.6. 
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Table 5.3: Mean endpoint titres  
Subjects grouped into those who developed malaria (PCR +) and those who did not (PCR - ), 
the PCR method used has a sensitivity of 20 parasites/mL blood. The mean endpoint titre 
for each antigen in these groups is shown. 



















































































































Figure 5.6: Endpoint titres by malaria outcome 
(PCR positive = Yes, PCR negative = No). Mann Whitney U test was used to calculate the 
following p values: LSA3 p = 0.64, STARP p = 0.79, TRAP p = 0.41, LSA1 p = 0.67. 
 
5.4  Discussion 
 
The data presented here support the view that T cell responses to the antigens 
selected may play a role in protection from malaria infection. While the presence of 
antibodies to the selected antigens was confirmed, sometimes at low levels, in this 
study, there was no clear link to protection from malaria infection. However, this 
may be a result of the particular study from which the samples were taken. There 
were insufficient diagnoses of clinical malaria during the study VAC029 to allow 
comparison of antibody response with time to malaria infection, and so for the Chapter 5 Lab Work 
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purpose of this analysis time to PCR positivity has been used instead. This is a 
poor surrogate for malaria infection, as demonstrated by this particular trial – some 
volunteers in the trial received a dose of sulfadoxine-pyrimethamine (SP) to 
prevent new infections of malaria during the follow up period. Although none of the 
developed clinical malaria, many of these volunteers developed low level 
parasitaemia detected by PCR measurement [221]. Thus PCR positivity is not an 
ideal measure of malaria infection, and this effect may well have influenced the 
results of this analysis. In order to examine this in more detail further samples from 
a different study, in which higher levels of clinical malaria were observed would 
need to be analysed. 
 
The T cell responses measured here do appear to be important in protection from 
malaria infection. However, care does need to be taken when interpreting these 
results. The samples used for this study were obtained after the follow up period 
during which data on malaria infection were collected. There is evidence that 
malaria infection itself modulates the immune response, leading to 
immunosuppression [60]. The results obtained here may just reflect this exposure 
to infection during the follow up period, with those who developed malaria infection 
remaining immunosuppressed at the time of follow up.  
 
The difficulty with performing studies of this sort with the aim of elucidating 
responses that may be important in protecting individuals from malaria infection is 
that the immune response to malaria is extremely dynamic. Both studies here take 
samples from one time point, and attempt to relate them to what happens (or has 
happened) to that individual over a period of time. It is clear that individuals 
become parasitaemic all the time, and that infection is sub clinical in many. These 
repeated low level infections are likely to alter the immune response of that 
individual [109]. The ‘snapshot’ approach used here, and in many other studies of 
this sort, will give some guidance, but it is difficult to extrapolate from these results. 
In order to really evaluate the importance of particular responses in protection from 
infection, it will be necessary to measure these responses over a period of time.  
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Chapter 6   Parasite Life Cycle 
Modelling 
6.1  Introduction 
Mathematical models of parasite growth have been developed for several reasons. 
They have been used, by making biologically plausible assumptions, to explain 
observed phenomena – for example parasite diversity or density regulation 
mechanisms – or to predict the impact of interventions e.g. use of anti-malarial 
medication. Other models were intended to provide a method for estimating total 
parasite burden, as it became clear disease severity was related to parasite 
burden, but that sequestration of infected erythrocytes meant estimations of 
parasitaemia from peripheral blood smear were underestimating this. In the 
context of clinical trials of a malaria vaccine, however, models of parasite growth 
have other uses as well. The primary outcome measure of a Phase IIa clinical trial 
is protection from malaria; however, it is also useful to be able to estimate rates of 
parasite growth, particularly in the assessment of a vaccine that is designed to 
induce blood stage immunity, as a useful impact on parasite growth rate may not 
lead to protection in each individual tested. An accurate model of parasite growth 
can significantly improve the capacity for evaluation of both pre-erythrocytic and 
blood stage vaccines in phase IIa studies. 
 
This Chapter contains a brief description of some of the published models in this 
field, and a comparison is made. Three categories of model have been used:  
 
1. Simple models based on the observation of a sinusoidal oscillating parasitaemia 
with an exponential growth rate,  
2. Time evolution models, which can be divided into continuous time or discrete 
time, and describe the rate of change of parasite density at the various stages of 
the parasite life cycle,  Chapter 6 Parasite Life Cycle Modelling 
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3. A sum of probability density functions describing the timings of various stages in 
the cycle.  
 
The third type of model is chosen as the most pertinent to the data collected 
during malaria challenge studies. This model is then used to fit data from the 
studies already described in this thesis (VAC030 and VAC027), and estimates for 
parasite growth rates, and the original number of infected hepatocytes for each 
individual obtained.  
 
6.2  Comparison of Models 
The simplest method of calculating parasite growth rates is to measure parasite 
density at two or more times during the course of infection, and draw a best fit 
straight line through these points. Calculating the gradient of this line will give an 
estimate of parasite growth rate over the measured period. There are a number of 
more sophisticated models for estimating parasite growth and burden, the most 
important of which are described below, where they have been grouped into the 
three broad categories described. It is not just parasite growth rate that is of 
interest, but, particularly in trials of pre-erythrocytic vaccines, the liver parasite 
burden.  
 
Some of these models have been used to predict the effect of an intervention, but 
never actually compared with data obtained from malaria infected individuals. 
Other studies have used data from the widespread use of malaria therapy for the 
treatment of neurosyphilis, both in the US and the UK, up to the early 1960s [222, 
223] or from other sources (for example, early clinical trials of anti-malarial 
treatment [224]) to validate their assumptions. 
 
6.2.1  Simple Models 
Simpson et al. [222] aimed to calculate the parasite multiplication rate and the 
periodicity in the first week of patent parasitaemia in the absence of anti-malarial 
treatment, and to compare this between different strains of falciparum. They chose 
a simple “non-linear mixed effects model” which consisted of two terms – one to Chapter 6 Parasite Life Cycle Modelling 
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describe the exponential parasite growth, which is linear in log10(parasitaemia), 
log10(p), and an oscillating sine wave function to model the observed periodicity. 
The equation of their model is as follows: 
 
log10(p) = a +  b*t + c sin(d*t +e)            (Equation 1) 
 
Where t is the time after parasites emerge from the liver, in days. Constants b, c 
and d have clear physical meaning: 
b = ½ log10 (2-day parasite multiplication rate)  
c = amplitude of the sine wave (the magnitude of the oscillation of log10(p)) 
d = 2π/period of oscillation in days (the frequency of the oscillation of log10(p)) 
The physical meaning of e, the phase (time) shift of the sine wave, is unclear.  
 
When e = 0, and t = 0 (time of release) 
a = log10 (initial number of parasites) 
 
However, this is not necessarily true when e ≠ 0. Chapter 6 Parasite Life Cycle Modelling 
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Figure 6.1: Diagram: the Simpson model.  
In blue, a linear function representing parasite growth, in pink a sine wave providing 
periodicity and in red, the sum of the two. 
 
Simpson et al. used this model to fit to the data from neurosyphilis patients treated 
with different strains of falciparum. The data was from the first week of 
parasitaemia in order to represent the ‘expansion phase’ of infection, before any 
induced control mechanisms could come into play.  Ten different strains of 
falciparum were used in these treatments, and thick and thin films were made 
daily, and the number of parasitized red blood cells per microlitre of blood was 
recorded. They found a wide variation in the parasite multiplication rate, this 
variation was shown to be the result of both host and parasite factors. However, 
they admit a ‘poor fit of the model’ for the data from a significant number of 
patients - as many as 35% (93 out of 245) and they exclude those from over 50% 
(128 out of 245). 
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Another paper using this method was published by Bejon et al. [214]. Again using 
sine wave and logarithmic functions to provide the observed fluctuations in 
parasite density and growth, it assumes all parasites emerge from liver at day 7 (t 
= 0 at day 7); and also that they have a 48 hour life cycle (d = 2π / 2 days = π). 
The parasite growth rate is calculated as the gradient of straight line drawn 
through the sine wave (green dotted line in figure 6.1). A constant, a, for initial 
parasite density is included in the equations, allowing back calculation of original 
numbers of parasites released from the liver, and hence estimation of the number 
of infected hepatocytes, although this is problematic, as discussed below. This 
method is essentially the same as that described above [222]. The model was 
used to fit data from sporozoite challenges of volunteers participating in malaria 
vaccine studies such as the ones already described in this thesis. 
 
Although adding a sine wave function and a logarithmic function appear to fit the 
data available (or at least some of it, in Simpson’s case), it doesn’t take into 
account what is understood about the biology of the malaria parasite. For 
example, it seems unlikely that all parasites are released from the liver at the 
same time in each volunteer, in the same way as asynchronous populations of 
parasites are observed in the blood stages. So assuming that all parasites are 
released by day 7 may not be valid. The assumption that the cycle time for each 
parasite is exactly 48 hours is also not based on good evidence. Simpson et al. 
[222] observed that the length of the parasite life cycle was generally greater than 
this, quoting a population mean of 55 hours (2.3 days). Interestingly, they also 
observed that there was negligible inter-patient variability in this parameter. It is 
not clear why this observation is not more widely accepted. Using this model to 
estimate the original numbers of parasites released from the liver, and hence 
extrapolating the number of infected hepatocytes is problematic. When the phase, 
e = 0, the original number of parasites released at time t=0, is calculated by the 
formula: 
  
p(t=0) = 10 
a                 (Equation 2) 
 Chapter 6 Parasite Life Cycle Modelling 
  147
However, if, in order to fit the data better, e has to be adjusted (perhaps because 
of variability in the release time) by half a day, then the estimate of parasites 
released from the liver according to this model is  
 
log(p) = a + c sin (e)               (Equation 3) 
p(t=0) = 10
 a + c sin (e) = 10
a 10
 c sin (e) 
Taking 10 
a as the estimate for the original number of parasites could, therefore be 
wrong by a factor as large as 10 
± c. 
 
If Equation 3 is used to estimate the original number of parasites, it implies that 
this number depends on the error in the estimation of release time, which is 
implausible. Because the release time is fixed at day 7, the phase parameter e has 
been introduced to account for any variability in this in practice. Unfortunately, this 
affects the estimate of the initial number of parasites p(t=0), where the line crosses 
the y axis. Any difference in the release time from day 7 therefore translates into 
an error in the estimate of the initial number of infected hepatocytes. This would 
not be a problem if the uncertainty in the release date were small, but for a 
variability of +/- ½ day (1/4 cycle), p (t=0) varies between 10 
a-c to 10 
a+c. 
 
This introduces substantial uncertainty into the method for the calculation of 
estimates for numbers of infected hepatocytes. In practice, this error is significant. 
As one of the principal reasons for developing such a model is to allow back 
calculation of numbers of infected hepatocytes, this is a major drawback of this 
technique. 
 
Even if the preset variables (release time, period) were allowed to vary, this model 
is unrealistic because it is not derived from an understanding of the biology of 
malaria. 
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6.2.2  Time Evolution Models 
6.2.2.1  Continuous Time Models – Partial Differential Equations 
Anderson 1989 [225] proposed a set of three coupled differential equations 
representing the rates of change in numbers of uninfected erythrocytes, 
parasitized erythrocytes, and merozoites over time. Their purpose was to compare 
the effectiveness of immune response against merozoites and parasitized red 
blood cells, although the terms relating to immune responses can be excluded 
from the model if desired. A shortcoming of this model is the inherent lack of any 
synchronicity or periodicity emerging from the model. Even if one assumes that all 
merozoites emerge from the liver during a limited time-window, no synchrony of 
the erythrocytic phase would be expected by this model, contrary to observed 
data. They use numerical simulation alone to test the model, and make no 
comparison at all with observed data.  
 
Another example of this kind of model is that proposed by White et al. [224]. This 
model makes two specific assumptions about the life cycle of falciparum parasites: 
that the period of the cycle is 48 hours exactly, and that all parasites are 
sequestered once they have reached an age of 26 hours. The partial differential 
equations were formulated to calculate the distribution of parasite stages, and 
assume that these form a Gaussian distribution. They were fitted by inspection to 
the parasite counts obtained from 4 patients in an unsuccessful trial of 
Ciprofloxacin for the treatment of falciparum malaria infection. Parasite density 
was assessed 6-12 hourly in these patients, by thick and thin films stained with 
Giemsa, and following the failure of Ciprofloxacin all patients were treated 
successfully with quinine. The parasite multiplication factor was estimated from the 
ratio of parasitaemia at the time of quinine treatment to that 48 h previously 
(equivalent to the best fit straight line approach). 
 
These first two models (by Anderson and White) have been taken up by Hoshen et 
al. [226] and combined to form a theory which can explain the periodicity of 
malaria solely through the 3-compartment (RBC, IRBC and merozoites) approach. 
This model again uses partial differential equations to describe the process of Chapter 6 Parasite Life Cycle Modelling 
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erythrocyte invasion, parasite survival and killing induced by immune responses. A 
48 hour parasite life cycle is again assumed, and the parasite multiplication rate is 
also preset at r = 16. However, they do fit their model to data obtained from one 
malaria therapy patient, and it seems to fit this data reasonably well. 
 
In 1991 Kwiatowski and Nowak [227] published a model that investigated the role 
of fever in inhibiting parasite growth and promoting parasite synchronisation in 
vivo. This was based on the observations that febrile temperatures are related to 
parasite growth cycle in erythrocytes, and, at the same time, damaging to P. 
falciparum parasites, particularly during the second half of their cycle. In this 
model, all parasitized red blood cells are divided into 4 ‘ages’, through which they 
progress until schizont rupture. The mathematical model uses partial differential 
equations to predict the survival of parasitized erythrocytes, and the passage of 
parasites from one cycle to the next. It behaves in a qualitatively realistic way (see 
also Molineaux and Dietz [228]) with numbers of PRBC rising rapidly to a plateau 
and then oscillating, a situation which generates a periodic fever, as observed in 
vivo. It also predicts irregular parasite population dynamics at high multiplication 
rates, consistent with the classical observation that P. falciparum causes less 
regular fever than other species of parasite. Gravenor et al. [229] describe a 
continuous time model based on that of Kwiatowski. This model is backed up by in 
vitro data obtained from parasite cultures, maintained at varying temperatures to 
model the situation in vivo. The parasite multiplication rate is included in the 
model; however, it is preset by the investigators depending on the situation they 
wish to model e.g. parasite multiplication rate (r) of 4 per cycle – slow parasite 
growth, r = 16 per cycle – rapid parasite growth. Their suggestion of a ‘pyogenic 
threshold’, a threshold parasite density above which the host will develop fever, is 
plausible. It is likely that this threshold is host dependent, indeed Jeffery et al. 
1959 [230] observed that patients receiving malaria therapy differed substantially 
in the parasite density associated with fever. However, when large variation in 
pyogenic threshold (observed in vivo) is incorporated into this model, it produces a 
large variation in the periodicity of parasite infections, which does not fit with in 
vivo experience. There is no attempt to fit either model to measured data from 
individuals with malaria infections.  
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6.2.2.2  Discrete Time Model 
Molineaux et al. [223] formulated a mathematical model for falciparum asexual 
parasitaemia. They selected data from 35 Afro-American neurosyphilis patients 
who were classified as ‘spontaneous cures’ from malaria treatment. They had no 
history of exposure to malaria, and were inoculated either by infected blood, or by 
infectious mosquito bite. Nearly half of them (16/35) received at least one dose of 
anti malarial medication during their therapy, and data was collected over a period 
of up to 250 days, all of them were slide negative for a period of at least 5 months 
before they were finally given ‘curative treatment’ and discharged. The model 
assumes a period cycle of 2 days, on the basis of observations of bouts of 2 day 
periodicity. It uses observations from Plasmodium knowlesi and chabaudi 
infections, showing in vivo evidence of the association between successive 
recrudescences of parasitaemia and expression of different variants of those 
parasites PfEMP1 analogues [231, 232] to incorporate assumptions of the 
appearance of variant strains of parasite, expressing variant PfEMP1. This was 
necessary to account for multiple episodes of apparent clearance of parasitaemia, 
followed by a recrudescence. This occurred as many as 14 times in an individual 
patient. The variables of interest in their model therefore, are parasite variant 
multiplication rates (which they assume to be normally distributed over a large 
range), and three functions describing the effect on parasite multiplication of the 
immune response, divided into three elements: 
•  innate and variant transcending, 
•  acquired and variant specific, 
•  acquired and variant transcending. 
The effects of these immune responses are formulated as probabilities (the 
probability that the parasites escape their effects) and the product of these three 
functions gives the probability that the parasite successfully escapes the effects of 
all three. The model simulates infections as if they are monoclonal, with a single 
pool of 50 variants. They did find a large range of parasite variant growth rates, 
which appeared dependent on both host and parasite factors. Their main focus 
however, was on accurately modelling the expressions of variant strains of 
parasite, based on the assumptions of a biologically plausible mechanism. The 
model itself is not directly applicable to the data obtained in our malaria vaccine Chapter 6 Parasite Life Cycle Modelling 
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trials, as the length of infection is rarely sufficient to allow emergence of new 
strains of parasite, and certainly not long enough for spontaneous resolution of the 
sort seen in these patients to occur. An investigational vaccine may also alter the 
pattern of emergence of variant strains of parasite, and this would also need to be 
included if this model were to be applied to data from vaccine trials. The model is 
included in this comparison as the main example from this category. It also forms 
the basis of the most comprehensive model yet published, described below. 
 
Smith et al. have published a series of papers developing a dynamic model for 
prediction of the epidemiologic and economic impact of a malaria vaccine [233]. 
Their model aims to take into account the characteristics of individual P. 
falciparum infections, short and long term effects on the vaccinated individual, the 
interdependence of hosts and epidemiological impact of a vaccine on 
transmission, and a cost effectiveness analysis. This is a complex model, and in 
order to perform the computational analysis, they divided it into a number of sub-
models, which are then combined. An important strength of this framework is that 
it ties together an ensemble of interconnected sub-models validated against actual 
field data from various settings across Africa. This is the most comprehensive 
population-based simulation of malaria yet developed, and so might be expected 
to be useful in this context. However, it is designed for use in studying the effect of 
a malaria vaccine on an African population, and not really for use in analysing data 
obtained from vaccine trials in the UK. The sub-model relating to the early stages 
of blood stage infection [234], that could potentially be relevant in this scenario, is 
largely based on that originally published by Molineaux et al. [223], described 
above. The variables of interest here are four parameters: the multiplication factor, 
the time of onset of adaptive immunity, and the parasite densities at which the 
innate and adaptive immune responses become active. Although useful in 
modelling the effects of hypothetical blood-stage vaccines, for example, and 
informing decisions about the endpoints and outcomes used in trials of such 
vaccines, it is not possible to compare this model usefully to the available data 
because of the number of variables involved and the complexity. 
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6.2.3  Probability Density Functions 
 
More recently, Hermsen et al. [203] have published a statistical method for 
calculating parasite growth rates. Their data comes from volunteers participating in 
challenge studies to test malaria vaccines, such as those described in this thesis, 
and they have used it to develop a statistical model, allowing estimation of various 
parameters including length of parasite life cycle and multiplication rates. Their 
model is of parasite densities expressed as a non linear function of time (days) 
since infection. They assume that the timing of appearance of the first and 
subsequent generations of parasites will be normally distributed; for example, that 
the timing of hepatocyte rupture, and first release of parasites into the blood, will 
be normally distributed, and that it may therefore be modelled using a normal 
probability density function. The duration of the presence of a given ring form is 
also assumed to be normally distributed and so is modelled in the same way. The 
convolution of both probability density functions thus gives a model of the timing of 
the disappearance of ring forms. They then perform a summation over all the 





















































Figure 6.2: Hermsen model 
Using the Hermsen model results in this graph of expected parasite density (log 
parasites/ml) in days following malaria infection. It shows the appearance and Chapter 6 Parasite Life Cycle Modelling 
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disappearance (sequestration) of successive generations of blood stage parasites. The red 
line is the sum of all blood stage parasites from all cycles. 
 
Similar biologically plausible assumptions made about the timings of the 
appearance and disappearance of subsequent generations of ring forms produce 
a statistical model which is then fitted to real data using a least squares 
optimization routine, and produces estimates of various parameters. The main 
drawback of this model is the number of parameters included in it – there are as 
many as nine unknown variables. This means that more data points are required 
in order to find a solution. In their paper, the authors fix some of these to constrain 
the optimizations. However, this model is still the one which most closely matches 
the problem of modelling parasite densities early in malaria infection, prior to 
volunteers becoming thick film positive. The model is fitted to data from volunteers 
participating in challenge studies, without any problems of poor fit, and by 
incorporating the variability of some parameters makes fewer assumptions about 
the behaviour of the parasites. 
 
6.3  Modelling of PCR Data from Clinical Trials 
The Bejon variant of the Simpson model, and that published by Hermsen were 
selected for further comparison. The Bejon variant was selected as it had been 
used to analyse data in Oxford previously, and is representative of the Simpson 
approach, and, after the Hermsen method, it is the best suited to analysing data 
from early in infection and calculating the variables that we are particularly 
interested in. The Bejon method is appealing because it is simple, although it has 
no clear foundation in biological terms. The main appeal of the Hermsen model, is 
that the terms have clear biological meaning and represent biological quantities. 
An additional advantage of the latter, because it relates clearly to the biology, is 
that it has potential for modelling the effects of a malaria vaccine, if terms 
predicting immune responses could be included, although it has not been used 
this way in this study. 
 
For the comparison itself, data obtained in the vaccine trial VAC030, described in 
chapter 4 of this thesis, was used. Both models were incorporated in an Excel™ Chapter 6 Parasite Life Cycle Modelling 
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spreadsheet and the built in constrained optimisation algorithm was used to 
compare the values calculated by the relevant model to measured data for each 
individual. The optimisation routine calculated the sum of squared differences 
between the model and measured data, and changed the variables included in 
each model within specified, realistic limits, in order to minimise the sum. The 
constraints that were included within the optimisation routine are described in table 
6.1. The variances were preset at the values shown, these were derived from the 
original paper published using this model [203]. No limits were required for the 
Bejon model. 
 
0.004 days^2 Sig3^2 Variance in duration until appearance of new 
generation ring forms in blood
>0.8, <1.5 days mu3 Mean duration until appearance of new 
generation ring forms in blood
0.03 days^2 Sig1^2 Variance in duration until appearance of 1st
generation ring forms in blood
>6.3, <7 days mu1 Mean duration until appearance of 1st generation 
ring forms in blood
0.004 days^2 Sig2^2 Variance in duration until sequestering of ring 
forms
>0.8, <1.5 days mu2 Mean duration until sequestering of ring forms
>1, <50 B2
Multiplication factor relating max. no. of ring 
forms of one cycle to previous cycle
>1, <1500 number/ml X*B1 Total no. of ring forms released from liver per ml 
blood
B1
Ring forms per hepatocyte per ml blood
X
Number of infected hepatocytes
Constraints Units Notation Parameter
0.004 days^2 Sig3^2 Variance in duration until appearance of new 
generation ring forms in blood
>0.8, <1.5 days mu3 Mean duration until appearance of new 
generation ring forms in blood
0.03 days^2 Sig1^2 Variance in duration until appearance of 1st
generation ring forms in blood
>6.3, <7 days mu1 Mean duration until appearance of 1st generation 
ring forms in blood
0.004 days^2 Sig2^2 Variance in duration until sequestering of ring 
forms
>0.8, <1.5 days mu2 Mean duration until sequestering of ring forms
>1, <50 B2
Multiplication factor relating max. no. of ring 
forms of one cycle to previous cycle
>1, <1500 number/ml X*B1 Total no. of ring forms released from liver per ml 
blood
B1
Ring forms per hepatocyte per ml blood
X
Number of infected hepatocytes
Constraints Units Notation Parameter
 
Table 6.1: Hermsen model parameters 
This table shows the parameters, notation and limits used to perform the constrained 
optimisation routine using the Hermsen model. 
 
In order to demonstrate this comparison, the following graphs are representative of 
data from 3 volunteers from VAC030. Each graph is of parasite density against Chapter 6 Parasite Life Cycle Modelling 
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time, and the measured PCR data is plotted, along with the data calculated using 






















































































































































Figure 6.3: Graphs of data from VAC030.  
The measured PCR data is plotted on each graph in blue, and the model in red. For each 
volunteer graph (A) shows the result of fitting the Hermsen model to the data, whilst graph 
(B) shows the Bejon model.  
 
For these three subjects at least, the Hermsen model appears to visually fit the 
raw data from early malaria infection better than the Bejon model. The ‘goodness 
of fit’ can be compared statistically, using the sum of squared errors for each Chapter 6 Parasite Life Cycle Modelling 
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model, and in this case the Hermsen model gives lower values (i.e. is a closer fit of 
the data) than the Bejon model. This is also demonstrated in table 6.2, which gives 
the values of the sum of the squared error for each model by volunteer for those 


























Table 6.2: Error values for each model 
 
Similar comparisons were made for all subjects from VAC030, and the squared 
error was lower with the Hermsen model than the Bejon model in the majority of 
the subjects, and gave a lower total summed error. Although growth rates 
calculated using these two models were different, they did have a positive 
correlation (see graph; Pearson correlation 0.63, p <0.01).  
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Figure 6.4: Scatter plot of parasite growth rates (PMR)  
Scatter plot demonstrating the positive correlation (shown by best fit straight line) of values 
calculated by the Bejon and Hermsen methods. Data from VAC030. 
 
In order to provide another independent method to assess these two models, an 
estimate of the initial number of parasites released into the blood of each volunteer 
was made using each one. This was then used to estimate the number of infected 
hepatocytes (making the standard assumptions that each infected hepatocyte 
releases 20,000 merozoites, and that the circulating volume is 5 litres). Volunteers 
receiving liver stage targeting vaccines might be expected to mount an immune c 
response against infected hepatocytes, so this number may be used as a 
surrogate marker of efficacy of these vaccines. However estimates of numbers of 
infected hepatocytes varied substantially from one model to the other, and there is 
no correlation between the two (see graph; Pearson correlation coefficient 0.069, p 
= 0.7). 
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Figure 6.5: Scatter plot of numbers of infected hepatocytes 
This scatter plot shows the estimated numbers of infected hepatocytes calculated using 
each model, and demonstrates the lack of correlation between the two models. Even if the 
one outlier is removed, the correlation between the two models is poor (Pearson correlation 
coefficient 0.4). Data from VAC030. 
 
These estimates of infected hepatocyte numbers were then plotted against the day 
of diagnosis. Volunteers with high numbers of infected hepatocytes would be 
expected to have higher parasitaemias earlier in infection, and hence to be 
diagnosed before those with a lower infectious burden. A negative correlation 
between liver parasite burden and day of diagnosis would be expected. Using 
Spearman’s correlation, for both models, the number of infected hepatocytes 
correlates with day of diagnosis (statistical model – Spearman's correlation 
coefficient = 0.77, p<0.01, sine model – Spearman's correlation coefficient = 
0.386, p = 0.038). However with the Bejon model, this is a positive correlation, 
suggesting the model is wrong. Scatter plots of the data are shown for comparison 
– the following graphs show the data from the Bejon model, with a positive Chapter 6 Parasite Life Cycle Modelling 
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correlation, and that from the Hermsen model. Best fit straight lines through the 
data points illustrate the positive and negative correlations. 
 



















































Figure 6.6: Scatter plot of infected hepatocytes (Bejon) and day of diagnosis.  
The lack of correlation between the estimated number of hepatocytes calculated using the 
Bejon method and the day of diagnosis is shown. If the one outlier is removed, the gradient 
does become negative, however there is no correlation (Pearson correlation coefficient 
0.165, p = 0.4) Data from VAC030. 
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Figure 6.7: Scatter plot of infected hepatocytes (Hermsen) and day of diagnosis 
The number of infected hepatocytes calculated using Hermsen’s model, correlates with the 
day of diagnosis, as shown by the best fit line. 
 
6.3.1  Delay to Parasitaemia and Liver Parasite Burden 
 
As many of the vaccines used in trials in Oxford have been primarily targeting liver 
stage antigens, it is particularly useful to be able to obtain an estimate of the initial 
number of infected hepatocytes. While we assume that any significant reduction in 
the liver parasite burden might result in a delay in the time to patent parasitaemia, 
it is possible that in the stringent challenge used in these studies, there are so 
many liver stage parasites that they overwhelm any induced immune response. In 
order to examine this in more detail, the data collected from two previous studies 
was examined. The trials, in each of which a group of vaccinated volunteers 
received FFM ME-TRAP, demonstrated a delay in time to patent parasitaemia in 
vaccinated volunteers in these groups, suggesting a vaccine induced impact on 
the liver stage burden. The Hermsen method was used to model PCR data from Chapter 6 Parasite Life Cycle Modelling 
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volunteers involved in this study, and the estimated number of infected 
hepatocytes was calculated for each volunteer. One would expect the group of 
vaccinated volunteers, in which a delay to diagnosis was seen, to have 
significantly fewer parasites released from the liver, resulting in a reduction in the 
calculated number of infected hepatocytes. Sporozoites which infect hepatocytes 
but which fail to transform into merozoites because of an induced immune 
response would not be included in the model because there would be no 
measurable effect on the numbers of blood stage parasites, so the estimated 
number of infected hepatocytes is a measure of successfully infected hepatocytes. 
 
PCR data from 19 vaccinated volunteers and 8 controls was used for these 
calculations; the volunteers participated in trials VAC012 and VAC015. The 
malaria challenge was performed as described elsewhere in this thesis. Of the 19 
vaccinees, data was available for only 16, (for 1 blood was collected by finger prick 
therefore there was no PCR data available, and for 2 there was insufficient data – 
only one or two positive PCR results). The mean number of infected hepatocytes 
for the 16 vaccinated volunteers was 66 (95% confidence intervals 30 – 101, 
standard deviation 67) and for the 8 controls volunteers it was 168 (95% 
confidence intervals 145 – 191, standard deviation 28). This does represent a 
significant reduction in infected hepatocytes in vaccinated volunteers (Mann 
Whitney two tailed p = 0.005) of 61%. The following box plot demonstrates the 



















































Figure 6.8: Box plot of infected hepatocytes in vaccinees and controls   
The estimated number of infected hepatocytes for vaccinated volunteers and controls 
participating in VAC012 and VA015. For Vaccinees n=16 and for Controls n=8. The outlying 
points in the Vaccinee box represent 3 volunteers, there were only 5-7 positive PCR results 
available for these volunteers, so while it is possible to fit the model, it is hard to be sure of 
the accuracy.  
 
6.3.2  Conclusion from Comparison of Methods and Modelling Data 
 
The Hermsen model seems to be the most likely to give realistic results, as it is 
based more upon the biological information we do have about parasite growth and 
invasion. The Hermsen model therefore appears to be superior to that of Bejon et 
al. in several important respects: 
i) The assumptions made fit the biology of the malaria parasite life cycle as it is 
currently understood. 
ii) Visually, the model fits the data from trial volunteers more closely, and the 
summed squared errors calculated are consistent with this better fit. Chapter 6 Parasite Life Cycle Modelling 
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iii) Using the model to estimate the number of infected hepatocytes (a procedure 
that requires the same assumptions to be made, whichever model is used) 
produces a number that correlates with the day of diagnosis of the volunteer with 
malaria. This shows that the model reflects the in vivo situation more accurately 
than the Bejon model. 
 
When the Hermsen model is used to calculate numbers of infected hepatocytes in 
groups of volunteers in whom a delay in time to patent parasitaemia was recorded, 
a reduction in the number of infected hepatocytes is seen in these volunteers 
versus controls, as would be expected. This is also true when the Bejon model is 
used to perform this calculation. 
 
On the basis of this, the Hermsen model was used for further analysis of parasite 
growth rates. Using this statistical model, the rates of parasite growth in groups of 
vaccinated and control volunteers for various studies are compared.  
 
 
6.4  Results 
6.4.1  VAC030 Results 
Using the Hermsen model to fit data obtained from volunteers taking part in 
VAC030 allowed estimation of parasite growth rates for each one. These are 
shown in figure 6.9, along with mean rates for each group of volunteers. 
 
As described in Chapter 4, Group 1 were vaccinated with PEV3A alone, Group 2 
received both PEV3A and FFM ME-TRAP, and they were all challenged along with 
a group of unvaccinated control volunteers. The mean rate of blood stage parasite 
growth in volunteers in group 1 was 5.7 parasites per ml per cycle (95% 
confidence intervals 4.1 - 7.3; standard deviation 2.6), for group 2 this was 6.3 
(95% CI 4.0 - 8.5; SD 3.5) and for controls it was 8.7 (95% CI 7.2 - 10.2; SD 1.2) 
(figure 6.9). Comparing the growth rates of vaccinated volunteers, those in group 1 
are not significantly different to those of volunteers in group 2 (Mann Whitney U 
test; two-tailed  p=0.63). Comparing group 1 to controls, growth rates are Chapter 6 Parasite Life Cycle Modelling 
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significantly lower in group 1 volunteers than in controls (Mann Whitney U; two-
tailed p = 0.02). For group 2 versus controls, there is again a significant difference 
(Mann Whitney U; two-tailed p = 0.02). Grouping all vaccinated volunteers 
together, and comparing them to controls, there is again a significant reduction in 
parasite growth rates; (Mann Whitney U; two-tailed p = 0.012). 
 
Figure 6.9: Scatter plot of growth rates by group 
Red lines represent mean for each group, dotted lines are inter quartile ranges. 
 
There is a significant difference in the parasite growth rates in vaccinated 
volunteers versus controls. This is observed in both groups of vaccinated 
volunteers, and is therefore likely to be related to vaccination with PEV3A rather 
than the FP9 or MVA ME-TRAP. This data brings us to the conclusion that PEV3A 
has induced an immune response that has an effect on parasite growth rates, 
although this was not sufficient to prevent or clear infection in this study. 
 
Looking at the estimated numbers of infected hepatocytes in the different groups, 
the following diagram shows the individual data by group, again with red lines Chapter 6 Parasite Life Cycle Modelling 
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representing the mean for each group. This suggests that there may be a 
difference between the groups, with volunteers in group 2 having lower numbers of 
infected hepatocytes – see figure 6.10. However, statistical analysis demonstrates 
no difference between groups 1 & 2 versus controls (Mann Whitney U test; two-
tailed p=0.34) or between either group of vaccinated volunteers and controls 
(group 1 versus controls, Mann Whitney U test; two-tailed p=0.34, group 2 versus 
controls, Mann Whitney U test; two-tailed p=0.43). 
 
 
Figure 6.10: Scatter plot of numbers of infected hepatocytes by group. 
Red lines represent mean for each group, dotted lines are inter quartile ranges. 
 
6.4.2  VAC027 Results 
Using the Hermsen model, the results from the challenge of VAC027 were also 
analysed. To recheck that the model remained valid for this data, the estimated 
number of infected hepatocytes was plotted against day of diagnosis, and as 
before there was the expected negative correlation between the two variables Chapter 6 Parasite Life Cycle Modelling 
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Figure 6.11: Scatter plot of number of infected hepatocytes vs. day of diagnosis 
Calculated using Hermsen model. Data from VAC027 
 
The mean rate of blood stage parasite growth in volunteers in VAC027 were as 
follows: in group 6, 7.5 parasites per ml per cycle (95% confidence intervals 3.9 – 
11; standard deviation 4.2), for group 7 this was 7.4 parasites per ml per cycle 
(95% CI 4.1 – 10.7; SD 3.5) and for controls it was 9.1 parasites per ml per cycle 
(95% CI 7.4 - 10.8; SD 1.6).  
 
There was no significant difference in growth rates between different groups of 
vaccinees, (Group 6 vs. Group 7, Mann Whitney U test, two tailed p = 0.95) or 
between control volunteers and those who received either vaccine regimen (Group 
6 plus Group 7 vs. Controls, Mann Whitney U, two tailed p = 0.19). Chapter 6 Parasite Life Cycle Modelling 
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As the vaccines used in VAC027 have both a liver stage and a blood stage 
component, as well as looking at the blood stage parasite growth rates, it is also 
useful to examine the numbers of infected hepatocytes in each group of 
volunteers. In this case, the numbers of infected hepatocytes were as follows: 
Group 6 mean 146 95% CI 60 - 232 SD 103 
Group 7 mean 133 95% CI -3 - 270 SD 148 
Controls mean 109 95% CI 33 - 183 SD 71 
 
There was no significant difference in the numbers of infected hepatocytes, either 
between group 6 and group 7 (Mann Whitney U, two tailed p = 0.56), or between 
all vaccinated volunteers together and controls (Group 6 + Group 7 vs. Controls, 
Mann Whitney U, two tailed p = 0.76). 
 
  
6.5  Discussion 
 
A selection of the most relevant published models have been described, and the 
major assumptions used discussed. The Hermsen model was selected as the 
most appropriate for use with the data collected during the clinical trials performed 
in Oxford following direct comparison with the Bejon model, previously used for 
this purpose. Using this Hermsen model, it has been possible to show that some 
of the candidate malaria vaccines tested in these studies in Oxford do exert some 
effect on blood stage parasite growth.  
 
VAC030 was the first to provide evidence of vaccine-induced blood stage 
protection in a healthy volunteer challenge study. An effective immune response 
against blood stage parasites has previously been achieved in a rodent malaria 
model by subpatent infection by blood stage malaria parasites [235], and recurrent 
subpatent infections of human volunteers has also been shown to induce 
protection from a subsequent challenge [109]. A study evaluating the efficacy of a 
candidate AMA1 vaccine in monkeys demonstrated some good protection from P. 
falciparum blood stage challenge [236]. This vaccine has been tested in a Phase I Chapter 6 Parasite Life Cycle Modelling 
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clinical trial in humans, and has been shown to elicit functional antibody responses 
[206], however as yet there has been no evidence of vaccine induced protection 
from infection in humans.  
 
Low levels of immunogenicity were measured throughout VAC027. It is perhaps 
therefore not surprising that no measurable effect on numbers of infected 
hepatocytes was seen. The blood stage components of the vaccine did not appear 
to have any effect on blood stage parasite growth either. The use of this model 
enables the conclusion that no part of the vaccine (neither the pre-erythrocytic 
components nor the blood stage antigens) has induced any useful immune 
response, even an only partially protective one. 
 
While it is useful to be able to model blood stage infections in this way it is also 
useful to be able to estimate the effect vaccines may have on liver stage parasites. 
In natural infection, it is unlikely that an individual would be exposed to such a high 
parasite load simultaneously. The estimated numbers of infected hepatocytes 
therefore, are useful in this context, as many of the vaccines that have been 
investigated in Oxford target liver stage antigens, and would so be expected to 
produce an effect at this stage rather than have any impact on blood stage 
parasite growth. In the studies where a delay in parasitaemia has been observed, 
this is associated with a reduction in the estimated numbers of infected 
hepatocytes as calculated using the Hermsen model.  
 
 Chapter 7 Challenge Controls 
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Chapter 7   Challenge Controls 
7.1  Introduction and Literature Review 
The challenge studies that are performed in Oxford play a vital role in establishing 
the potential of a particular vaccine regimen to provide any protection from malaria 
infection. As part of each challenge study, a number of healthy control volunteers 
are recruited, and infected with malaria, without prior administration of any 
vaccine. The purpose of these volunteers is to prove the integrity of the infectious 
system, and also to act as a comparison group when calculating parasite growth 
rates and time to patent parasitaemia in vaccinated volunteers. The data collected 
from these controls represents a valuable model in which to study malaria 
infection, at an earlier stage than they would usually present for medical attention.  
 
Before examining the symptoms that volunteers report during the challenge phase 
of these studies, it is important to note that none of the volunteers studied here 
become as ill as those with malaria described in the Oxford textbook of medicine 
(below). As discussed in Chapter 2 of this thesis, when considering carrying out 
work of this sort, considerable care must be taken to ensure the safety of the 
participants involved. 
 
In all of the challenge studies performed by the Oxford group, over 230 volunteers 
have been infected with falciparum malaria. All have subsequently been 
successfully treated, and have completely recovered from the infection. Only 2 
have ever required admission to hospital, one who became dehydrated as a result 
of nausea and vomiting, and was admitted for intravenous fluid rehydration, and 
the second following an idiosyncratic reaction to chloroquine.  
 
The symptoms of malaria infection are well described in the medical literature. 
Fever, rigours, arthralgia, nausea and vomiting, anaemia caused by haemolysis, 
haemoglobinuria, and convulsions are those commonly listed. This classical Chapter 7 Challenge Controls 
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description of the clinical syndrome of malaria infection is from the Oxford 
Textbook of Medicine:  
 
“Several days of prodromal symptoms such as malaise, headache, myalgia, 
anorexia, and mild fever are interrupted by the first paroxysm. Suddenly the 
patient feels inexplicably cold (in a hot climate) and apprehensive. Mild shivering 
quickly turns into violent shaking with teeth-chattering. There is intense peripheral 
vasoconstriction and gooseflesh. Some patients vomit…. The rigor lasts up to 1 h 
and is followed by a hot flush with throbbing headache, palpitations, tachypnoea, 
prostration, postural syncope, and further vomiting while the temperature reaches 
its peak. Finally, a drenching sweat breaks out and the fever defervesces over the 
next few hours. The exhausted patient sleeps. The whole paroxysm is over in 8 to 
12 h, after which the patient may feel remarkably well. Classical tertian or 
subtertian periodicity (48 and 36 h between fever spikes) is rarely seen with 
falciparum malaria. A high irregularly spiking, continuous or remittent fever, or 
daily (quotidian) paroxysm, is more usual. Other common symptoms are 
headache, backache, myalgias, dizziness, postural hypotension, nausea, dry 
cough, abdominal discomfort, diarrhoea, and vomiting. The non-immune patient 
with falciparum malaria usually looks severely ill, with ‘typhoid’ facies and, in dark-
skinned races, a curious greenish complexion. Commonly, there is anaemia and a 
tinge of jaundice, with moderate tender enlargement of the spleen and liver. Useful 
negative findings are the lack of lymphadenopathy and rash (apart from herpes 
simplex ‘cold sores’) and focal signs [8]” 
 
It is important to review our experience of this method for testing potential vaccine 
candidates, in order to ensure continued safety, efficiency and reproducibility of 
the technique. We have not previously reviewed the normal clinical course of 
malaria during these studies. It is useful to review this data, partly to explain to 
prospective volunteers what to expect from taking part in a study, but also to 
assess its safety and reliability. 
 
There is very little published literature relating parasitaemia to symptoms in 
malaria infection. As mentioned elsewhere parasitaemia generally correlates with 
severity of infection [237], so patients with very high parasite burdens tend to have Chapter 7 Challenge Controls 
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more severe disease, and one might assume therefore, more symptoms. 
However, little is known about the relationship between parasitaemia and 
symptoms at the other end of the disease spectrum.  
 
The objectives of this study were therefore to collate the data gathered from all 
control volunteers who have taken part in malaria challenge studies in Oxford. The 
aim was to describe the symptoms and signs reported by these volunteers, and 
any laboratory abnormalities reported during the follow up period. A secondary 
objective was to examine if there was any correlation between symptoms and 
levels of parasitaemia as determined by PCR, at these low levels of infection. 
  
7.2  Methods 
7.2.1  Challenge Method 
The protocol for the challenge phase of each vaccine study has remained largely 
unchanged throughout the many different trials that have been carried out. The 
model itself is derived from one originally described by Chulay et al. [202]. The P. 
falciparum strain used is the 3D7 clone of strain NF54, isolated by Prof. D. 
Walliker. 3D7 parasite cultures are maintained in a continuous culture system in a 
medium containing 10% v/v human AB serum (from the Blood Transfusion 
Service, Colindale, UK) heat inactivated at 56° C for 30 min. The blood products 
come from volunteers who have been screened as per UK Blood Bank (antibodies 
for HIV, HBV, HCV and syphilis). A large master seed lot of 3D7 has been 
prepared for the human studies under GMP conditions and only parasites from this 
master seed are used to infect mosquitoes. 
 
Anopheles stephensi (originally obtained from Nijmegen-strain SF500) are infected 
with the cultured material 17 days from the beginning of gametocyte culture when 
sufficient mature gametocytes are present, as indicated by the ability of the 
microgametocytes to exflagellate. The mosquitoes are allowed one blood meal at 
this time, given via a membrane feeder. This contains the cultured parasite 
material (at 17 days), plus fresh red cells from a donor and AB human serum. 
Again, the blood products come from volunteers who have been screened as per Chapter 7 Challenge Controls 
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UK Blood Bank (antibodies for HIV, HBV, HCV and syphilis). The fed mosquitoes 
are then maintained on a fructose/ paba solution. 7-9 days after the infective feed, 
samples of the mosquitoes are checked for the presence of oocysts. 16 days after 
the blood meal, samples of the mosquitoes are again checked, this time for the 
presence of sporozoites in the salivary glands. The remaining infected mosquitoes 
are then transferred to small pots containing 1-5 mosquitoes ready for feeding on 
the volunteers. 
 
Each volunteer is taken into the insectary at Imperial College in London, and given 
a cardboard container, covered with netting, initially containing five mosquitoes. 
The subject rests his or her forearm on the screened top of the carton. The 
mosquitoes are allowed to feed undisturbed for 5 minutes. After this period the cup 
is removed, and fed mosquitoes, as indicated by the presence of a blood meal in 
the abdomen, are individually dissected, and the paired salivary glands of each fed 
mosquito are transferred to a microscope slide. A cover slip is placed on the slide 
and the salivary glands are gently squashed to release the sporozoites. Under the 
microscope, glands are rated 0 to +4 according to the gland rating index for 
sporozoites: any mosquito with a gland rating of +2 (i.e. more than 11 sporozoites 
present) or more qualifies as being infective. The scale is illustrated in table 7.1.  
 
>1000 sporozoites observed +4
101 – 1000 sporozoites observed +3
11 – 100 sporozoites observed +2
1 – 10 sporozoites observed +1
No sporozoites observed 0 
No. of sporozoites Gland rating
>1000 sporozoites observed +4
101 – 1000 sporozoites observed +3
11 – 100 sporozoites observed +2
1 – 10 sporozoites observed +1
No sporozoites observed 0 
No. of sporozoites Gland rating
 
Table 7.1: Salivary gland sporozoite rating index 
 
If by this method the volunteer is found to have been inoculated by fewer than five 
infected mosquitoes, further infected mosquitoes are allowed to feed on the 
volunteer until a total of 5 infected mosquitoes have fed. New mosquitoes are 
added to a carton depending on the number of infective bites still required. The Chapter 7 Challenge Controls 
  173
bite-challenge procedure continues until each subject has received bites from 5 
infectious mosquitoes. 
 
These challenge procedures are performed within the insectary of the Alexander 
Fleming Building, Imperial College London. The insectary is one of only 3 such 
facilities worldwide, and is isolated by vacuum traps to prevent escape of any 
uncontained mosquitoes.  
 
7.2.2  Challenge Follow-up and Treatment 
From the evening of day 6 after the day of challenge, each volunteer is followed up 
twice daily for a maximum of 7 days, and then once daily for up to another 7 days. 
At each visit, volunteers are asked about symptoms of malaria infection using a 
structured questionnaire. An example of the questionnaires used is shown. The 
replies are recorded in the case record forms for each volunteer, and blood is 



























Tick if YES Symptoms
 
Table 7.2: Symptom questionnaire used during challenge study 
 
When one viable parasite was detected by microscopy in the blood of a volunteer, 
they were commenced on treatment. In the early challenge studies, the treatment 
given was Chloroquine. Chloroquine 150mg (base) was administered as 4 tablets 
orally at time 0, then 2 tablets at 6 hours, 2 tablets at 24 hours and 2 tablets at 48 
hours. In 2004, this was changed to artemisinin combination therapy (ACT) with 
oral Riamet®, partly to minimise reported toxicity, and also because of the shorter 
reported half life of Riamet® (4.5 days) [238] compared to that of chloroquine (60 
days) [239]) This was to minimise the effect of previous antimalarial treatment on 
vaccinated volunteers that might be re-challenged (for example, if they were 
protected at first challenge, a subsequent challenge enables the duration of 
protection to be established). This change was also in line with the updated WHO 
guidance on the treatment of uncomplicated falciparum malaria [240]. Riamet® is 
a combination drug consisting of artemether (20 mg) and lumefantrine (120 mg) Chapter 7 Challenge Controls 
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per tablet. A treatment course of Riamet® consists of 6 times 4 tablets. The first 4 
tablets were given when diagnosis was made, followed by additional doses after 8, 
24, 36, 48 and 60 hours. At least 3 out of the 6 doses were observed by the 
investigators. Regardless of the treatment given, slide reading was continued daily 
until two consecutive slides were negative for parasites. 
 
7.2.3  Slide Reading Methods 
To assess the development of parasitaemia after challenge, microscopy was 
performed on thick smears using a standard operating procedure by two 
experienced microscopists. Blood collected by venepuncture into an EDTA tube 
was prepared by spreading approximately 10 µl over one thousand high powered 
fields on a glass microscope slide. Slides were allowed to dry, and then stained 
with Field’s stain.  Field's stain was applied by dipping the slide into Field's stain A 
for 3 seconds, then into tap water for 3 seconds (with gentle agitation), into Field's 
stain B for a further 3 seconds and then washing gently in tap water to remove 
excess stain. The slide was then air dried for at least 30 minutes. After drying, they 
are then examined under oil immersion (Microil, BDH) at high power (magnification 
X1000). A minimum of 200 high power fields must be examined before a film can 
be declared negative, this ensures at least 2 µl of blood are examined for 
parasites.  
 
7.2.4  PCR Method 
During the challenge follow up, in addition to the thick film, blood was taken for 
PCR analysis for parasite DNA. This was performed in real time, although the 
clinicians assessing the volunteers were blinded to the results. The method used 
is described in detail in [194].  
 
7.2.5  Data Collation and Analysis 
Case record forms completed during each study for each volunteer were reviewed. 
The detailed answers to the malaria symptom questionnaire on each visit from 
Day 6 post infection, initially twice daily, then once daily, either until Day 21, or Chapter 7 Challenge Controls 
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until the day of diagnosis with malaria. Adverse event records were collated into 
an Excel ™ spreadsheet.  
 
The incubation period is defined as the time from challenge until the first onset of 
two or more symptoms of malaria, and the pre-patent period is the time until first 
positive blood smear. Clinical laboratory data from blood samples collected during 
the challenge period was also examined. PCR data calculating the numbers of 
parasites per mL of blood for each volunteer at each time point during the follow 
up period was collected for inclusion in the analysis.  
  
7.3  Results 
A total of 50 control volunteers were included in this analysis. All volunteers were 
healthy, malaria naïve individuals aged 18-50 years. They participated in nine 
different malaria challenge studies that took place in Oxford between August 2001 
and December 2006. All volunteers provided fully informed consent to participate 
in each study by signing a written consent form. Exclusion criteria included a prior 
history of malaria, risk of exposure in the preceding 6 months, 
immunosuppression, epilepsy, infection with Hepatitis B, Hepatitis C or HIV, 
pregnancy, drug or alcohol abuse, significant psychiatric disorder or other 
significant illness. All studies received ethical approval from the Oxfordshire 
Research Ethics Committee. The studies that were included, their ethics reference 
number, and the volunteer numbers of the controls analysed here, are listed in 
table 7.3. 
546 605 466 383 451
544 600 464 381 435 355 335 191 151
542 596 463 380 417 354 331 190 149
539 592 462 378 411 352 326 180 145
538 591 459 377 410 350 311 179 143
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Table 7.3: Malaria challenge studies  
Challenge studies used in this analysis, and volunteer numbers of control subjects included Chapter 7 Challenge Controls 
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The mean pre-patent period for all controls was 11.5 days (range 8 – 14.5), with a 
standard deviation of 1.49 days. The summary statistics for the pre-patent period 
for control volunteers from each study are shown in table 7.4. 
 
14.5 14.5 13.0 14.0 12.0 14.0 13.0 12.5 13.0 Max
8.0 11.0 11.0 11.0 9.0 9.5 9.0 10.5 9.5 Min
2.1 1.4 0.9 1.1 1.3 1.7 1.7 0.8 1.4 S.D.
11.0 12.8 11.8 11.8 11.3 11.0 10.0 12.0 11.0 Median
13.4 14.3 12.8 13.2 12.1 13.7 12.5 12.6 13.1




11.2 12.8 11.8 12.0 10.7 11.6 10.4 11.6 11.3 Mean (days)
VAC030 VAC027 VAC023 VAC022 VAC021 VAC018 VAC017 VAC015 VAC012 STUDY
14.5 14.5 13.0 14.0 12.0 14.0 13.0 12.5 13.0 Max
8.0 11.0 11.0 11.0 9.0 9.5 9.0 10.5 9.5 Min
2.1 1.4 0.9 1.1 1.3 1.7 1.7 0.8 1.4 S.D.
11.0 12.8 11.8 11.8 11.3 11.0 10.0 12.0 11.0 Median
13.4 14.3 12.8 13.2 12.1 13.7 12.5 12.6 13.1




11.2 12.8 11.8 12.0 10.7 11.6 10.4 11.6 11.3 Mean (days)
VAC030 VAC027 VAC023 VAC022 VAC021 VAC018 VAC017 VAC015 VAC012 STUDY
 
Table 7.4: Summary statistics for pre-patent period  
Statistics from control volunteers from each study included in this analysis, demonstrating 
no heterogeneity. 
 
There is no significant difference between the pre-patent periods in any of the 
trials included in this analysis (one way ANOVA p =0.2). The spread of the data is 
represented in the following bar chart, showing that the majority of volunteers are 
diagnosed on day 11. 
 Chapter 7 Challenge Controls 
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Figure 7.1: Bar chart of numbers diagnosed each day after challenge  
The number of control volunteers diagnosed on each day after challenge is shown, n=50. 
 
7.3.1  Symptoms 
The mean incubation period was 9.6 days, (range 6.5 – 14 days) with a standard 
deviation of 1.9 days. Thus on average, volunteers reported symptoms for 2 days 
prior to a diagnosis of malaria being made.  
 
Summarising all the solicited symptoms over the period of the challenge follow up, 
the most commonly reported symptom was that of headache, comprising nearly 
20% of all symptoms. Each symptom is recorded at each clinic visit, so if one 
subject reports any symptom twice in one day, then it is included as two separate 
reports of that symptom. The frequency of each solicited symptom is presented in 
table 7.5. Low back pain was sometimes reported as a form of myalgia/arthralgia. 
The severity of each symptom was not recorded, however all volunteers were Chapter 7 Challenge Controls 
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managed successfully as outpatients indicating that all reported symptoms were 
mild or moderate. 
 
0 1 2 0 1 2 2 1 1 2 2 14.5
0 2 2 0 2 2 4 2 1 2 3 14
0 2 3 0 1 2 2 2 1 2 2 13.5
1 3 2 0 4 2 3 3 1 1 3 13
1 4 5 0 3 4 6 4 1 5 6 12.5
2 6 6 0 4 4 10 6 1 6 5 12
2 7 8 0 3 5 8 1 0 7 1 11.5
3 11 8 1 7 7 11 5 2 5 6 11
6 4 6 0 5 5 11 2 0 1 4 10.5
4 5 9 0 5 4 5 3 2 2 8 10
2 6 10 0 5 2 12 2 2 3 4 9.5
2 7 7 0 3 4 6 1 1 3 3 9
3 6 3 1 4 4 7 0 0 0 2 8.5
1 6 3 1 4 1 6 0 0 1 1 8
3 0 2 1 5 4 7 0 0 2 1 7.5
3 2 2 3 4 2 4 0 0 1 3 7









Anorexia Headache Sweats Rigors Chills Feverish Day
0 1 2 0 1 2 2 1 1 2 2 14.5
0 2 2 0 2 2 4 2 1 2 3 14
0 2 3 0 1 2 2 2 1 2 2 13.5
1 3 2 0 4 2 3 3 1 1 3 13
1 4 5 0 3 4 6 4 1 5 6 12.5
2 6 6 0 4 4 10 6 1 6 5 12
2 7 8 0 3 5 8 1 0 7 1 11.5
3 11 8 1 7 7 11 5 2 5 6 11
6 4 6 0 5 5 11 2 0 1 4 10.5
4 5 9 0 5 4 5 3 2 2 8 10
2 6 10 0 5 2 12 2 2 3 4 9.5
2 7 7 0 3 4 6 1 1 3 3 9
3 6 3 1 4 4 7 0 0 0 2 8.5
1 6 3 1 4 1 6 0 0 1 1 8
3 0 2 1 5 4 7 0 0 2 1 7.5
3 2 2 3 4 2 4 0 0 1 3 7









Anorexia Headache Sweats Rigors Chills Feverish Day
 
Table 7.5: Frequency of each solicited symptom by day after challenge 
 






















Figure 7.2: Bar chart of reported symptoms 
‘Other’ includes: dizziness, tiredness / fatigue and malaise. Chapter 7 Challenge Controls 
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The number of symptoms reported each day gradually increased from the first day 
(6.5) up to a peak on day 11, which corresponds with the mean day of diagnosis 


























Figure 7.3: Total number of symptoms reported each day.  
The peak number of symptoms is reported on day 11, corresponding with the peak day of 
diagnosis. 
 
The frequency of reports of each symptom varies, although most rise with time 
after challenge. The following two graphs demonstrate this. 









































































































































































Figure 7.4: Number of reports of each symptom by day  
 
From these graphs, it can be seen that the common early symptoms are those of 
headache, myalgia, arthralgia. As time progresses, reports of headache rise, but 
so too do those of low back pain, feverishness, chills and sweats.  
 
Examining the data by volunteer rather than by total number of reports, a total of 
43/50 (86%) of control volunteers reported headache at least once during the 
follow up period, meaning that headache is also reported by a majority of 
volunteers, rather than just a few, but on several occasions. Feverishness, chills, 
myalgia / arthralgia, and low back pain are also reported by 50-60% of volunteers 
representing the next most commonly reported symptoms. Rigours are 
experienced by relatively few people, only 10/50 in this series (20%). The majority Chapter 7 Challenge Controls 
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of these symptoms are relatively short lived, all having a mean and median 
duration of less than 1 day (<24 hours). Table 7.6 lists the frequency of each 
symptom and their duration.  
 
0.68, (0.33) 1, (1 – 1.5) 18/50, (36) Other
0.90, (0.90) 1, (1 – 5.5) 29/50, (58) Low Back Pain
0.91, (0.85) 1, (1 – 5.5) 30/50, (60) Myalgia/Arthralgia
0.56, (0.18) 1, (1 – 1) 8/50, (16) Diarrhoea
0.87, (0.61) 1, (1 – 2.5) 22/50, (44) Nausea/Vomiting
0.78, (0.40) 1, (1 – 1.5) 26/50, (52) Anorexia
0.84, (0.54) 1, (1 – 3) 43/50, (86) Headache
0.84, (0.60) 1, (1 – 2.5) 17/50, (34) Sweats
0.59, (0.20) 1, (1 – 1) 10/50, (20)  Rigors
0.74, (0.34) 1, (1 – 1.5) 26/50, (52)  Chills
0.76, (0.51) 1, (1 – 3) 28/50, (56)  Feverish
Mean (SD) Median 
(range)
Duration, days Frequency 
(%)
Symptom
0.68, (0.33) 1, (1 – 1.5) 18/50, (36) Other
0.90, (0.90) 1, (1 – 5.5) 29/50, (58) Low Back Pain
0.91, (0.85) 1, (1 – 5.5) 30/50, (60) Myalgia/Arthralgia
0.56, (0.18) 1, (1 – 1) 8/50, (16) Diarrhoea
0.87, (0.61) 1, (1 – 2.5) 22/50, (44) Nausea/Vomiting
0.78, (0.40) 1, (1 – 1.5) 26/50, (52) Anorexia
0.84, (0.54) 1, (1 – 3) 43/50, (86) Headache
0.84, (0.60) 1, (1 – 2.5) 17/50, (34) Sweats
0.59, (0.20) 1, (1 – 1) 10/50, (20)  Rigors
0.74, (0.34) 1, (1 – 1.5) 26/50, (52)  Chills
0.76, (0.51) 1, (1 – 3) 28/50, (56)  Feverish
Mean (SD) Median 
(range)




Table 7.6: Solicited symptoms 
Frequency and duration of all solicited symptoms, n=50 
 
Only one volunteer out of 50 (2%) reported no symptoms of malaria at all up to the 
time of diagnosis, but 11/50, (22%) reported 3 different symptoms or fewer at any 
time during the challenge. Most volunteers (52%) reported more than 5 symptoms, 
however, only 9/50 (18%) reported nine or 10 different symptoms. 
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Figure 7.5: Number of symptoms reported by each volunteer  
Total number of symptoms reported by each volunteer during the challenge follow up 
period 
 
7.3.2  Parasite Density and Symptoms 
To examine if there was any relationship between parasite density and number of 
reported symptoms, the parasite density measured by PCR at each time point was 
plotted against the number of symptoms reported at that visit by each volunteer. 
There is a poor positive correlation between the individual values for each 
volunteer (data not shown), and the Pearson correlation coefficient is 0.11 (not 
significant). 
 
However, if this data is analysed by the day of peak PCR measurement for each 
volunteer, and this is compared with the day that volunteer reported the most 
symptoms, there is a correlation between the two. So, while the numbers of 
symptoms reported on a daily basis do not correlate with parasite density, the 
worst symptoms (i.e. maximum number) do correlate with the highest parasite 
density. This is the first time such a correlation has been shown at such low 
parasite densities. The data is shown in figure 7.6, and the Pearson correlation 
coefficient is 0.67 
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Figure 7.6: Scatter plot of peak PCR measurement vs. maximal symptoms. 
 
7.3.3  Laboratory Results  
The schedule for collection of blood for monitoring of routine haematological and 
biochemical parameters has varied between studies. Table 7.7 outlines the 
principal time points for sampling for control volunteers in the trials under 
consideration.  
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C +7 C +7 C +7 C +7 C +7 C +7
C C




VAC030  VAC027 VAC023 VAC022 VAC021 VAC018 VAC017 VAC015 VAC012 STUDY
 
Table 7.7: Time points for safety blood collection 
S = Screening, C = Challenge, C + 7 = 7 days post challenge etc. 
 
There have been few clinically significant alterations in safety blood parameters 
during these challenge studies. Table 7.8 demonstrates all out of range blood tests 
for these control volunteers throughout each challenge study. Of the clinically 
significant abnormalities, only two were thought to be related to malaria infection. 
These included a mild neutropenia, reflected in a low white cell count, another Chapter 7 Challenge Controls 
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volunteer had a transient rise in AST, which resolved on repeat testing. A raised 
creatine kinase, of up to 1642, was temporally related to a period of vigorous 
exercise, and this was thought to be the likely cause. None of the other out of 
range values were thought to be clinically significant 
 
3.6 on repeat 
testing
3.1 3.5-5.0 mmol/l Potassium Screening VAC030 539
Clinically well. 
Transiently raised 
prior to enrolment 
in trial only.
61 ≤60 IU/l ALT Screening VAC027 596
Subject well, 
exercise related
328 <100 U/l Creatine Kinase DOC +7 VAC022 380
Subject suffering 
from malaria. 29 
on repeat testing
86 >80 IU/l AST DOC +7 VAC022 378
Subject well, 3.6 
on repeat testing
3.1 3.5-5.0 mmol/l Potassium Screening VAC022 378
Subject well, 
related to vigorous 








Subject well, 33 
and 44 on repeat 
testing




Subject well, not 
clinically 
significant
3.2 3.5-5.0 mmol/l Potassium DOC + 90 VAC018 352
Subject well, not 
clinically 
significant
3.1 3.5-5.0 mmol/l Potassium DOC +7 VAC015 191
Subject suffering 
from malaria
2.29 3.0-14.0 x 109/l White cell count DOC+7 VAC015 179
Subject well, K 
3.6 on retesting.
3.1 3.5-5.0 mmol/l Potassium Screen VAC012 126
Clinical Details Value Reference 
Range
Safety Test Time point Study Subject 
id
3.6 on repeat 
testing
3.1 3.5-5.0 mmol/l Potassium Screening VAC030 539
Clinically well. 
Transiently raised 
prior to enrolment 
in trial only.
61 ≤60 IU/l ALT Screening VAC027 596
Subject well, 
exercise related
328 <100 U/l Creatine Kinase DOC +7 VAC022 380
Subject suffering 
from malaria. 29 
on repeat testing
86 >80 IU/l AST DOC +7 VAC022 378
Subject well, 3.6 
on repeat testing
3.1 3.5-5.0 mmol/l Potassium Screening VAC022 378
Subject well, 
related to vigorous 








Subject well, 33 
and 44 on repeat 
testing




Subject well, not 
clinically 
significant
3.2 3.5-5.0 mmol/l Potassium DOC + 90 VAC018 352
Subject well, not 
clinically 
significant
3.1 3.5-5.0 mmol/l Potassium DOC +7 VAC015 191
Subject suffering 
from malaria
2.29 3.0-14.0 x 109/l White cell count DOC+7 VAC015 179
Subject well, K 
3.6 on retesting.
3.1 3.5-5.0 mmol/l Potassium Screen VAC012 126
Clinical Details Value Reference 
Range
Safety Test Time point Study Subject 
id
 
Table 7.8: Out of range lab values  
All out of range lab values for control volunteers participating in challenge studies are 
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7.4  Discussion 
 
No volunteer in these studies has developed severe malaria, and all subjects were 
successfully treated as outpatients. No symptoms were considered serious or life 
threatening. There have been no cases of recrudescence of malaria after 
successful treatment. 
 
The mean pre-patent period for these volunteers is 11.5 days, which is slightly 
longer than that reported by the US Navy in their recent publication reviewing their 
experience in studies of this sort [172]. 
 
Analysis of the commonly reported symptoms following malaria infection in a 
challenge study has shown that the most prominent symptom is that of headache. 
All other expected symptoms of malaria are reported, although some rarely – there 
are only 10 reports of diarrhoea, making up less than 2% of the total number of 
symptoms. The majority of volunteers taking part in the challenge study will report 
at least 5 or more symptoms of malaria infection, with the majority of these being 
reported on the day of diagnosis (data not shown). On an individual volunteer 
level, the symptoms do often appear to occur in paroxysms, as described in the 
medical textbooks; however, when examining the symptoms of the whole group, 
this effect is lost.  
 
Thick films are used in this study to examine a larger volume of blood, and 
therefore detect parasites at a lower density than would be possible using thin 
films. It has been shown that thick films consistently underestimate the parasite 
density when compared to PCR [241]. 
 
At the low parasite densities seen in volunteers taking part in these challenge 
studies, however, there is a correlation between the peak parasite density and 
peak number of symptoms reported. Previous work looking at the relationship 
between parasitaemia and clinical symptoms indicates that this is complex, even 
in well studied populations such as P. falciparum infected children in sub-Saharan 
Africa, and much of the published evidence appears contradictory [242]. A recent Chapter 7 Challenge Controls 
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study used data from malaria treated neurosyphilis patients to examine the 
relationship between fever, parasitaemia and gametocyte development and 
density [242]. This shows a link between the development of gametocytaemia and 
fever, rather than parasitaemia as whole. Epstein et al. [172] failed to demonstrate 
a correlation between parasitaemia and severity of symptoms in their report. 
 
The analysis here confirms that this experimental challenge method employed in 
the evaluation of malaria vaccines is a safe and reliable method. The pre-patent 
and incubation period was remarkably constant between studies. In our 
experience, experimental infection of healthy volunteers with malaria is a safe, 
reproducible, efficient, and cost effective method for the testing of new malaria 
vaccines. It requires that volunteers are closely monitored throughout the 
challenge period. All volunteers should expect that they are likely to become mildly 
to moderately ill, and to remain ill for several days, but to continue to be able to 
perform the activities of daily living. They may also experience mild derangements 
in the values of haematological and biochemical indices, which are generally 
transient.  
 
In contrast to the recently published experience of the Naval Medical Research 
Centre in the States, [172], control volunteers participating in our studies appear to 
have fewer symptoms, and they last for shorter periods of time. For direct 
comparison, their data is shown in table 7.9, alongside the data obtained from the 
work described in this chapter. Chapter 7 Challenge Controls 
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2.29 2.35 1,9 1 36 17 Arthralgia
1.82 3.00 1,9 3 81 38 Myalgia
0.89 1.67 1,4 1.5 26 12 Diarrhea
0.41 1.68 1,2 1 13 6 Vomiting
1.20 1.83 1,6 1 62 29 Nausea
2.20 3.75 1,9 3 100 47 Headache
0.71 1.50 1,3 1 38 18 Rigors





0.85 0.91 1,6 0.5 60 30 Myalgia/Arthralgia
0.18 0.56 1,1 0.5 16 8 Diarrhoea
0.61 0.87 1,3 0.5 44 22 Nausea/Vomiting
0.40 0.78 1,2 0.5 52 26 Anorexia
0.54 0.84 1,3 0.5 86 43 Headache
0.20 0.59 1,1 0.5 20 10 Rigors









Duration (days) % n Symptom Site
2.29 2.35 1,9 1 36 17 Arthralgia
1.82 3.00 1,9 3 81 38 Myalgia
0.89 1.67 1,4 1.5 26 12 Diarrhea
0.41 1.68 1,2 1 13 6 Vomiting
1.20 1.83 1,6 1 62 29 Nausea
2.20 3.75 1,9 3 100 47 Headache
0.71 1.50 1,3 1 38 18 Rigors





0.85 0.91 1,6 0.5 60 30 Myalgia/Arthralgia
0.18 0.56 1,1 0.5 16 8 Diarrhoea
0.61 0.87 1,3 0.5 44 22 Nausea/Vomiting
0.40 0.78 1,2 0.5 52 26 Anorexia
0.54 0.84 1,3 0.5 86 43 Headache
0.20 0.59 1,1 0.5 20 10 Rigors









Duration (days) % n Symptom Site
 
Table 7.9: Comparison of symptoms  
Symptoms of malaria infection reported by subjects participating in studies at different 
sites. The data shown is only for those symptoms that are directly comparable between the 
two groups. Differences in recording methods mean that it is not possible to compare all of 
the reported symptoms. 
 
This demonstrates that in the US Navy studies, generally more volunteers report 
each of the symptoms, and they last for a longer period. Overall, the numbers of 
volunteers reporting each symptom are not significantly different. However, the 
mean duration of symptoms reported by the American group is significantly longer 
than that reported in our group (mean duration for US Navy volunteer is 2.3 days, 
whilst that for Oxford University volunteers is 0.8 days, two tailed t test p = 0.001). 
There is a possibility that this difference in duration could be due to the different 
protocols for challenge visits. Volunteers participating in studies run by the US 
Navy are reviewed only once a day, and so the minimum duration for any reported 
symptom is one day, whereas those in Oxford were reviewed twice daily. Chapter 7 Challenge Controls 
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However, even if this is taken into account by rounding up the duration of 
symptoms for the Oxford data the difference in duration is still significant (two 
tailed t test p = 0.004). 
 
This is possibly related to the strain of malaria used; the Navy use the NF54 strain 
of P. falciparum rather than 3D7, which is a laboratory clone of NF54. It would 
seem that our experience lends credence to the belief that 3D7 challenge, whilst 
remaining a stringent test for a potential vaccine candidate, appears to cause a 
similar number or fewer symptoms, and these last for a shorter period of time. 
Data concerning the severity of reported symptoms has not been collected during 
the Oxford challenges, so it is not possible to perform a direct comparison of 
severity. The Navy report an incidence of severe symptoms of 21%, although the 
definition of a severe symptom is not clear.  
 
In our overall experience, less than 1% (0.85%) of all challenged volunteers have 
been hospitalised (none of those analysed here – both were vaccinated 
volunteers), so this is unlikely, and the likelihood of developing severe malaria is 
extremely unlikely (none of those in our experience). Volunteers should continue 
to be informed of these potential risks of participation, but reassured by the low 
frequency with which they have occurred up to now.  
 Chapter 8 Conclusions 
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Chapter 8   Conclusions 
8.1  Vaccine trials 
8.1.1  VAC027 
This trial examined the safety and immunogenicity of the novel candidate malaria 
vaccines FP9 and MVA PP, encoding a string of six pre-erythrocytic antigens 
[167]. It was hoped that a broad response against multiple parasite epitopes might 
enhance the immune response and provide immune protection. However, the 
immunogenicity following vaccination in all study groups was disappointing, 
perhaps relating to inadequate expression of this very large insert to allow good 
immunogenicity in humans. Both vaccines were tested for potency prior to use in 
the study, and both passed. However, in keeping with the low immunogenicity 
observed, no efficacy was demonstrated in the sporozoite challenge study. All 
volunteers succumbed to malaria infection by day 14.5 after the challenge.  
 
The clinical safety profile of these vaccines was good. 34 volunteers were enrolled 
and 31 (91%) completed the trial successfully. The safety profile reported provides 
support for an ongoing program to develop effective vaccines against malaria, 
tuberculosis and HIV employing these vectors, and also for exploring the use of 
other recombinant viral vectors to enhance immunogenicity. There are no further 
plans for use of the polyprotein construct at present, although it is possible that 
using these antigens in a construct with a more potent vector may produce the 
desired broad response to multiple epitopes. 
 
8.1.2  VAC030 
This trial was the first to investigate the approach of combining two existing 
vaccine strategies, one T cell inducing and one antibody inducing, in the hope that 
they would work synergistically to improve protection. This hypothesis was based 
on studies in an animal model [169]. Some evidence of vaccine-induced blood 
stage parasite activity and partial protection was observed, for the first time in a Chapter 8 Conclusions 
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healthy volunteer challenge study such as this. As described, two major 
observations led to this conclusion. However, the dramatic increase in 
immunogenicity and protection seen in the murine model was not observed in this 
human study. In fact, as the positive results were distributed across all vaccinees, 
it would seem that any efficacy demonstrated was a result of the antibody inducing 
vaccine PEV3A, and the contribution of FP9 and MVA ME-TRAP appears to have 
been minimal. 
 
The reason for this may be related to the batch of vaccines used, or to the 
approach. In the successful animal model, the best results (i.e. highest levels of 
protection from a subsequent malaria challenge) were obtained when the vaccines 
were mixed physically in the same syringe and administered at the same site. Both 
T cells and antibodies were shown to be important in mediating this protection. 
Administering the vaccines at separate sites should have compartmentalised the 
vaccine induced responses (opposite arms have different draining lymph nodes) 
and thence may have led to the lack of synergism. It is possible that the immune 
responses induced by one antigen interfered with the induced response to the 
other. However, as observed in VAC027, the immunogenicity produced by the T 
cell inducing component of the combination vaccine was disappointing. Again, 
both vaccines (FP9 and MVA ME-TRAP) were tested for potency prior to use in 
the study, and were found to be immunogenic , so it appears likely that co-
administration of these different vaccines, even using different immunisation sites 
had an adverse effect of the immunogenicity of the poxvirus vaccines in humans. 
 
An effective malaria vaccine may need to target multiple parasite antigens from 
different stages of the life cycle.  This study provides evidence of a vaccine-
induced blood stage protection for the first time, and it supports the further 
development of the virosomal system as an effective vector for malaria vaccines. 
A Phase IIB study, using the vaccine candidate PEV3A, is currently being planned 
in Africa, and Pevion also have plans to produce virosomal vaccines containing 
multiple blood stage antigens. 
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8.1.3  Vaccine Issues 
Previous human trials of poxviruses encoding P. falciparum antigens have 
produced specific T cell responses of the order of 400 spot forming units per 
million PBMC. The most effective prime-boost group in VAC027 achieved a 
summed response to the whole insert of just under 100 spots per million PBMC at 
the peak time point, whilst in VAC030, the peak response was even lower, at 
under 50 spots per million PBMC. The reasons for the poor immune responses 
generated by these vaccines are not clear. All vaccines were stored as 
recommended by the manufacturer and remained infectious and potent when 
tested prior to use. The intradermal route has proved the most immunogenic in 
previous trials of poxvirus vaccines encoding malaria antigens in humans (a 
previous study [216] compared intradermal and intramuscular routes, although 
again poor immunogenicity complicated these results). It is possible that the low 
immunogenicity is a result of changes in the manufacturing process. These 
vaccines were all manufactured under contract by IDT, Germany, and significant 
changes have been introduced in recent years in order to scale up their 
manufacturing processes. Further work to determine if any vaccine related stability 
issues could have contributed to the reduction in immunogenicity has been 
undertaken without identifying any evidence of loss of potency with time.  
 
8.2  Lab Work 
In this study, T cell, and antibody responses to polyprotein antigens are identified 
in samples from and African population. T cell, but not antibody, responses are 
shown to play a role in protection from malaria infection. However, caution is 
required in interpreting results obtained from samples such as these, as malaria 
infection itself may have modulated the observed response. This work provides a 
clue that responses to these antigens may be important, but in order to extend 
this, a longitudinal study of responses would be required. Unfortunately, it was not 
possible to find the samples necessary to perform a study such as this. This data 
adds to understanding of the development of clinical immunity. It also provides 
further support for the approach of developing T cell inducing vaccines in order to 
protect against disease. Chapter 8 Conclusions 
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8.3  Parasite Life Cycle Modelling 
Multiple models of parasite growth have been published. The Hermsen model was 
selected from these as the most appropriate for use with the data collected during 
the clinical trials performed in Oxford, and using this Hermsen model, it was 
possible to show that some of the candidate malaria vaccines tested in these 
studies in Oxford do exert an effect on blood stage parasite growth. Examining 
previous studies where pre-erythrocytic efficacy has been observed further 
validated the use of this model.  In the studies where a delay in parasitaemia has 
been observed, as expected this is associated with a reduction in the estimated 
numbers of infected hepatocytes calculated. 
 
8.4  Challenge Safety Data  
Analysis of the data obtained from challenging 50 malaria naïve, unvaccinated 
individuals provides an insight into the course of early malaria infection. The data 
presented confirm that this is a safe method for testing the efficacy of candidate 
malaria vaccines, and that the pre-patent and incubation periods remained 
remarkably constant throughout multiple trials.  A correlation of the peak in 
parasitaemia with the peak of reported symptoms was observed for the first time at 
the relatively low parasite densities reached in these studies. A comparison with 
published data from the US Navy demonstrates that the Oxford challenge appears 
to be better tolerated. This may be related to the parasite strain used. 
 
8.5  Overall conclusions 
The two clinical studies presented in this thesis represent two successful trials, 
which were satisfactorily conducted, with no serious safety or other issues. The 
results of these trials were disappointing, in that immunogenicity of the vectored 
vaccines was in both cases lower than anticipated, and no complete protection 
from malaria was observed. However, they do provide us with important insights 
into the relative roles of T cell and antibody mediated immunity. The holy grail of Chapter 8 Conclusions 
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an immune correlate of protection remains to be elucidated, and in the study 
where some efficacy was demonstrated (VAC030), none of the measured immune 
responses correlated clearly with time to parasitaemia. The other work presented 
demonstrates the complexity of unravelling the immune response to malaria, and 
the mechanisms of clinical immunity. Modelling parasite growth is an important 
part of these clinical trials, and examining the relevant models in detail in order to 
select one has highlighted the many assumptions that need to be made, which 
may not be correct. 
 
Malaria remains a serious problem throughout the world, and the work presented 
has contributed to our understanding of the immune response to malaria infection, 
and allowed selection of one vaccine candidate for further studies. It has also 
highlighted a problem of poor immunogenicity associated with the pox viral 
vectored vaccines studied, which has led to the development of alternative 
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